(dp0
(S'ZEB1'
p1
S'FOXA1'
p2
S'increases'
p3
tp4
(lp5
s(S'FOXJ1'
p6
S'GATA6'
p7
S'increases'
p8
tp9
(lp10
s(S'TFAP4'
p11
S'FOXD3'
p12
S'increases'
p13
tp14
(lp15
s(S'TBP'
p16
S'MEIS1'
p17
S'increases'
p18
tp19
(lp20
s(S'GCM1'
p21
S'GATA6'
p22
S'increases'
p23
tp24
(lp25
s(S'T-DHT'
p26
S'SRC'
p27
S'adds_modification'
p28
tp29
(lp30
s(S'MAZ'
p31
S'GABPB2'
p32
S'increases'
p33
tp34
(lp35
s(S'HMGA1'
p36
S'EN1'
p37
S'increases'
p38
tp39
(lp40
s(S'CYP26A1'
p41
S'NRAS'
p42
S'increases'
p43
tp44
(lp45
s(S'CUX1'
p46
S'MEIS1'
p47
S'increases'
p48
tp49
(lp50
s(S'REPIN1'
p51
S'BACH1'
p52
S'increases'
p53
tp54
(lp55
s(S'TFDP1'
p56
S'HOXA9'
p57
S'increases'
p58
tp59
(lp60
s(S'NFE2L1'
p61
S'CYP26A1'
p62
S'increases'
p63
tp64
(lp65
s(S'MAZ'
p66
S'GATA1'
p67
S'increases'
p68
tp69
(lp70
s(S'TCF12'
p71
S'GABPB2'
p72
S'increases'
p73
tp74
(lp75
s(S'ETS2'
p76
S'FOXO3'
p77
S'increases'
p78
tp79
(lp80
s(S'hsa-let-7c-5p'
p81
S'NRAS'
p82
S'decreases'
p83
tp84
(lp85
s(S'SPI1'
p86
S'CYP26A1'
p87
S'increases'
p88
tp89
(lp90
s(S'RAC1/GTP'
p91
S'MKK4'
p92
S'adds_modification'
p93
tp94
(lp95
s(S'Quercetin'
p96
S'KRAS MRNA'
p97
S'decreases'
p98
tp99
(lp100
s(S'INSULIN RECEPTOR/INSULIN/SHC'
p101
S'GRB2'
p102
S'binds'
p103
tp104
(lp105
s(S'TAp63a (tetramer)'
p106
S'PKC DELTA'
p107
S'increases'
p108
tp109
(lp110
s(S'FOXO1'
p111
S'POU2F1'
p112
S'increases'
p113
tp114
(lp115
s(S'FOXL1'
p116
S'EN1'
p117
S'increases'
p118
tp119
(lp120
s(S'TBP'
p121
S'CYP26A1'
p122
S'increases'
p123
tp124
(lp125
s(S'Heptachlor'
p126
S'HRAS MRNA'
p127
S'decreases'
p128
tp129
(lp130
s(S'PCBP1'
p131
S'CYP26A1'
p132
S'increases'
p133
tp134
(lp135
s(S'ZBTB18'
p136
S'CYP26A1'
p137
S'increases'
p138
tp139
(lp140
s(S'GATA2'
p141
S'CYP26A1'
p142
S'increases'
p143
tp144
(lp145
s(S'Cadmium'
p146
S'KRAS MRNA'
p147
S'increases'
p148
tp149
(lp150
s(S'HNF1A'
p151
S'POU2F1'
p152
S'increases'
p153
tp154
(lp155
s(S'ABT-100'
p156
S'HRAS PROTEIN'
p157
S'inhibits_modification'
p158
tp159
(lp160
s(S'ELF1'
p161
S'CYP26A1'
p162
S'increases'
p163
tp164
(lp165
s(S'LEF1'
p166
S'KRAS'
p167
S'increases'
p168
tp169
(lp170
s(S'NKX2-1'
p171
S'FOXD3'
p172
S'increases'
p173
tp174
(lp175
s(S'PI-3-4-5-P3'
p176
S'BTK-ITK'
p177
S'translocates'
p178
tp179
(lp180
s(S'POU6F1'
p181
S'HOXA9'
p182
S'increases'
p183
tp184
(lp185
s(S'Myb'
p186
S'MYB'
p187
S'increases'
p188
tp189
(lp190
S"The B-Myb responsive plasmid pGL2-mim1, containing five MYB binding sites, was constructed as follws: two oligonucleotides 5' CAA CGT TAT AGT GAG CTA AGA ACG TTA TAG TGA GCT AAG AAC GTT ATA GTG AGC TAA GAA CGT TAT AGT GAG CTA AGA ACG TTA TAG TGA GCT AAG C 3' and 5' TCG AGC TTA GCT CAC TAT AAC GTT CTT AGC TCA CTA TAA CGT TCT TAG CTC ACT ATA ACG TTC TTA GCT CAC TAT AAC GTT CTT AGC TCA CTA TAA CGT TGG TAC 3' were annealed and subcloned into the pGL2-promoter vector (Promega, USA)."
p191
aS'B-Myb is a member of the vertebrate MYB family of nuclear transcription factors.'
p192
as(S'PAX5'
p193
S'CYP26A1'
p194
S'increases'
p195
tp196
(lp197
s(S'FOXO4'
p198
S'FOXD3'
p199
S'increases'
p200
tp201
(lp202
s(S'CYP26A1'
p203
S'FOXO4'
p204
S'increases'
p205
tp206
(lp207
s(S'cell adhesion'
p208
S'HRAS/GDP'
p209
S'increases_activity'
p210
tp211
(lp212
s(S'IRF7'
p213
S'CYP26A1'
p214
S'increases'
p215
tp216
(lp217
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p218
S'KRAS PROTEIN'
p219
S'increases'
p220
tp221
(lp222
s(S'PITX2'
p223
S'POU2F1'
p224
S'increases'
p225
tp226
(lp227
s(S'E2F1'
p228
S'CYP26A1'
p229
S'increases'
p230
tp231
(lp232
s(S'ATF1'
p233
S'CYP26A1'
p234
S'increases'
p235
tp236
(lp237
s(S'PI3K'
p238
S'PKC DELTA'
p239
S'adds_modification'
p240
tp241
(lp242
s(S'SOX5'
p243
S'HOXA9'
p244
S'increases'
p245
tp246
(lp247
s(S'FOXO4'
p248
S'POU2F1'
p249
S'increases'
p250
tp251
(lp252
s(S'FOXO4'
p253
S'GATA6'
p254
S'increases'
p255
tp256
(lp257
s(S'LEF1'
p258
S'FOXF2'
p259
S'increases'
p260
tp261
(lp262
s(S'Insulin Receptor/Insuli/IRS1/GRB2/SHC/Sos'
p263
S'HRAS/GDP'
p264
S'increases_activity'
p265
tp266
(lp267
s(S'TLX2'
p268
S'RUNX1'
p269
S'increases'
p270
tp271
(lp272
s(S'ALX4'
p273
S'JUN'
p274
S'increases'
p275
tp276
(lp277
s(S'RHOA/GTP'
p278
S'RHOGDI'
p279
S'binds'
p280
tp281
(lp282
s(S'GCM1'
p283
S'CYP26A1'
p284
S'increases'
p285
tp286
(lp287
s(S'RB1'
p288
S'ONECUT1'
p289
S'increases'
p290
tp291
(lp292
s(S'NHLH1'
p293
S'CYP26A1'
p294
S'increases'
p295
tp296
(lp297
s(S'NR3C1'
p298
S'BACH1'
p299
S'increases'
p300
tp301
(lp302
s(S'HNF4A'
p303
S'CYP26A1'
p304
S'increases'
p305
tp306
(lp307
s(S'YY1'
p308
S'FOXO3'
p309
S'increases'
p310
tp311
(lp312
s(S'GRB2:SOS1'
p313
S'P-EGFR MUTANTS DIMER'
p314
S'binds'
p315
tp316
(lp317
s(S'P-Y349,350-SHC1:P-ERBB4'
p318
S'GRB2:SOS1'
p319
S'binds'
p320
tp321
(lp322
s(S'FOXN1'
p323
S'ONECUT1'
p324
S'increases'
p325
tp326
(lp327
s(S'TFAP4'
p328
S'MYC'
p329
S'increases'
p330
tp331
(lp332
s(S'MYC'
p333
S'EN1'
p334
S'increases'
p335
tp336
(lp337
s(S'Antigen/IgE/Fc epsilon R1/LYN/SYK'
p338
S'SHC/GRB2/SOS1'
p339
S'increases_activity'
p340
tp341
(lp342
s(S'14-3-3 BETA, ZETA'
p343
S'GARNL4'
p344
S'binds'
p345
tp346
(lp347
s(S'SMAD1'
p348
S'EN1'
p349
S'increases'
p350
tp351
(lp352
s(S'Raf-1'
p353
S'MEK1-2'
p354
S'adds_modification'
p355
tp356
(lp357
s(S'POU2F1'
p358
S'FOXO3'
p359
S'increases'
p360
tp361
(lp362
s(S'NGF (dimer)/TRKA'
p363
S'RASGRF1'
p364
S'adds_modification'
p365
tp366
(lp367
s(S'TCF4'
p368
S'CYP26A1'
p369
S'increases'
p370
tp371
(lp372
s(S'STAT5B'
p373
S'TLX2'
p374
S'increases'
p375
tp376
(lp377
s(S'CYP26A1'
p378
S'SRF'
p379
S'increases'
p380
tp381
(lp382
s(S'STAT1'
p383
S'NRAS'
p384
S'increases'
p385
tp386
(lp387
s(S'TFDP1'
p388
S'GATA1'
p389
S'increases'
p390
tp391
(lp392
s(S'PI3K'
p393
S'ALPHA6/BETA4 INTEGRIN/LAMININ'
p394
S'binds'
p395
tp396
(lp397
s(S'FOXF2'
p398
S'NRAS'
p399
S'increases'
p400
tp401
(lp402
s(S'CUX1'
p403
S'POU2F1'
p404
S'increases'
p405
tp406
(lp407
s(S'ETS2'
p408
S'STAT4'
p409
S'increases'
p410
tp411
(lp412
s(S'EN1'
p413
S'CYP26A1'
p414
S'increases'
p415
tp416
(lp417
s(S'COMPLEX (RAS/GTP)'
p418
S'RAF'
p419
S'binds'
p420
tp421
(lp422
s(S'LEF1'
p423
S'EN1'
p424
S'increases'
p425
tp426
(lp427
s(S'FOXL1'
p428
S'NRAS'
p429
S'increases'
p430
tp431
(lp432
s(S'ELF2'
p433
S'CYP26A1'
p434
S'increases'
p435
tp436
(lp437
s(S'Src Family Kinases-active'
p438
S'EGF/EGFR'
p439
S'adds_modification'
p440
tp441
(lp442
s(S'RUNX1'
p443
S'POU2F1'
p444
S'increases'
p445
tp446
(lp447
s(S'RHOA/GTP'
p448
S'CITRON-N'
p449
S'increases_activity'
p450
tp451
(lp452
s(S'PAX4'
p453
S'SRF'
p454
S'increases'
p455
tp456
(lp457
s(S'Vitamin E'
p458
S'HRAS MRNA'
p459
S'increases'
p460
tp461
(lp462
s(S'CDX2'
p463
S'FOXD3'
p464
S'increases'
p465
tp466
(lp467
s(S'Plant Extracts'
p468
S'KEAP1 PROTEIN'
p469
S'decreases'
p470
tp471
(lp472
s(S'PAX4'
p473
S'CBFA2T3'
p474
S'increases'
p475
tp476
(lp477
s(S'FOXD1'
p478
S'CYP26A1'
p479
S'increases'
p480
tp481
(lp482
s(S'Antigen/IgE/Fc epsilon R1/LYN/SYK'
p483
S'VAV1'
p484
S'adds_modification'
p485
tp486
(lp487
s(S'PCBP1'
p488
S'MEIS1'
p489
S'increases'
p490
tp491
(lp492
s(S'FOXI1'
p493
S'FOXD3'
p494
S'increases'
p495
tp496
(lp497
s(S'GATA4'
p498
S'MEIS1'
p499
S'increases'
p500
tp501
(lp502
s(S'STAT5B'
p503
S'CEBPG'
p504
S'increases'
p505
tp506
(lp507
s(S'TFDP2'
p508
S'MAZ'
p509
S'increases'
p510
tp511
(lp512
s(S'PI3K'
p513
S'SHP2'
p514
S'binds'
p515
tp516
(lp517
S'D) Immunoprecipitation and immunostaining analysis of c-Cbl, Grb2, Shc, Gab1, p85 (PI3K) and SHP2 interaction with EGFR and EGFR:HER2.'
p518
aS'Note that the interaction of Grb2 and Shc was higher in the control cells and lower in the HER2 cells, and the opposite was true for Gab1, p85 (PI3K) and SHP2.'
p519
as(S'SPI1'
p520
S'ONECUT1'
p521
S'increases'
p522
tp523
(lp524
s(S'STAT6'
p525
S'EN1'
p526
S'increases'
p527
tp528
(lp529
s(S'TLX2'
p530
S'CYP26A1'
p531
S'increases'
p532
tp533
(lp534
s(S'RAF1'
p535
S'MEK1-2'
p536
S'increases_activity'
p537
tp538
(lp539
s(S'STAT5A'
p540
S'IRF1'
p541
S'increases'
p542
tp543
(lp544
s(S'2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine'
p545
S'HRAS MRNA'
p546
S'increases'
p547
tp548
(lp549
s(S'MAZ'
p550
S'POU2F1'
p551
S'increases'
p552
tp553
(lp554
s(S'MAZ'
p555
S'SRF'
p556
S'increases'
p557
tp558
(lp559
s(S'GATA1'
p560
S'JUN'
p561
S'increases'
p562
tp563
(lp564
s(S'FOXA1'
p565
S'NRAS'
p566
S'increases'
p567
tp568
(lp569
s(S'STAT1'
p570
S'EN1'
p571
S'increases'
p572
tp573
(lp574
s(S'GTF2A2'
p575
S'MAX'
p576
S'increases'
p577
tp578
(lp579
s(S'LMO2'
p580
S'EN1'
p581
S'increases'
p582
tp583
(lp584
s(S'MYOD1'
p585
S'LEF1'
p586
S'increases'
p587
tp588
(lp589
s(S'ATF3'
p590
S'JUN'
p591
S'increases'
p592
tp593
(lp594
S'c-jun, JUNB, JUND, ATF2, ATF3/LRF1, B-ATF, JDP1, JDP2, c-Maf, MafB, MafA, MafG/F/K, Nrl, c-fos, Fra-1, Fra-2, FOSL or FosB.'
p595
as(S'GRB2:SOS1'
p596
S'ACTIVATED FGFR:P-SHC1'
p597
S'binds'
p598
tp599
(lp600
s(S'MAFG'
p601
S'BACH1'
p602
S'increases'
p603
tp604
(lp605
s(S'POU3F2'
p606
S'POU2F1'
p607
S'increases'
p608
tp609
(lp610
s(S'K 7174'
p611
S'KRAS MRNA'
p612
S'increases'
p613
tp614
(lp615
s(S'POU1F1'
p616
S'RUNX1'
p617
S'increases'
p618
tp619
(lp620
s(S'HRAS protein'
p621
S'CCND1 MRNA'
p622
S'increases'
p623
tp624
(lp625
s(S'YY1'
p626
S'EN1'
p627
S'increases'
p628
tp629
(lp630
s(S'resveratrol'
p631
S'HRAS MRNA'
p632
S'increases'
p633
tp634
(lp635
s(S'NKX2-1'
p636
S'HOXA9'
p637
S'increases'
p638
tp639
(lp640
s(S'HSF1'
p641
S'CYP26A1'
p642
S'increases'
p643
tp644
(lp645
s(S'MYC'
p646
S'HOXA9'
p647
S'increases'
p648
tp649
(lp650
s(S'Raf'
p651
S'MEK'
p652
S'adds_modification'
p653
tp654
(lp655
S'Ras activates serine/threonine protein kinase Raf, which in turn activates another serine/threonine protein kinase MEK that triggers MAPK.'
p656
aS'Raf, MEK, and MAPK are considered mitogen-activated kinases.'
p657
aS'Classic downstream pathways of the EGFR signal pathway are Ras/Raf/MEK/ERK/MAPK and PI3K/PDK1/Akt (protein kinase B [PKB]),'
p658
aS'Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor that targets the mitogen-activated protein kinase pathway or the Raf/MEK/ERK pathway.'
p659
aS'The Ras-Raf-MEK pathway and the phosphoinositide-3 kinase (P13K)-Akt pathway are the key regulators of cell proliferation.'
p660
aS'Studies have shown that there is a link between aberrant PI(3)K-Akt-mTOR and Ras-Raf-MEK-Erk1/2 signaling in PanNETs.'
p661
aS'Activation of the VEGF receptor leads to signaling via the Ras/Raf/MEK/ERK pathway.'
p662
aS'Sorafenib acts by inhibiting the activity of c-Raf and B-Raf; vascular endothelial growth factor receptors (VEGFR); the mitogen-activated protein kinases MEK and ERK; and platelet derived growth factor receptors (PDGFR).'
p663
aS'A consequence of doxorubicin treatment may be the induction of the Raf/MEK/ERK pathway which may have some anti-apoptotic effects ['
p664
aS'The schematic overview shows that IL-6 family cytokines activate the three major signaling pathways Jak/STAT, Ras/Raf/MEK/ERK, and Akt/PI3K.'
p665
aS'There is a growing body of evidence that bFGF promotes cancer cell proliferation through the activation of the Ras/Raf/MEK/ERK pathway ['
p666
aS'The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways are often activated by mutations within individual components of these pathways, as well as the aberrant activation of upstream growth factor receptors.'
p667
aS'Both studies indicated that sensitivity to inhibitors was often linked with genetic mutations at key elements in the Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and some other pathways.'
p668
aS'Sensitivity to MEK and Raf inhibitors was often investigated in these studies.'
p669
aS'Effective inhibitors specific for many of the key components of the Ras/Raf/MEK/ERK/MNK, Ras/PI3K/PTEN/mTOR and other pathways have been developed.'
p670
aS'The p21-activated protein kinase 1 (PAK1) kinase also interacts with the Ras/Raf/MEK/ERK and the PI3K/PTEN/Akt/mTOR cascades.'
p671
aS'Neurofibromin normally can regulate cell motility often via the Ras/Raf/MEK/ERK cascade by an interaction of the Ras GTPase-activating protein-related domain (GRD) present on Neurofibromin.'
p672
aS'The PIM kinases can also interact with the EGFR/Ras/Raf/MEK/ERK pathway and certain PIM kinase inhibitors will induce the '
p673
aS'It has been proposed that targeting of both Raf and MEK or Raf and ERK may be useful in certain cancer therapies ['
p674
aS'The Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR, Wnt/beta-catenin, Notch, Hedgehog and other pathways are being shown to play key roles in cancer initiating cells (CICs) and leukemia initiating cells (LIC).'
p675
aS'Both the PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways can interact with the p53 pathway at various levels.'
p676
aS'IGF-1R = Insulin-like Growth Factor-1 Receptor, PI3 k = phosphatidylinositol 3 kinase, mTOR = mammalian target of rapamycin, S6RP = S6 ribosomal protein, 4EBP1 = eukaryotic initiation factor 4E (elF-4E) binding protein-1, Ras = rat sarcoma, Raf = rapidly accelerated fibrosarcoma, MEK = mitogen/extracellular signal-regulated kinase, Erk = extracellular signal regulated kinase.'
p677
aS'The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK).'
p678
aS'Before we discuss the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR signaling cascades, it is important to define some genetic terms as they are critical to understanding the importance of these pathways and the classes of genes and mutations that occur in components of these cascades.'
p679
aS'This event can result in the activation of many downstream signaling cascades including the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways.'
p680
aS'Regulation of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways is mediated by a series of kinases, phosphatases, GTP:GDP exchange and scaffolding proteins.'
p681
aS'Activation of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways can occur by upstream mutations in growth factor receptors or by mutations in upstream kinases and coupling molecules.'
p682
aS'Genes in the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways that have activating mutations detected in human cancer and proliferative diseases are indicated in red ovals.'
p683
aS'Raf phosphorylates and activates the mitogen-activated protein kinase kinase-1 (MEK1) (a dual specificity kinase (T/Y) on S/T residues ['
p684
aS'ERK can phosphorylate members of the Ras/Raf/MEK/ERK pathway and even upstream EGFR.'
p685
aS'The Raf/MEK/ERK pathway exhibits properties of a negative feedback amplifier (NFA).'
p686
aS'These properties of the Raf/MEK/ERK NFA are important in determining activation kinetics, response to drugs and various other downstream effects of activated ERK ['
p687
aS'These examples of feed-back loops become important in consideration of whether to just target MEK or to target both Raf and MEK in various cancers.'
p688
aS'There are numerous scaffolding/chaperonin proteins which interact with various components of the Raf/MEK/ERK cascade ('
p689
aS'Thus the Ras/Raf/MEK/ERK pathway is important in determining cellular shape and mobility/invasion.'
p690
aS'Thus the reader begins to understand how the Ras/Raf/MEK/ERK pathways can regulate the expression of many genes involved in the response to growth factors and mitogens.'
p691
aS'An overview of the effects of the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways on key regulatory pathways is presented in Figure '
p692
aS'One central molecule involved in cell growth is p70S6K which is regulated by both the Ras/PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways ['
p693
aS'In this review, we have discussed the various types of mutations which occur in the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathways and how they can lead to cancer as well as other diseases.'
p694
aS'Some scientists and clinicians have considered that the simultaneous targeting of Raf and MEK by individual or dual inhibitors may be more effective in cancer therapy than just targeting Raf or MEK by themselves.'
p695
aS'This is based in part on the fact that there are intricate feed-back loops from ERK which can inhibit Raf and MEK.'
p696
aS'This is a rationale for treatment with both MEK and Raf inhibitors or dual inhibitors.'
p697
aS'Finally, an emerging concept is the targeting of two different signal transduction pathways, Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR for example.'
p698
aS'Sometimes dysregulated expression of growth factor receptors occurs by increased expression, genetic translocations or genomic amplifications which can lead to activation of the Ras/Raf/MEK/ERK, Ras/PI3K/PTEN/Akt/mTOR and other signaling pathways.'
p699
aS'Genes in the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways that have activating mutations detected in human cancer and proliferative diseases are indicated in red ovals and squares.'
p700
aS'NF1 normally serves to regulate Ras and thus is implicated in the regulation of both the PI3K/PTEN/Akt/mTORC1 and Raf/MEK/ERK pathways.'
p701
aS'Targeting signaling molecules involved with the PI3K/PTEN/Akt/mTORC1 and Raf/MEK/ERK pathways may be appropriate to overcome resistance to chemo- and hormonal therapy.'
p702
aS'The Raf/MEK/ERK pathway is also important in breast cancer drug resistance ['
p703
aS'The Ras/Raf/MEK/ERK pathway also interacts with key proteins involved in protein translation (indicated in green ovals).'
p704
aS'Further studies indicated that cross-talk between ERalpha+ and Raf/MEK/ERK signaling pathways is a key oncogenic axis which is responsible in part for the development of ER-independent growth of breast cancers which were initially ERalpha+ and hormone sensitive.'
p705
aS'The Ras/Raf/MEK/ERK pathway also interacts with key proteins involved in protein translation (indicated in green ovals).'
p706
aS'These cells did not express activated HER2, but they did express the PI3K/PTEN/Akt/mTORC and Raf/MEK/ERK pathways which is believed to be due to activated Src family members.'
p707
aS'The possibility of targeting mTORC1 and other signaling pathways such as Raf/MEK/ERK, PI3K, IGF-1R to treat breast cancer is also being examined ['
p708
aS'ROS can induce the calcium calmodulin kinase (CaM-K) cascade which can induce Ras which can subsequently activate both the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades (most components of the two cascades which promote signaling are show in green ovals, transcription factors activated by events are shown in yellow diamonds, transcription factors inactivated by events shown in black diamonds).'
p709
aS'Induction of the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways can result in the activation of many survival pathways, and regulate both cell cycle progression as well as protein translation.'
p710
aS'The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK).'
p711
aS'Effective inhibitors specific for many of the key components of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/mTOR pathways have been developed ['
p712
aS'Raf inhibitors have in general exhibited greater response rates in clinical trails than MEK inhibitors which may be related to the broader therapeutic index of Raf inhibitors that suppress ERK activity in a mutant-allele specific fashion as opposed to MEK inhibitors which suppress MEK activity in tumor and normal cells ['
p713
aS'Sites of mutation which result in sensitivity to Raf and MEK inhibitors are indicated in red irregular circles.'
p714
aS'The tumor microenviroment can secrete growth factors such as hepatocyte growth factor (HGF) which results in activation of the HGF receptor MET and subsequent downstream Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling which results in resistance to the small molecule inhibitors ['
p715
aS'An advantage of targeting MEK is that the Ras/Raf/MEK/ERK pathway is a convergence point where a number of upstream signaling pathways can be blocked with the inhibition of MEK.'
p716
aS'Recently a dual B-Raf/Raf-1 and MEK inhibitor has been described ['
p717
aS'The possibility of treating certain patients with a Raf and a MEK inhibitors is a concept which is gaining more acceptance as it may be a therapeutic possibility to overcome resistance ['
p718
aS'There are at least two ERK molecules regulated by the Raf/MEK/ERK cascade, ERK1 and ERK2.'
p719
aS'Previously, we have predominantly discussed studies that employed a single Raf or MEK inhibitor, sometimes in combination with a chemotherapeutic drug.'
p720
aS'Combinations of Raf and PI3K/mTOR or MEK and PI3K/mTOR inhibitors are in clinical trials.'
p721
aS'Chemotherapeutic drugs can activate the Ras/Raf/MEK/ERK pathway by diverse mechanisms.'
p722
aS'Drugs such as doxorubicin can activate p53 which can lead to increased expression of the discoidin domain receptor (DDR), which in turn can result in Raf/MEK/ERK pathway activation.'
p723
aS'As mentioned previously, a side effect of some chemotherapeutic drugs, such as paclitaxel, is the induction of the Raf/MEK/ERK pathway.'
p724
aS'Also the PI3K/PTEN/Akt/mTOR pathway can modulate the Raf/MEK/ERK pathway and altering MEK activity can have opposing effects on different cell types ['
p725
aS'A side effect of radiotherapy in some cells is induction of the Ras/Raf/MEK/ERK cascade ['
p726
aS'Inhibitors to the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways have been isolated and developed by various screening approaches and then in some cases modified by medicinal chemistry.'
p727
aS'However, MEK inhibitors may have limited effectiveness in treating human cancers, unless the particular cancer proliferates directly in response to the Raf/MEK/ERK pathway.'
p728
aS'Some scientists and clinicians have considered that the simultaneous targeting of Raf and MEK by individual inhibitors may be more effective in cancer therapy than just targeting Raf or MEK by themselves.'
p729
aS'This is based in part on the fact that there are intricate feed-back loops from ERK which can inhibit Raf and MEK.'
p730
aS'This is a rationale for treatment with either dual Raf/MEK inhibitors or simultaneously with both Raf and MEK individual inhibitors.'
p731
aS'Finally, an emerging concept is the dual targeting of two different signal transduction pathways, Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR for example.'
p732
aS'For example, cancer researchers predominantly feel that Raf, MEK, PI3K, Akt and mTOR inhibitors will suppress the growth of malignant cancer cells.'
p733
aS'Recently it has been observed that the suppression of the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathways may prevent the induction of cellular senescence and aging.'
p734
aS'Dimerization results in auto-phosphorylation of EGFR with the subsequent activation of a number of downstream signaling pathways, including the PI3K/Akt/mTOR and the Ras/Raf/MEK/ERK pathways (Figure '
p735
aS'The Ras/Raf/MEK/ERK pathway, also known as the MAPK (mitogen-activated protein kinase) pathway, is a signaling pathway consisting of a kinase cascade regulated by phosphorylation and de-phosphorylation by specific kinases and phosphatases as well as GTP/GDP exchange proteins, adaptor proteins and scaffolding proteins (Figure '
p736
aS'Deregulation of the Ras/Raf/MEK/ERK pathway plays a key role in the pathogenesis of several human cancers ['
p737
aS'Other well known risk factors for HCC such as HBV and HCV infection also seem to utilize the Raf/MEK/ERK pathway for the control of hepatocyte survival and viral replication ['
p738
aS'Activation of Ras/Raf/MEK/ERK signaling in HCC may result from up-regulation of IGF ['
p739
aS'In addition to Raf inhibition, preclinical studies have demonstrated the potential of MEK inhibition to suppress hepatoma cell proliferation and tumorigenicity ['
p740
aS'Moreover, Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) 1/2 signaling positively regulates mTORC1 activity, as both ERK 1/2 and p90 ribosomal S6 kinase (p90'
p741
aS'To study the molecular events resulting from treatment with celastrol and its derivatives, we detected the levels and phosphorylation status of several HSP90/CDC37 client protein kinases that are known to be highly activated in HCC, including the Raf family proteins, AKT, MEK1/2, CDK4, and EGFR.'
p742
aS'For example, acquired drug resistance to sorafenib (targeting angiogenesis and Raf/MEK/ERK signaling pathways) have been attributed to the activation of PI3K/AKT and EGFR ['
p743
aS'Although RKIP was best studied for its inhibition of Raf-initiated activation of MEK ['
p744
aS'Two pathways that are often upregulated in chemo- and hormonal-resistance are the PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways.'
p745
aS'These results indicate that up regulation of the Ras/PI3K/PTEN/Akt/mTOR pathway in the presence of elevated Ras/Raf/MEK/ERK signaling together can contribute to drug-resistance by diminishing cell senescence in response to chemotherapy.'
p746
aS'In addition to deregulation of the PI3K/mTOR pathway, the Ras/Raf/MEK/ERK pathway plays a critical role in cellular transformation and drug resistance.'
p747
aS'In the following study, we examined the effects of activated PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways on the induction of cellular senescence in response to chemo-/hormonal therapy.'
p748
aS'Our results suggest that deregulation of PI3K/PTEN/Akt/mTOR, and to a lesser extent the Ras/Raf/MEK/ERK pathway, decreases drug-induced cellular senescence in response to chemo-/hormonal therapy.'
p749
aS'Since we observed elevated activated ERK1/2 expression in MCF7/DoxR cells, the activity of the Raf/MEK/ERK cascade was manipulated in MCF-7 cells in order to determine whether signals transduced by this pathway control the induction of drug-induced senescence.'
p750
aS'Together, these results suggest that presence activated PI3K/PTEN/Akt/mTOR pathway in the presence of acquired drug resistant Raf/MEK/ERK pathway activation is sufficient to block drug-induced senescence to both doxorubicin and 4HT.'
p751
aS'Doxorubicin induces the Raf/MEK/ERK pathway in MCF-7 cells and higher levels of active ERK are detected in MCF7/DoxR cells than in drug sensitive MCF-7 cells.'
p752
aS'Taken together with the results observed with MCF7/DoxR cells, which express high levels of activated ERK, it is likely that increased levels of the Raf/MEK/ERK pathway does not inhibit the induction of cellular senescence induced by either 4HT or doxorubicin.'
p753
aS'In some cases, the Ras/Raf/MEK/ERK pathway may induce cellular senescence ['
p754
aS'SkE also abrogated MEK1/2 and B-Raf phosphorylation but had no effect on Ras activity.'
p755
aS'Importantly, SkE resensitized the PLX-4032-resistant 451Lu melanoma cell line (451Lu-R) and was more efficient than U0126, a MEK inhibitor, and PLX-4032 (PLX) at inducing the apoptosis of two Hairy Cell Leukemia (HCL) patient samples carrying the B-Raf-V600E mutation.'
p756
aS'The Ras/Raf/MEK/ERK pathway is frequently altered in cancer cells, and mutations in this pathway are recurrent in several hematopoietic and non-hematopoietic malignancies ['
p757
aS'The Ras/Raf/MEK/ERK cascade is a very attractive target in cancer therapy.'
p758
aS'Of note, SkE was highly efficient in cells exhibiting constitutive activation of the Ras/Raf/MEK/ERK pathway.'
p759
aS'We next sought to identify the specific point in the Ras/Raf/MEK/ERK pathway affected by SkE in different cellular models with either constitutive or inducible MAPK kinase activation.'
p760
aS'Importantly, SkE impaired the activities of both MEK and B-Raf.'
p761
aS'Consistent with our data, recent studies have shown that TRAIL-resistant cells were sensitized by combinatorial treatment of TRAIL with cetuximab (an anti-EGFR monoclonal antibody) or sorafenib (a multi-kinase inhibitor that acts on Raf kinases, MEK, and ERK signaling) in different cancer cell lines and tumor xenograft models ['
p762
aS'MEK1 and MEK2 are kinases that link the cascade between Raf and ERK, and their inactive unphosphorylated forms (u-MEK1/2) become phosphorylated (p-MEK1/2) and hence activated by Raf kinase.'
p763
aS'In this paper, we further describe how this characteristic of JTP-74057 is relevant to its very potent and prolonged inhibition of Raf-MEK-ERK signaling in cancer cells.'
p764
aS'To address the effects of JTP-74057 on MEK kinase activity, we examined its ability to inhibit various enzymatic reactions of Raf, MEK and ERK, relative to that of PD0325901.'
p765
aS'B-Raf (V600E), active Raf-1 (truncated), active MEK1, inactive MEK1, active MEK2, inactive MEK2, inactive MAPK2/ERK2 and bovine MBP were purchased from Upstate Technology (Waltham, MA).'
p766
aS'The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK).'
p767
aS'Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways play key roles in the regulation of normal and malignant cell growth.'
p768
aS'The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR signaling cascades have been extensively studied over the past few decades.'
p769
aS'Signaling through the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways are carefully orchestrated events generally starting from the cell surface and leading to controlled gene expression within the nucleus.'
p770
aS'Sometimes dysregulated expression of growth factor receptors occurs by increased expression, genetic translocations or genomic amplifications which can lead to activation of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways.'
p771
aS'Genes in the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways that have activating mutations detected in human cancer and proliferative diseases are indicated in blue ovals.'
p772
aS'A: The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways are both activated by upstream receptor ligation and frequently co-regulate many downstream targets in parallel.'
p773
aS'C. As described previously, both the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways regulate the activity of apoptotic proteins by post-translational mechanisms.'
p774
aS'Effective inhibitors specific for many of the key components of the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/mTOR pathways have been developed ['
p775
aS'An advantage of targeting MEK is that the Ras/Raf/MEK/ERK pathway is a convergence point where a number of upstream signaling pathways can be blocked with the inhibition of MEK.'
p776
aS'There are at least two ERK molecules regulated by the Raf/MEK/ERK cascade, ERK1 and ERK2.'
p777
aS'Furthermore, the negative side effects of mTOR inhibition on the activation of the Raf/MEK/ERK pathway might be alleviated with the PI3K inhibitor activity in the dual inhibitor.'
p778
aS'Previously, we have predominantly discussed studies that employed a single Raf or MEK inhibitor, sometimes in combination with a chemotherapeutic drug.'
p779
aS'The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways can interact at many different levels.'
p780
aS'Chemotherapeutic drugs such as Doxorubicin and Docetaxel may also induce the Raf/MEK/ERK pathway which may contribute to emergence of drug resistant clones.'
p781
aS'The Raf/MEK/ERK pathway may regulate downstream transcription factors such as GATA-1 which control the transcription of genes such as XRCC1 and ERCC1 which are involved in DNA repair and their aberrant expression may contribute to drug resistance.'
p782
aS'As mentioned previously, a side effect of some chemotherapeutic drugs, such as paclitaxel, is the induction of the Raf/MEK/ERK pathways.'
p783
aS'Also the PI3K/PTEN/Akt/mTOR pathway can modulate the Raf/MEK/ERK pathway and altering MEK activity can have opposing effects on different cell types ['
p784
aS'A side effect of radiotherapy in some cells is induction of the Ras/Raf/MEK/ERK cascade ['
p785
aS'An overview of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in some of novel aspects of their usage is presented in Figure '
p786
aS'The Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways also play critical roles in the regulation of cellular senescence and quiescence ['
p787
aS'While we have discussed the roles of these pathways in cancer in significant detail, an additional important aspect of targeting the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways is to halt cellular aging, which in the end, kills all those who either do not have or have been fortunate to survive cancer and other diseases.'
p788
aS'Various pharmaceutical companies have developed inhibitors to the Ras/Raf/MEK/ERK pathway.'
p789
aS'However, these inhibitors may have limited effectiveness in treating human cancers, unless the particular cancer proliferates directly in response to the Raf/MEK/ERK pathway.'
p790
aS'Mutations at many of the upstream receptor genes or Ras can result in abnormal Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathway activation.'
p791
aS'If the tumor exhibits a dependency on the Ras/Raf/MEK/ERK pathway, then it may be sensitive to Raf and MEK inhibitors.'
p792
aS'In contrast, tumors that do not display enhanced expression of the Ras/Raf/MEK/ERK pathway may not be sensitive to either Raf or MEK inhibitors but if the Ras/PI3K/Akt/mTOR pathway is activated, it may be sensitive to specific inhibitors that target this pathway.'
p793
aS'Some scientists and clinicians have considered that the simultaneous targeting of Raf and MEK by individual inhibitors may be more effective in cancer therapy than just targeting Raf or MEK by themselves.'
p794
aS'This is based in part on the fact that there are intricate feed-back loops from ERK which can inhibit Raf and MEK.'
p795
aS'This is a rationale for treatment with both MEK and Raf inhibitors.'
p796
aS'Finally, an emerging concept is the dual targeting of two different signal transduction pathways, Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR for example.'
p797
aS'For example, cancer researchers predominantly feel that Raf, MEK, PI3K, Akt and mTOR inhibitors will suppress the growth of malignant cancer cells.'
p798
aS'Recently it has been observed that the suppression of the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathways may prevent the induction of cellular senescence and aging.'
p799
aS'Recent findings suggest that eIF4E activity is a key determinant of the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK mediated tumorigenic activity and targeting eIF4E should have a major impact on these pathways in human cancer.'
p800
aS"Such inhibitor compounds will serve as chemical biology tools for pharmacological target validation in terms of Mnk's role in regulation of Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways in cancers, as well as their functions required for normal physiological process."
p801
aS'However, both mTORC1 and eIF4B are targeted also by the Ras/Raf/MEK/ERK pathway.'
p802
aS'(B) Phosphorylation of Raf-1, MEK1/2 and ERK1/2 in SK-OV-3, OVCAR3 and A2780 cells infected with shRASAL2-1, shRASAL2-2 or scramble-shRNA was analyzed by Western blot.'
p803
aS'Xenograft tumor sections (SK-OV-3) were also examined for levels of p-ERK by IHC (C) and for p-Raf-1 and p-MEK by Western blot (D).'
p804
aS'MEK1 and MEK2 are activated by phosphorylation catalyzed by Raf family kinases.'
p805
aS'Many studies have shown that drugs targeting the S1P pathway can modulate crucial pro-survival signaling cascades such as PI3K/Akt/mTOR and Ras/Raf/MEK/ERK ['
p806
aS'A key Ras effector pathway is the mitogen-activated protein kinase (MAPK), Raf-MEK-ERK pathway.'
p807
aS'Active Raf dimer phosphorylates and activates mitogen-activated protein kinase kinase 1 and 2 (MEK1/2), which induces ERK1/2 activation.'
p808
aS'PIP3 embedded in cellular membranes recruits the PH-domain containing protein Gab1, which in turn recruits PI3K and at the same time binds to Shp2 (Src homology 2 domain-containing protein tyrosine phosphatase) to promote the activation of Ras-Raf-MEK1/2-Erk1/2 pathway['
p809
aS'We next decided to dissect the nodal protein(s) in the canonical Raf-MEK1/2-Erk1/2-RSK and PI3K-Akt-mTOR pathways contributing to inhibition of Erk1/2 phosphorylation by X-370 using a panel of pharmacological inhibitors to interrogate the key pathway components.'
p810
aS'Signaling dynamics are often influenced positively or negatively by an interplay between Ras-Raf-MEK-Erk and PI3K-Akt-mTOR pathways the two pathways ['
p811
aS'Apart from the Ras/Raf/MEK/ERK/MNK pathway, effective inhibitors specific for many of the key components of the Ras/PI3K/PTEN/mTOR have also been developed since both of these pathways are often implicated in therapeutic resistance and interact with other pathways ['
p812
aS'The p21-activated protein kinase 1 (PAK1) also interacts with the Ras/Raf/MEK/ERK and the PI3K/PTEN/Akt/mTOR cascades.'
p813
aS'The GRD domain inhibits the Ras-dependent pathway, which controls Raf-MEK-Erk-dependent gene expression and the motility and spreading of NF1'
p814
aS'We will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mTORC1, Ras/Raf/MEK/ERK, Wnt/beta-catenin, Hedgehog, Notch and others.'
p815
aS'Some of the regulatory interactions between GSK-3 and Ras/PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways are indicated.'
p816
aS'This figure is provided to give the reader an idea of the complex interactions of GSK-3 with various signaling molecules in the Ras/PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways which are key in regulating cellular proliferation survival and often become dysregulated in cancer.'
p817
aS'Expression of HBx in hepatocytes activates the Ras/Raf/MEK/ERK signaling cascade.'
p818
aS'Interestingly, cross-talk between the Ras/Raf/MEK/ERK and Wnt/beta-catenin signaling has been observed in hepatoma cells ['
p819
aS'GSK-3 also interacts with the Raf/MEK/ERK, Hh, Notch, and other important regulatory pathways.'
p820
aS'In ERK pathway, ERK is a downstream target of ERK kinase (MEK) which can be activated by Raf serine/threonine kinases ['
p821
aS'Sorafenib is an oral multi-target inhibitor of the Raf-1 and B-Raf kinases, which are members of the Raf/MEK/ERK signaling pathway.'
p822
aS'it was demonstrated that the differentiation of monocytes into immature DC was accompanied by activation of the Raf/MEK/ERK and PI3K/AKT signaling pathways, whereas p38 MAPK was identified as a negative regulator of DC differentiation.'
p823
aS'The Raf/MEK/ERK (Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase) pathway plays a critical role in cell proliferation, apoptosis and malignant transformation ['
p824
aS'RKIP plays important role in cancer cell growth, apoptosis and transformation by affecting several protein kinase signaling cascades such as Raf/MEK/ERK, G-protein signaling and NF-kappaB signalling ['
p825
aS'These pathways include the PI3-kinase/Akt, Raf/MEK/ERK and mTOR pathways ['
p826
aS'Current molecular strategies involve interrupting intracellular signal transduction pathways at specific targets, such as B-Raf, Ras, MEK, PI3K, RET, cMet, and epidermal growth factor ['
p827
aS'By binding to Raf-1 or MEK, RKIP interferes with MEK activation by Raf-1, thus inhibiting ERK activation ('
p828
aS'The Raf/MEK/ERK signaling pathway is downstream of Ras activation, and tyrosine phosphorylation of these signaling molecules is essential to cancer cell proliferation ('
p829
aS'The AC5 KO model of aging protects against oxidative stress by reducing cAMP and protein kinase A (PKA), which in turn activates the Raf/MEK/ERK pathway, which increases MnSOD and protects against oxidative stress ['
p830
aS'We previously found that AC5 KO increases longevity and stress resistance via activation of the Raf/MEK/ERK signaling pathway ['
p831
aS'Inhibition of AC5 activates SIRT1/FoxO3a and Raf/MEK/ERK pathways, and both pathways upregulate the antioxidant, MnSOD, resulting in resistance to oxidative stress during aging.'
p832
aS'Growth factors and mitogens use the Ras/Raf/MEK/ERK signaling cascade to transmit signals from their receptors to regulate gene expression and prevent apoptosis in normal condition.'
p833
aS'Aberrant Ras/Raf/MEK/ERK signaling is one of the most prevalent oncogenic alterations and confers survival advantage to tumor cells.'
p834
aS'The Ras/Raf/MEK/ERK pathway is aberrantly activated in most tumor cells due to '
p835
aS'Sorafenib is the first FDA-approved multi-kinase inhibitor drug that targets the Ras/Raf/MEK/ERK pathway, which is aberrantly activated in a majority of cancers due to '
p836
aS'Evident in our data is the separation of tumor size and the ability to metastasize (i.e., B-Raf, Tpl2, MEKK3).'
p837
aS'MEK inhibitors induce epidermal growth factor-induced AKT activation, ERK phosphorylates TSC2 and RAPTOR to promote TORC1 activity, and AKT can phosphorylate Raf at inhibitory sites that negatively regulate MEK activity ('
p838
aS'Characterization of the negative effect of ATF2 on transformation by v-Rel revealed a novel role for ATF2 in the regulation of the Ras-Raf-MEK-ERK signaling pathway.'
p839
aS'Although ATF2 inhibited v-Rel-induced activation of the Ras-Raf-MEK-ERK pathway, the overexpression of ATF2 alone in DT40 cells resulted in the slight activation of Ha-Ras ('
p840
aS'In fibroblasts, the overexpression of ATF2 (in the absence or presence of v-Rel) blocked the activation of c-Raf, MEK1/2, and ERK.'
p841
aS'However, in the DT40 B-cell line, overexpression of ATF2 in the absence of v-Rel increased Ha-Ras activity and phosphorylated c-Raf (Ser338) levels whereas phospho-MEK1/2 and phospho-ERK levels were found to be decreased.'
p842
aS'Our results suggest that negative regulation of c-Raf activity is responsible for the reduced levels of phosphorylated MEK1/2 and ERK.'
p843
aS'Our results indicate that ATF2 can regulate the Ras-Raf-MEK-ERK pathway at multiple steps.'
p844
aS'Model for the regulation of Ras-Raf-MEK-ERK pathway by v-Rel and ATF2.'
p845
aS'We next examined the importance of the PI3K/AKT and Raf/MEK/ERK pathways for ductal cyst formation in Het/Kras mice.'
p846
aS'A similar analysis was performed on the Raf/MEK/ERK pathway.'
p847
aS'The downstream effectors of BCR-ABL include the JAK/signal transducer and activator of transcription, Raf/MEK/extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase/AKT/mammalian target of rapamycin (mTOR) pathways, all of which affect cell viability, cell-cycle progression and leukemogenesis ('
p848
aS'In melanoma, the Ras-Raf-MEK-ERK (MAPK) signaling pathway is constitutively activated through multiple mechanisms, including '
p849
aS'In melanoma, the Ras-Raf-MEK-ERK (MAPK) signaling pathway is constitutively activated through multiple mechanisms.'
p850
aS'The Raf/MEK/MAPK cascade is a crucial signaling pathway for the development of CCA ('
p851
aS'Both the PI3K/Akt and Raf/MEK/ERK pathways are downstream of EGFR activation.'
p852
aS'There was strong rational for this approach since sorafenib targets EGFR-Ras-Raf-MEK-ERK signaling pathway as well as angiogenesis.'
p853
aS'Inhibitors for p38MAPK (SB202190, #559388), MEK1/2 (PD98059, #513000, or U0126, #662005), and Raf1 (5-iodo-3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-2-indolinone, #553008) were from Calbiochem.'
p854
as(S'TFDP1'
p855
S'MAZ'
p856
S'increases'
p857
tp858
(lp859
s(S'SPRED1'
p860
S'HRAS'
p861
S'binds'
p862
tp863
(lp864
s(S'MYCN'
p865
S'CYP26A1'
p866
S'increases'
p867
tp868
(lp869
s(S'AHR'
p870
S'FOXD3'
p871
S'increases'
p872
tp873
(lp874
s(S'SF1'
p875
S'CYP26A1'
p876
S'increases'
p877
tp878
(lp879
s(S'MEIS1'
p880
S'ETS1'
p881
S'increases'
p882
tp883
(lp884
s(S'Copper Sulfate'
p885
S'HRAS MRNA'
p886
S'decreases'
p887
tp888
(lp889
s(S'MAZ'
p890
S'MYC'
p891
S'increases'
p892
tp893
(lp894
s(S'E4F1'
p895
S'HOXA9'
p896
S'increases'
p897
tp898
(lp899
s(S'GATA1'
p900
S'GATA6'
p901
S'increases'
p902
tp903
(lp904
S'GATA1, GATA2 and GATA3 from the GATA transcription factor family are involved in cellular lineage and hematopoietic development while GATA4, GATA5 and GATA6 are involved in epithelial and endodermal differentiations ('
p905
as(S'RUNX2'
p906
S'POU2F1'
p907
S'increases'
p908
tp909
(lp910
s(S'CYP26A1'
p911
S'GATA6'
p912
S'increases'
p913
tp914
(lp915
s(S'PAX4'
p916
S'GATA1'
p917
S'increases'
p918
tp919
(lp920
s(S'ELF2'
p921
S'STAT5A'
p922
S'increases'
p923
tp924
(lp925
s(S'CART1'
p926
S'NRAS'
p927
S'increases'
p928
tp929
(lp930
s(S'IGF-1R heterotetramer/IGF1/GRB2/Sos/Shc'
p931
S'HRAS/GDP'
p932
S'increases_activity'
p933
tp934
(lp935
s(S'RB1'
p936
S'CYP26A1'
p937
S'increases'
p938
tp939
(lp940
s(S'CEBPG'
p941
S'HOXA9'
p942
S'increases'
p943
tp944
(lp945
s(S'GRB2/SOS1/SHC'
p946
S'IGF-1R HETEROTETRAMER/IGF1'
p947
S'binds'
p948
tp949
(lp950
s(S'PRRX2'
p951
S'CYP26A1'
p952
S'increases'
p953
tp954
(lp955
s(S'TEAD1'
p956
S'CYP26A1'
p957
S'increases'
p958
tp959
(lp960
s(S'STAT5A'
p961
S'FOXA1'
p962
S'increases'
p963
tp964
(lp965
s(S'ATF2'
p966
S'FOXD3'
p967
S'increases'
p968
tp969
(lp970
s(S'REPIN1'
p971
S'FOXO4'
p972
S'increases'
p973
tp974
(lp975
s(S'FOXF2'
p976
S'ETS1'
p977
S'increases'
p978
tp979
(lp980
s(S'ETV7'
p981
S'MEIS1'
p982
S'increases'
p983
tp984
(lp985
s(S'RUNX2'
p986
S'RUNX1'
p987
S'increases'
p988
tp989
(lp990
S'Coexpression of Myc-RUNXs with HA-PIAS1 and FLAG-SUMO1 resulted in band shifts of RUNX1 and RUNX2 as well as RUNX3, suggesting that all three RUNXs are target of PIAS1-mediated sumoylation ('
p991
aS'Furthermore, we showed that dPias/PIAS1 sumoylates lz/RUNXs at K144 of RUNX1, K187 of RUNX2, K148 of RUNX3 and K372 of lz.'
p992
as(S'OR5I1'
p993
S'GATA1'
p994
S'increases'
p995
tp996
(lp997
s(S'MSX1'
p998
S'EN1'
p999
S'increases'
p1000
tp1001
(lp1002
s(S'GTF3A'
p1003
S'IRF1'
p1004
S'increases'
p1005
tp1006
(lp1007
s(S'POU2F1'
p1008
S'SRF'
p1009
S'increases'
p1010
tp1011
(lp1012
s(S'PLC-GAMMA'
p1013
S'COMPLEX (GADS/SLP-76)'
p1014
S'binds'
p1015
tp1016
(lp1017
s(S'STAT4'
p1018
S'STAT5A'
p1019
S'increases'
p1020
tp1021
(lp1022
S'The signal transducers and activators of transcription (STAT) family of transcription factors comprises seven members (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6), all of which are activated by cytokines ('
p1023
aS'In addition to signaling pathways several key transcription factors were down regulated including, STAT1, STAT3, STAT4, STAT5A/B, STAT6 and p53.'
p1024
aS'However, like LS180 and LoVo the combination seemed to have effects on the STAT transcription factor family including STAT1, STAT2, STAT4, STAT5A, STAT5B, and STAT6.'
p1025
as(S'JUN'
p1026
S'BACH1'
p1027
S'increases'
p1028
tp1029
(lp1030
s(S'POU1F1'
p1031
S'HOXA9'
p1032
S'increases'
p1033
tp1034
(lp1035
s(S'docetaxel'
p1036
S'HRAS PROTEIN'
p1037
S'increases'
p1038
tp1039
(lp1040
s(S'MAX'
p1041
S'LEF1'
p1042
S'increases'
p1043
tp1044
(lp1045
s(S'FOXA1'
p1046
S'CYP26A1'
p1047
S'increases'
p1048
tp1049
(lp1050
s(S'GATA4'
p1051
S'FOXD3'
p1052
S'increases'
p1053
tp1054
(lp1055
s(S'ZBTB18'
p1056
S'RUNX1'
p1057
S'increases'
p1058
tp1059
(lp1060
s(S'ATF3'
p1061
S'RUNX1'
p1062
S'increases'
p1063
tp1064
(lp1065
s(S'NKX2-1'
p1066
S'CYP26A1'
p1067
S'increases'
p1068
tp1069
(lp1070
s(S'NR3C1'
p1071
S'FOXA1'
p1072
S'increases'
p1073
tp1074
(lp1075
s(S'RAS family/GTP'
p1076
S'RIN1'
p1077
S'increases_activity'
p1078
tp1079
(lp1080
s(S'COMPLEX (RAS/GTP/ RAF)'
p1081
S'MEK'
p1082
S'binds'
p1083
tp1084
(lp1085
s(S'CDC5L'
p1086
S'NRAS'
p1087
S'increases'
p1088
tp1089
(lp1090
s(S'Vitamin E'
p1091
S'NRAS MRNA'
p1092
S'decreases'
p1093
tp1094
(lp1095
s(S'NF1'
p1096
S'LEF1'
p1097
S'increases'
p1098
tp1099
(lp1100
s(S'ETS1'
p1101
S'EN1'
p1102
S'increases'
p1103
tp1104
(lp1105
s(S'CRAF'
p1106
S'YWHAB'
p1107
S'binds'
p1108
tp1109
(lp1110
s(S'CEBPD'
p1111
S'JUN'
p1112
S'increases'
p1113
tp1114
(lp1115
s(S'MAX'
p1116
S'RUNX2'
p1117
S'increases'
p1118
tp1119
(lp1120
s(S'CEBPA'
p1121
S'MECOM'
p1122
S'increases'
p1123
tp1124
(lp1125
s(S'PAX2'
p1126
S'GATA1'
p1127
S'increases'
p1128
tp1129
(lp1130
s(S'CYP26A1'
p1131
S'TLX2'
p1132
S'increases'
p1133
tp1134
(lp1135
s(S'GFI1'
p1136
S'ETS1'
p1137
S'increases'
p1138
tp1139
(lp1140
s(S'14-3-3:P-S259,Y340,Y341,S621-RAF1:RAS:GTP'
p1141
S'MEK'
p1142
S'binds'
p1143
tp1144
(lp1145
s(S'P-S,T-MEK2'
p1146
S'ERK2'
p1147
S'binds'
p1148
tp1149
(lp1150
s(S'HRAS/GTP'
p1151
S'RIN2'
p1152
S'increases_activity'
p1153
tp1154
(lp1155
s(S'Ras-GTP'
p1156
S'P42/P44MAPKS'
p1157
S'adds_modification'
p1158
tp1159
(lp1160
s(S'SRF'
p1161
S'CYP26A1'
p1162
S'increases'
p1163
tp1164
(lp1165
s(S'FOXL1'
p1166
S'RUNX2'
p1167
S'increases'
p1168
tp1169
(lp1170
s(S'EGR4'
p1171
S'LEF1'
p1172
S'increases'
p1173
tp1174
(lp1175
s(S'P-IRS1,2'
p1176
S'GRB2:SOS1'
p1177
S'binds'
p1178
tp1179
(lp1180
s(S'VEGFR2 (dimer)/VEGFA (dimer)/alphav/beta3 Integrin/Vitronectin'
p1181
S'SRC'
p1182
S'adds_modification'
p1183
tp1184
(lp1185
s(S'BACH2'
p1186
S'BACH1'
p1187
S'increases'
p1188
tp1189
(lp1190
s(S'ONECUT1'
p1191
S'RUNX1'
p1192
S'increases'
p1193
tp1194
(lp1195
s(S'FOXJ2'
p1196
S'RUNX2'
p1197
S'increases'
p1198
tp1199
(lp1200
s(S'PI-3-4-5-P3'
p1201
S'AKT1'
p1202
S'translocates'
p1203
tp1204
(lp1205
s(S'TFAP4'
p1206
S'BACH1'
p1207
S'increases'
p1208
tp1209
(lp1210
s(S'MEKK1/4'
p1211
S'MKK3/6'
p1212
S'adds_modification'
p1213
tp1214
(lp1215
s(S'VSX1'
p1216
S'MECOM'
p1217
S'increases'
p1218
tp1219
(lp1220
s(S'IRF1'
p1221
S'GATA6'
p1222
S'increases'
p1223
tp1224
(lp1225
s(S'MAX'
p1226
S'HOXA9'
p1227
S'increases'
p1228
tp1229
(lp1230
s(S'RB1'
p1231
S'MAZ'
p1232
S'increases'
p1233
tp1234
(lp1235
s(S'GATA1'
p1236
S'EN1'
p1237
S'increases'
p1238
tp1239
(lp1240
s(S'HIF1A'
p1241
S'SRF'
p1242
S'increases'
p1243
tp1244
(lp1245
s(S'IRF8'
p1246
S'CYP26A1'
p1247
S'increases'
p1248
tp1249
(lp1250
s(S'MTF1'
p1251
S'CYP26A1'
p1252
S'increases'
p1253
tp1254
(lp1255
s(S'PI-3-4-5-P3'
p1256
S'GAB1'
p1257
S'translocates'
p1258
tp1259
(lp1260
s(S'PI-3-4-5-P3'
p1261
S'AKT1'
p1262
S'adds_modification'
p1263
tp1264
(lp1265
s(S'RXRA'
p1266
S'HOXA9'
p1267
S'increases'
p1268
tp1269
(lp1270
s(S'AKT1'
p1271
S'RAF1'
p1272
S'binds'
p1273
tp1274
(lp1275
s(S'HSF2'
p1276
S'JUN'
p1277
S'increases'
p1278
tp1279
(lp1280
s(S'PAX2'
p1281
S'CYP26A1'
p1282
S'increases'
p1283
tp1284
(lp1285
s(S'ETV7'
p1286
S'CYP26A1'
p1287
S'increases'
p1288
tp1289
(lp1290
s(S'FOXO3'
p1291
S'NRAS'
p1292
S'increases'
p1293
tp1294
(lp1295
s(S'TP53'
p1296
S'REPIN1'
p1297
S'increases'
p1298
tp1299
(lp1300
s(S'STAT6'
p1301
S'CYP26A1'
p1302
S'increases'
p1303
tp1304
(lp1305
s(S'JUN'
p1306
S'NRAS'
p1307
S'increases'
p1308
tp1309
(lp1310
s(S'MYCN'
p1311
S'NRAS'
p1312
S'increases'
p1313
tp1314
(lp1315
s(S'STAT3'
p1316
S'YY1'
p1317
S'increases'
p1318
tp1319
(lp1320
s(S'Methyl Methanesulfonate'
p1321
S'HRAS MRNA'
p1322
S'increases'
p1323
tp1324
(lp1325
s(S'RHOA/GTP'
p1326
S'PKN'
p1327
S'increases_activity'
p1328
tp1329
(lp1330
s(S'NHLH1'
p1331
S'FOXJ2'
p1332
S'increases'
p1333
tp1334
(lp1335
s(S'RAS family/GTP'
p1336
S'BRAF'
p1337
S'adds_modification'
p1338
tp1339
(lp1340
s(S'RELA'
p1341
S'FOXJ2'
p1342
S'increases'
p1343
tp1344
(lp1345
s(S'TCF3'
p1346
S'RUNX1'
p1347
S'increases'
p1348
tp1349
(lp1350
s(S'FOXF2'
p1351
S'FOXO4'
p1352
S'increases'
p1353
tp1354
(lp1355
s(S'ATF4'
p1356
S'FOXD3'
p1357
S'increases'
p1358
tp1359
(lp1360
s(S'HAND1'
p1361
S'MECOM'
p1362
S'increases'
p1363
tp1364
(lp1365
s(S'RHOA/GTP'
p1366
S'P27KIP1'
p1367
S'adds_modification'
p1368
tp1369
(lp1370
s(S'SRF'
p1371
S'NRAS'
p1372
S'increases'
p1373
tp1374
(lp1375
s(S'ESRRA'
p1376
S'POU3F2'
p1377
S'increases'
p1378
tp1379
(lp1380
s(S'BRAF'
p1381
S'MEK1'
p1382
S'adds_modification'
p1383
tp1384
(lp1385
S'The development of mutant BRAF and of MEK1/2 inhibitors has markedly improved treatment of advanced BRAF-mutant melanoma ['
p1386
aS'Dasatinib has a wide kinase profile at higher doses and in addition to SRC, dasatinib targets a number of important protein kinases including other SRC family kinases, ABL, KIT, EPH receptors, EGFR, PDGFRA and MAPK proteins including BRAF, CRAF and MEK1 ['
p1387
aS'An extensive study examined potential involvement of mutations in BRAF, NRAS, KRAS, and MEK1 in a large number of resistant tumors, and found no evidence of secondary mutations in these genes with the exception of BRAF, where mutations were identified in 2 of 195 (1%) biopsies ['
p1388
aS'BRAF is a serine-threonine kinase whose only known substrates are MEK1 and MEK2 in the MAPK pathway.'
p1389
aS'BRAF mutant tumors are also targeted using the combination of inhibitors of both MAPK and AKT/PI3K pathways in early-phase trials NCT01363232 (MEK162 and BKM120) and NCT01449058 (MEK162 and BYL719).'
p1390
aS'PD98059 is a MEK1 inhibitor that targets the RET-RAS-BRAF-MEK-ERK pathway.'
p1391
as(S'Cadmium Chloride'
p1392
S'KRAS PROTEIN'
p1393
S'increases'
p1394
tp1395
(lp1396
s(S'PRRX2'
p1397
S'MEIS1'
p1398
S'increases'
p1399
tp1400
(lp1401
s(S'MYC'
p1402
S'NRAS'
p1403
S'increases'
p1404
tp1405
(lp1406
s(S'MAZ'
p1407
S'KRAS'
p1408
S'increases'
p1409
tp1410
(lp1411
s(S'Rho Family GTPase-active'
p1412
S'PI3K'
p1413
S'increases_activity'
p1414
tp1415
(lp1416
s(S'STAT2'
p1417
S'CYP26A1'
p1418
S'increases'
p1419
tp1420
(lp1421
s(S'hsa-let-7a-5p'
p1422
S'KRAS'
p1423
S'decreases'
p1424
tp1425
(lp1426
s(S'POU3F2'
p1427
S'NRAS'
p1428
S'increases'
p1429
tp1430
(lp1431
s(S'SRF'
p1432
S'FOXO4'
p1433
S'increases'
p1434
tp1435
(lp1436
s(S'S1P1/Sphingosine-1-phosphate/PDGF-BB/PDGFRB (dimer)'
p1437
S'SRC FAMILY KINASES'
p1438
S'increases_activity'
p1439
tp1440
(lp1441
s(S'MYC/Max'
p1442
S'ERBB2'
p1443
S'decreases'
p1444
tp1445
(lp1446
s(S'SREBF1'
p1447
S'CBFA2T3'
p1448
S'increases'
p1449
tp1450
(lp1451
s(S'PI3K'
p1452
S'GELSOLIN/PI-3-4-5-P3'
p1453
S'binds'
p1454
tp1455
(lp1456
s(S'NHLH1'
p1457
S'EN1'
p1458
S'increases'
p1459
tp1460
(lp1461
s(S'LMO2'
p1462
S'GATA6'
p1463
S'increases'
p1464
tp1465
(lp1466
s(S'POU1F1'
p1467
S'FOXD3'
p1468
S'increases'
p1469
tp1470
(lp1471
s(S'hsa-miR-148b-3p'
p1472
S'NRAS'
p1473
S'decreases'
p1474
tp1475
(lp1476
s(S'Quercetin'
p1477
S'KRAS PROTEIN'
p1478
S'decreases'
p1479
tp1480
(lp1481
s(S'PAK2'
p1482
S'MEKK1'
p1483
S'adds_modification'
p1484
tp1485
(lp1486
s(S'LMO2'
p1487
S'MAZ'
p1488
S'increases'
p1489
tp1490
(lp1491
s(S'FOXO1'
p1492
S'POU3F2'
p1493
S'increases'
p1494
tp1495
(lp1496
s(S'NKX2-1'
p1497
S'MAZ'
p1498
S'increases'
p1499
tp1500
(lp1501
s(S'GRB2/SOS1'
p1502
S'PDGF-BB/PDGFRB (DIMER)/P52 SHC'
p1503
S'binds'
p1504
tp1505
(lp1506
s(S'PI3K'
p1507
S'CRK/P130 CAS/PAXILLIN'
p1508
S'increases_activity'
p1509
tp1510
(lp1511
s(S'ATF1'
p1512
S'FOXD3'
p1513
S'increases'
p1514
tp1515
(lp1516
s(S'GATA1'
p1517
S'SRF'
p1518
S'increases'
p1519
tp1520
(lp1521
s(S'TFAP2C'
p1522
S'CYP26A1'
p1523
S'increases'
p1524
tp1525
(lp1526
s(S'AHR'
p1527
S'MEIS1'
p1528
S'increases'
p1529
tp1530
(lp1531
s(S'ETS2'
p1532
S'CYP26A1'
p1533
S'increases'
p1534
tp1535
(lp1536
s(S'Estradiol'
p1537
S'NRAS MRNA'
p1538
S'increases'
p1539
tp1540
(lp1541
s(S'E2F1'
p1542
S'HOXA9'
p1543
S'increases'
p1544
tp1545
(lp1546
s(S'PDGF-BB/PDGFRB (DIMER)'
p1547
S'RASGAP'
p1548
S'binds'
p1549
tp1550
(lp1551
s(S'E2F1'
p1552
S'GABPB2'
p1553
S'increases'
p1554
tp1555
(lp1556
s(S'FOXJ1'
p1557
S'POU3F2'
p1558
S'increases'
p1559
tp1560
(lp1561
s(S'VSX1'
p1562
S'CYP26A1'
p1563
S'increases'
p1564
tp1565
(lp1566
s(S'SPI1'
p1567
S'CDC5L'
p1568
S'increases'
p1569
tp1570
(lp1571
s(S'Gi family'
p1572
S'HRAS/GDP'
p1573
S'increases_activity'
p1574
tp1575
(lp1576
s(S'TCF3'
p1577
S'CYP26A1'
p1578
S'increases'
p1579
tp1580
(lp1581
s(S'IGF-1R HETEROTETRAMER/IGF1/IRS1'
p1582
S'GRB2/SOS1'
p1583
S'binds'
p1584
tp1585
(lp1586
s(S'RAS family/GTP'
p1587
S'RALGDS'
p1588
S'translocates'
p1589
tp1590
(lp1591
s(S'PI3K'
p1592
S'RAC1/GDP'
p1593
S'increases_activity'
p1594
tp1595
(lp1596
s(S'Ca2+'
p1597
S'PKC'
p1598
S'increases_activity'
p1599
tp1600
(lp1601
s(S'ZIC1'
p1602
S'CYP26A1'
p1603
S'increases'
p1604
tp1605
(lp1606
s(S'IRF7'
p1607
S'TLX2'
p1608
S'increases'
p1609
tp1610
(lp1611
s(S'SHC/SHIP'
p1612
S'HRAS/GDP'
p1613
S'decreases_activity'
p1614
tp1615
(lp1616
s(S'hsa-let-7a-5p'
p1617
S'HRAS'
p1618
S'decreases'
p1619
tp1620
(lp1621
s(S'GATA4'
p1622
S'MAZ'
p1623
S'increases'
p1624
tp1625
(lp1626
s(S'EN1'
p1627
S'NRAS'
p1628
S'increases'
p1629
tp1630
(lp1631
s(S'PI3K'
p1632
S'BAM32'
p1633
S'adds_modification'
p1634
tp1635
(lp1636
s(S'GABPB1'
p1637
S'CYP26A1'
p1638
S'increases'
p1639
tp1640
(lp1641
s(S'Trifluoroethanol'
p1642
S'HRAS'
p1643
S'increases_activity'
p1644
tp1645
(lp1646
s(S'SOX5'
p1647
S'CYP26A1'
p1648
S'increases'
p1649
tp1650
(lp1651
s(S'GRB2/SOS1'
p1652
S'HGF(DIMER)/MET(DIMER)/P52 SHC'
p1653
S'binds'
p1654
tp1655
(lp1656
s(S'TCF12'
p1657
S'EN1'
p1658
S'increases'
p1659
tp1660
(lp1661
s(S'SOX9'
p1662
S'MEIS1'
p1663
S'increases'
p1664
tp1665
(lp1666
s(S'RB1'
p1667
S'MYC'
p1668
S'increases'
p1669
tp1670
(lp1671
S'However, progression events that can occur in all of the different molecular subtypes of MM include: additional cytogenetic and epigenetic abnormalities, activating mutations of N- and K-RAS, AKT pathway mutations, NFkB pathway mutations, p53 deletion or mutation, RB1 or p18CDKN2c inactivation, and MYC rearrangements['
p1672
as(S'RXRA'
p1673
S'FOXA1'
p1674
S'increases'
p1675
tp1676
(lp1677
s(S'decitabine'
p1678
S'HRAS MRNA'
p1679
S'decreases'
p1680
tp1681
(lp1682
s(S'VSX1'
p1683
S'EN1'
p1684
S'increases'
p1685
tp1686
(lp1687
s(S'FOXL1'
p1688
S'CYP26A1'
p1689
S'increases'
p1690
tp1691
(lp1692
s(S'PAX2'
p1693
S'RUNX1'
p1694
S'increases'
p1695
tp1696
(lp1697
s(S'MEKK1/4'
p1698
S'MKK4/7'
p1699
S'adds_modification'
p1700
tp1701
(lp1702
s(S'HOXA9'
p1703
S'CYP26A1'
p1704
S'increases'
p1705
tp1706
(lp1707
s(S'TRKC'
p1708
S'NT3 (DIMER)'
p1709
S'binds'
p1710
tp1711
(lp1712
s(S'PTF1A'
p1713
S'REPIN1'
p1714
S'increases'
p1715
tp1716
(lp1717
s(S'TGIF'
p1718
S'CYP26A1'
p1719
S'increases'
p1720
tp1721
(lp1722
s(S'MYOD1'
p1723
S'MYC'
p1724
S'increases'
p1725
tp1726
(lp1727
s(S'PKCT'
p1728
S'KRAS ISO2'
p1729
S'adds_modification'
p1730
tp1731
(lp1732
s(S'RAS family/GTP'
p1733
S'BRAF'
p1734
S'increases_activity'
p1735
tp1736
(lp1737
s(S'SPZ1'
p1738
S'CYP26A1'
p1739
S'increases'
p1740
tp1741
(lp1742
s(S'HRAS/GTP'
p1743
S'GALECTIN-1'
p1744
S'binds'
p1745
tp1746
(lp1747
s(S'DBP'
p1748
S'FOXD3'
p1749
S'increases'
p1750
tp1751
(lp1752
s(S'E2F1'
p1753
S'POU2F1'
p1754
S'increases'
p1755
tp1756
(lp1757
s(S'MEIS1'
p1758
S'CYP26A1'
p1759
S'increases'
p1760
tp1761
(lp1762
s(S'YY1'
p1763
S'NRAS'
p1764
S'increases'
p1765
tp1766
(lp1767
s(S'RAS:RAF'
p1768
S'YWHAB'
p1769
S'binds'
p1770
tp1771
(lp1772
s(S'NFE2L2'
p1773
S'CYP26A1'
p1774
S'increases'
p1775
tp1776
(lp1777
s(S'FARNESYL'
p1778
S'KRAS'
p1779
S'increases_activity'
p1780
tp1781
(lp1782
s(S'MTF1'
p1783
S'MECOM'
p1784
S'increases'
p1785
tp1786
(lp1787
s(S'TLX2'
p1788
S'FOXD3'
p1789
S'increases'
p1790
tp1791
(lp1792
s(S'Insulin Receptor/Insulin/SHC/GRB2/Sos1'
p1793
S'HRAS/GDP'
p1794
S'increases_activity'
p1795
tp1796
(lp1797
s(S'MYC'
p1798
S'ELK1'
p1799
S'increases'
p1800
tp1801
(lp1802
s(S'ONECUT1'
p1803
S'POU2F1'
p1804
S'increases'
p1805
tp1806
(lp1807
s(S'Paraquat'
p1808
S'HRAS MRNA'
p1809
S'translocates'
p1810
tp1811
(lp1812
s(S'GRB2/SOS1'
p1813
S'PDGF-BB/PDGFRB (DIMER)/SHP2'
p1814
S'binds'
p1815
tp1816
(lp1817
s(S'ONECUT1'
p1818
S'CYP26A1'
p1819
S'increases'
p1820
tp1821
(lp1822
s(S'MYC'
p1823
S'FOXO3'
p1824
S'increases'
p1825
tp1826
(lp1827
s(S'PAX3'
p1828
S'ELK1'
p1829
S'increases'
p1830
tp1831
(lp1832
s(S'DOK-R'
p1833
S'RASGAP'
p1834
S'binds'
p1835
tp1836
(lp1837
s(S'HOXA4'
p1838
S'HOXA9'
p1839
S'increases'
p1840
tp1841
(lp1842
s(S'MAX'
p1843
S'POU3F2'
p1844
S'increases'
p1845
tp1846
(lp1847
s(S'Estradiol'
p1848
S'KRAS MRNA'
p1849
S'decreases'
p1850
tp1851
(lp1852
s(S'KRAS ISOFORM 4B/GTP'
p1853
S'CAM/CA2+'
p1854
S'binds'
p1855
tp1856
(lp1857
s(S'MAZ'
p1858
S'FOXO4'
p1859
S'increases'
p1860
tp1861
(lp1862
s(S'hsa-miR-181a-5p'
p1863
S'KRAS'
p1864
S'decreases'
p1865
tp1866
(lp1867
s(S'GATA1'
p1868
S'CYP26A1'
p1869
S'increases'
p1870
tp1871
(lp1872
s(S'PGR'
p1873
S'ETS1'
p1874
S'increases'
p1875
tp1876
(lp1877
s(S'GATA1'
p1878
S'POU2F1'
p1879
S'increases'
p1880
tp1881
(lp1882
s(S'BRAF'
p1883
S'MEK1-2'
p1884
S'increases_activity'
p1885
tp1886
(lp1887
s(S'LEF1'
p1888
S'GABPB2'
p1889
S'increases'
p1890
tp1891
(lp1892
s(S'CYP26A1'
p1893
S'MYC'
p1894
S'increases'
p1895
tp1896
(lp1897
s(S'STAT1'
p1898
S'IRF1'
p1899
S'increases'
p1900
tp1901
(lp1902
S'Loss of the STAT1 downstream transcription factor IRF1 has been reported in MIN cases of human breast cancer ['
p1903
aS'Low expression of IRF1 protein correlates with STAT1 expression.'
p1904
aS'To investigate the role of STAT1 and IRF1 in MIN formation, we employed an '
p1905
aS'Under normal conditions, STAT1 puts the brakes on cell proliferation in mammary epithelial cells, presumably via the transcription factor IRF1.'
p1906
aS'When REIC/Dkk-3 is overexpressed by Ad-REIC in normal cells, for example human fibroblasts, ER stress signaling of the p38, STAT1 and IRF1 pathways is activated.'
p1907
aS'Ad, adenovirus; REIC, reduced expression in immortalized cells; JNK, c-Jun N-terminal kinase; ER, endoplasmic reticulum; Dkk-3, dickkopf-3; U-REICs, unfolded REIC/Dkk-3 protein; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein; STAT1, signal transducer and activator of transcription 1; IRF1, interferon regulatory factor 1; IL, interleukin; TAAs, tumor-associated antigens; DC, dendritic cell; CTLs, cytotoxic T lymphocytes; NK, natural killer.'
p1908
aS'Antibodies to the phosphorylated forms of STAT1, JAK1, JAK2, TYK2, or IRF1 and IRF7 were purchased from Cell Signalling Technology.'
p1909
aS'(C) Q-PCR validation confirmed reduced expression of selected ISGs (OAS2, IRF9, MX2, STAT1, GBP1 and IRF1) in LMP2A/2B expressing cells and EBV infected cells.'
p1910
as(S'SMAD1'
p1911
S'RUNX2'
p1912
S'increases'
p1913
tp1914
(lp1915
s(S'ZEB1'
p1916
S'TLX2'
p1917
S'increases'
p1918
tp1919
(lp1920
s(S'STAT5B'
p1921
S'IRF1'
p1922
S'increases'
p1923
tp1924
(lp1925
s(S'POU6F1'
p1926
S'CYP26A1'
p1927
S'increases'
p1928
tp1929
(lp1930
s(S'Vincristine'
p1931
S'HRAS MRNA'
p1932
S'increases'
p1933
tp1934
(lp1935
s(S'DAG'
p1936
S'RASGRP1'
p1937
S'adds_modification'
p1938
tp1939
(lp1940
s(S'PI3K'
p1941
S'PDK1'
p1942
S'increases_activity'
p1943
tp1944
(lp1945
g658
aS'BAG956 is a cell-permeable dual inhibitor of PI3K and PDK1.'
p1946
aS'BKM120 inhibits all class I PI3K isoforms with at least 50-fold selectivity for mTOR and other protein kinases, such as HER1, JAK2, and PDK1.'
p1947
aS'We observed significant differences in the phosphorylation status of several intracellular signaling mediators (CREB, PDK1, SRC, STAT1, p38, STAT3, rpS6) that are important for PI3K-Akt-mTOR signaling and/or transcriptional regulation.'
p1948
aS'An important upstream regulator of mTOR is the oncogenic kinase Akt, which itself is activated via the enzyme cascade of PI3K (phosphatidylinositol-3-kinase) and PDK1 (phosphoinositide-dependent kinase-1).'
p1949
aS'AKT is a serine/threonine protein kinase, which is activated by phosphorylation at T308 by PI3K-PDK1 and at S473 residue by mTOR kinase associated with the TORC2 complex ['
p1950
aS'Stimulation of PI3K, e.g., by growth factors, initiates a cascade of events: PDK1 activates AKT which phosphorylates TSC2, thereby inactivating the TSC1/TSC2 complex.'
p1951
aS'Deptor: DEP-domain-containing mTOR interacting protein; 4E-BP1: eukaryotic initiation factor 4E-binding protein 1; eIF4B: eukaryotic initiation factor 4B; eIF4E: eukaryotic initiation factor 4E; ERK: extracellular signal-regulated kinase; IGF-1R: insulin-like growth factor-1 receptor; IRS-1/2: insulin receptor substrate 1/2; MEK: mitogen-activated protein kinase kinase; mLST8: mammalian Lethal-with-Sec-Thirteen 8; mTOR: mammalian target of rapamycin; mTORC1: mTOR complex 1; mTORC2: mTOR complex 2; PDK1: phosphatidylinositol-dependent kinase 1; PI3K: phosphatidylinositol 3-kinase; PRAS40: proline-rich Akt substrate 40; Protor: protein observed with Rictor; PtdIns 4,5P2: PtdIns-4,5-bisphosphate; PtdIns 3,4,5P3: PtdIns-3-4,5-trisphosphate; p70S6K: p70S6 kinase; p90RSK: p90 ribosomal S6 kinase; Raptor: regulatory associated protein of mTOR; Rheb: Ras homolog enriched in brain; Rictor: rapamycin-insensitive companion of mTOR; TRK: receptor tyrosine kinase; SIN1: stress-activated protein kinase-interacting protein 1; S6RP: S6 ribosomal protein; TSC1: tuberous sclerosis 1; TSC2: tuberous sclerosis 2.'
p1952
aS'This drug was originally described as a dual PI3K/PDK1 inhibitor ['
p1953
aS'Small molecules known to inhibit different elements of the PI3K/Akt signaling pathway such as broad and isoform-specifc PI3K inhibitors, Akt inhibitors and PDK1 inhibitors decrease the activity of the downstream effector kinase Akt releasing FOXO proteins from their 14-3-3 anchors ['
p1954
aS'(A-C) X-370 inhibited Erk1/2 phosphorylation via PI3K-PDK1-MEK1/2 cascade but not the PI3K-Gab1 positive feedback loop.'
p1955
aS'PI3K activates AKT, SGK, PDK1, mTOR, and several other molecules involved in cell cycle progression and survival.'
p1956
aS'Here, we demonstrate that a dual PI3K/PDK1 inhibitor, NVP-BAG956, displayed the most powerful cytotoxic effects against T-ALL cell lines and primary patients samples, when compared with a pan class I PI3K inhibitor (GDC-0941), an allosteric Akt inhibitor (MK-2206), an mTORC1 allosteric inhibitor (RAD-001), or an ATP-competitive mTORC1/mTORC2 inhibitor (KU-63794).'
p1957
aS'The highest cytotoxic potential against T-ALL cell lines and patient lymphoblasts was displayed by NVP-BAG956, a dual PI3K/PDK1 inhibitor which has been shown to be effective against BCR-ABL- and mutant FLT3-expressing acute leukemia cells ['
p1958
aS'The present study identified that the ectopic expression of miR-375 may suppress PDK1 mRNA and protein levels, indicating that miR-375 may also interfere with PI3K-Akt-mTOR signaling.'
p1959
aS'Signaling cascades downstream of c-Src include EGFR transactivation followed by PI3K/AKT or ERK activation (for AngII) (a) and direct PDK1/PAK phosphorylation (for PDGF) (b).'
p1960
aS'Thr308 is phosphorylated by phosphoinositide kinase 1 (PDK1), which is immediately downstream of PI3K('
p1961
aS'A model of the regulation of MYC family protein stability by the RAS, RAF/MEK/ERK and PI3K/PDK1/AKT/GSK3 pathways.'
p1962
aS'Inhibition of RAF/MEK/ERK and/or PI3K/PDK1/AKT pathways by small-molecule inhibitors [e.g., U0126 ('
p1963
as(S'ETS2'
p1964
S'PAX4'
p1965
S'increases'
p1966
tp1967
(lp1968
s(S'NR3C1'
p1969
S'ONECUT1'
p1970
S'increases'
p1971
tp1972
(lp1973
s(S'CUX1'
p1974
S'CYP26A1'
p1975
S'increases'
p1976
tp1977
(lp1978
s(S'ZEB1'
p1979
S'GATA1'
p1980
S'increases'
p1981
tp1982
(lp1983
s(S'NRF1'
p1984
S'POU2F1'
p1985
S'increases'
p1986
tp1987
(lp1988
s(S'FOXJ2'
p1989
S'MECOM'
p1990
S'increases'
p1991
tp1992
(lp1993
s(S'MAZ'
p1994
S'MYCN'
p1995
S'increases'
p1996
tp1997
(lp1998
s(S'Hydrogen Peroxide'
p1999
S'HRAS MRNA'
p2000
S'increases'
p2001
tp2002
(lp2003
s(S'RASA1'
p2004
S'P-EPHBS:EFNBS'
p2005
S'binds'
p2006
tp2007
(lp2008
s(S'SPI1'
p2009
S'CEBPG'
p2010
S'increases'
p2011
tp2012
(lp2013
s(S'EGR1'
p2014
S'LEF1'
p2015
S'increases'
p2016
tp2017
(lp2018
s(S'RET51/GFRALPHA1/GDNF'
p2019
S'P62DOK'
p2020
S'binds'
p2021
tp2022
(lp2023
s(S'TFDP2'
p2024
S'CYP26A1'
p2025
S'increases'
p2026
tp2027
(lp2028
s(S'matrine'
p2029
S'NRAS MRNA'
p2030
S'increases'
p2031
tp2032
(lp2033
s(S'Isotretinoin'
p2034
S'KRAS MRNA'
p2035
S'decreases'
p2036
tp2037
(lp2038
s(S'PITX2'
p2039
S'FOXF2'
p2040
S'increases'
p2041
tp2042
(lp2043
s(S'MYOD1'
p2044
S'POU2F1'
p2045
S'increases'
p2046
tp2047
(lp2048
s(S'sodium arsenite'
p2049
S'KRAS PROTEIN'
p2050
S'increases'
p2051
tp2052
(lp2053
s(S'TCF4'
p2054
S'CBFA2T3'
p2055
S'increases'
p2056
tp2057
(lp2058
s(S'CYP26A1'
p2059
S'FOXA1'
p2060
S'increases'
p2061
tp2062
(lp2063
s(S'TP53'
p2064
S'CYP26A1'
p2065
S'increases'
p2066
tp2067
(lp2068
s(S'ATF3'
p2069
S'FOXD3'
p2070
S'increases'
p2071
tp2072
(lp2073
s(S'POU2F1'
p2074
S'NRAS'
p2075
S'increases'
p2076
tp2077
(lp2078
s(S'NRF1'
p2079
S'GABPB2'
p2080
S'increases'
p2081
tp2082
(lp2083
s(S'PAX4'
p2084
S'TLX2'
p2085
S'increases'
p2086
tp2087
(lp2088
s(S'PITX2'
p2089
S'FOXA1'
p2090
S'increases'
p2091
tp2092
(lp2093
s(S'GTF3A'
p2094
S'POU2F1'
p2095
S'increases'
p2096
tp2097
(lp2098
s(S'HLF'
p2099
S'FOXO3'
p2100
S'increases'
p2101
tp2102
(lp2103
s(S'PAX4'
p2104
S'FOXO4'
p2105
S'increases'
p2106
tp2107
(lp2108
s(S'CEBPA'
p2109
S'FOXD3'
p2110
S'increases'
p2111
tp2112
(lp2113
s(S'NFE2'
p2114
S'CYP26A1'
p2115
S'increases'
p2116
tp2117
(lp2118
s(S'MYB'
p2119
S'GABPB2'
p2120
S'increases'
p2121
tp2122
(lp2123
s(S'MYC'
p2124
S'CEBPA'
p2125
S'increases'
p2126
tp2127
(lp2128
s(S'ELK1'
p2129
S'EN1'
p2130
S'increases'
p2131
tp2132
(lp2133
s(S'E2F1'
p2134
S'CDC5L'
p2135
S'increases'
p2136
tp2137
(lp2138
s(S'YWHAZ (DIMER)'
p2139
S'RAF1'
p2140
S'binds'
p2141
tp2142
(lp2143
s(S'ATF6'
p2144
S'CYP26A1'
p2145
S'increases'
p2146
tp2147
(lp2148
s(S'sodium arsenite'
p2149
S'HRAS MRNA'
p2150
S'increases'
p2151
tp2152
(lp2153
s(S'EGR3'
p2154
S'CYP26A1'
p2155
S'increases'
p2156
tp2157
(lp2158
s(S'lead acetate'
p2159
S'HRAS PROTEIN'
p2160
S'increases_activity'
p2161
tp2162
(lp2163
s(S'REPIN1'
p2164
S'MYC'
p2165
S'increases'
p2166
tp2167
(lp2168
s(S'CEBPA'
p2169
S'NRAS'
p2170
S'increases'
p2171
tp2172
(lp2173
s(S'Quercetin'
p2174
S'NRAS MRNA'
p2175
S'decreases'
p2176
tp2177
(lp2178
s(S'14-3-3 E'
p2179
S'TERT'
p2180
S'binds'
p2181
tp2182
(lp2183
s(S'Antigen/IgE/Fc epsilon R1/LYN/SYK'
p2184
S'BTK'
p2185
S'adds_modification'
p2186
tp2187
(lp2188
s(S'HSF2'
p2189
S'CBFA2T3'
p2190
S'increases'
p2191
tp2192
(lp2193
s(S'Fluorouracil'
p2194
S'HRAS MRNA'
p2195
S'increases'
p2196
tp2197
(lp2198
s(S'STAT4'
p2199
S'MECOM'
p2200
S'increases'
p2201
tp2202
(lp2203
s(S'ETS2'
p2204
S'ETS1'
p2205
S'increases'
p2206
tp2207
(lp2208
S'Our previous results suggested that promoter hypomethylation, especially around the ETS1 and ETS2 motifs, may be involved in the up-regulation of PARP1 expression in BRCA1-mutated ovarian cancer.'
p2209
aS'To further confirm the role of the cytosine located at the ETS1 and ETS2 motifs, a point mutation of cytosine to thymine was constructed (Fig. '
p2210
aS'(A) the schematic represents the cytosine located at the ETS1 and ETS2 motif that were point mutated to generate the thymine.'
p2211
as(S'CEBPG'
p2212
S'CYP26A1'
p2213
S'increases'
p2214
tp2215
(lp2216
s(S'Complex (PDGF receptor A/PDGF receptor B)'
p2217
S'NCK'
p2218
S'adds_modification'
p2219
tp2220
(lp2221
s(S'Fog1'
p2222
S'MYB'
p2223
S'decreases'
p2224
tp2225
(lp2226
s(S'CREB1'
p2227
S'FOXD3'
p2228
S'increases'
p2229
tp2230
(lp2231
s(S'Numb'
p2232
S'NICS'
p2233
S'translocates'
p2234
tp2235
(lp2236
s(S'STAT6'
p2237
S'STAT5A'
p2238
S'increases'
p2239
tp2240
(lp2241
g1023
ag1024
aS'In regards to transcription factor activity, the combination of dasatinib and cetuximab resulted modulation of phosphorylation of several STAT family members including STAT2, STAT3, STAT5A, STAT5B and STAT6.'
p2242
ag1025
as(S'RAF1/14-3-3'
p2243
S'BRAF/14-3-3'
p2244
S'binds'
p2245
tp2246
(lp2247
s(S'B-cell antigen/BCR complex/LYN/SYK/BLNK'
p2248
S'SHC/GRB2/SOS1'
p2249
S'increases_activity'
p2250
tp2251
(lp2252
s(S'IRF2'
p2253
S'CYP26A1'
p2254
S'increases'
p2255
tp2256
(lp2257
s(S'GATA6'
p2258
S'CYP26A1'
p2259
S'increases'
p2260
tp2261
(lp2262
s(S'HMGA1'
p2263
S'CYP26A1'
p2264
S'increases'
p2265
tp2266
(lp2267
s(S'MTF1'
p2268
S'FOXO4'
p2269
S'increases'
p2270
tp2271
(lp2272
s(S'STAT1'
p2273
S'GABPB2'
p2274
S'increases'
p2275
tp2276
(lp2277
s(S'manumycin'
p2278
S'HRAS PROTEIN'
p2279
S'decreases'
p2280
tp2281
(lp2282
s(S'STAT5A'
p2283
S'ETS1'
p2284
S'increases'
p2285
tp2286
(lp2287
s(S'SPI1'
p2288
S'CBFA2T3'
p2289
S'increases'
p2290
tp2291
(lp2292
s(S'GMCSF/GMR ALPHA/CSF2RB/JAK2 (DODECAMER)/SHC'
p2293
S'GRB2/SOS1'
p2294
S'binds'
p2295
tp2296
(lp2297
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p2298
S'NRAS PROTEIN'
p2299
S'increases'
p2300
tp2301
(lp2302
s(S'CDC5L'
p2303
S'CYP26A1'
p2304
S'increases'
p2305
tp2306
(lp2307
s(S'PAX4'
p2308
S'POU3F2'
p2309
S'increases'
p2310
tp2311
(lp2312
s(S'SPRED2'
p2313
S'HRAS'
p2314
S'binds'
p2315
tp2316
(lp2317
s(S'PITX2'
p2318
S'FOXO4'
p2319
S'increases'
p2320
tp2321
(lp2322
s(S'FOXD3'
p2323
S'CYP26A1'
p2324
S'increases'
p2325
tp2326
(lp2327
s(S'NFIL3'
p2328
S'FOXO3'
p2329
S'increases'
p2330
tp2331
(lp2332
s(S'MTF1'
p2333
S'POU2F1'
p2334
S'increases'
p2335
tp2336
(lp2337
s(S'TFCP2'
p2338
S'BACH1'
p2339
S'increases'
p2340
tp2341
(lp2342
s(S'NF1'
p2343
S'MECOM'
p2344
S'increases'
p2345
tp2346
(lp2347
s(S'FOXO3'
p2348
S'FOXD3'
p2349
S'increases'
p2350
tp2351
(lp2352
s(S'STAT5A'
p2353
S'TLX2'
p2354
S'increases'
p2355
tp2356
(lp2357
s(S'RIN1'
p2358
S'HRAS/GTP'
p2359
S'adds_modification'
p2360
tp2361
(lp2362
s(S'STAT5A'
p2363
S'CEBPG'
p2364
S'increases'
p2365
tp2366
(lp2367
s(S'DAG'
p2368
S'PKC'
p2369
S'increases_activity'
p2370
tp2371
(lp2372
S'As already reported, nuclear amount of DAG peaks at G2/M, attracting PKCs to translocate into the nucleus ['
p2373
aS'Hyperglycemia activates different PKC isoforms through OxS or by employing the DAG/IP3 pathway.'
p2374
aS'AGE, advanced glycosylation endproducts; Ang II, angiotensin II; DAG/PKC, diacylglycerol protein kinase C; AR, aldose reductase; DME, diabetic macular edema; DR, diabetic retinopathy; eNOS, endothelial nitric oxide synthase; GSH, glutathione; Mt, mitochondria; NADPH, reduced nicotinamide adenine dinucleotidephosphate; NF'
p2375
aS'Thus, In 1998 Koya and King suggested that the glucose adverse effects in diabetes and hyperglycemia might be a consequence of ROS-stimulated activation of diacylglycerol (DAG)/PKC enzymatic pathway because the treatment with '
p2376
aS'Glucose and insulin stimulated the enhanced ROS formation in enzymatic cascades with activation of diacylglycerol (DAG)/protein kinase C (PKC), protein kinase C'
p2377
aS'PKC enzymes are activated by signals, such as increases in the concentration of DAG or calcium ions (Ca'
p2378
as(S'HNF4A'
p2379
S'FOXA1'
p2380
S'increases'
p2381
tp2382
(lp2383
s(S'LEF1'
p2384
S'MAZ'
p2385
S'increases'
p2386
tp2387
(lp2388
s(S'hsa-miR-124-3p'
p2389
S'NRAS'
p2390
S'decreases'
p2391
tp2392
(lp2393
s(S'RAF1'
p2394
S'14-3-3 E'
p2395
S'binds'
p2396
tp2397
(lp2398
s(S'GATA1'
p2399
S'MYB'
p2400
S'decreases'
p2401
tp2402
(lp2403
s(S'LMO2'
p2404
S'GATA1'
p2405
S'increases'
p2406
tp2407
(lp2408
s(S'HRAS/GTP'
p2409
S'RAF1'
p2410
S'increases_activity'
p2411
tp2412
(lp2413
s(S'MYCN'
p2414
S'RUNX2'
p2415
S'increases'
p2416
tp2417
(lp2418
s(S'STAT5B'
p2419
S'CYP26A1'
p2420
S'increases'
p2421
tp2422
(lp2423
s(S'ZIC2'
p2424
S'MYCN'
p2425
S'increases'
p2426
tp2427
(lp2428
s(S'FOXL1'
p2429
S'FOXD3'
p2430
S'increases'
p2431
tp2432
(lp2433
s(S'ZBTB18'
p2434
S'CBFA2T3'
p2435
S'increases'
p2436
tp2437
(lp2438
s(S'HSF1'
p2439
S'IRF1'
p2440
S'increases'
p2441
tp2442
(lp2443
s(S'SPZ1'
p2444
S'MAZ'
p2445
S'increases'
p2446
tp2447
(lp2448
s(S'SRY'
p2449
S'CYP26A1'
p2450
S'increases'
p2451
tp2452
(lp2453
s(S'FOXO4'
p2454
S'HOXA9'
p2455
S'increases'
p2456
tp2457
(lp2458
s(S'IGF-1R heterotetramer/IGF1/IRS1/GRB2/Sos'
p2459
S'HRAS/GDP'
p2460
S'increases_activity'
p2461
tp2462
(lp2463
s(S'hsa-miR-615-3p'
p2464
S'HRAS'
p2465
S'decreases'
p2466
tp2467
(lp2468
s(S'ESRRA'
p2469
S'FOXD3'
p2470
S'increases'
p2471
tp2472
(lp2473
s(S'ELK1'
p2474
S'CYP26A1'
p2475
S'increases'
p2476
tp2477
(lp2478
s(S'Hexane-1,6-Diol'
p2479
S'HRAS'
p2480
S'increases_activity'
p2481
tp2482
(lp2483
s(S'MAZ'
p2484
S'NRAS'
p2485
S'increases'
p2486
tp2487
(lp2488
s(S'MIF'
p2489
S'CYP26A1'
p2490
S'increases'
p2491
tp2492
(lp2493
s(S'AHR'
p2494
S'POU2F1'
p2495
S'increases'
p2496
tp2497
(lp2498
s(S'SMAD3'
p2499
S'CYP26A1'
p2500
S'increases'
p2501
tp2502
(lp2503
s(S'PI-3-4-5-P3'
p2504
S'GELSOLIN'
p2505
S'binds'
p2506
tp2507
(lp2508
s(S'ADP'
p2509
S'P-S724-IRE1 DIMER'
p2510
S'binds'
p2511
tp2512
(lp2513
s(S'testosterone enanthate'
p2514
S'KRAS MRNA'
p2515
S'increases'
p2516
tp2517
(lp2518
s(S'CYP26A1'
p2519
S'ONECUT1'
p2520
S'increases'
p2521
tp2522
(lp2523
s(S'Valproic Acid'
p2524
S'NRAS MRNA'
p2525
S'decreases'
p2526
tp2527
(lp2528
s(S'GTF2A2'
p2529
S'CYP26A1'
p2530
S'increases'
p2531
tp2532
(lp2533
s(S'CEBPA'
p2534
S'FOXO3'
p2535
S'increases'
p2536
tp2537
(lp2538
s(S'GATA3'
p2539
S'POU2F1'
p2540
S'increases'
p2541
tp2542
(lp2543
s(S'PI3K'
p2544
S'RAC1B/GDP'
p2545
S'increases_activity'
p2546
tp2547
(lp2548
s(S'CDC25C'
p2549
S'YWHAB'
p2550
S'binds'
p2551
tp2552
(lp2553
s(S'RAC1/GTP'
p2554
S'PAK1/BETAPIX/PKL/NCK1-2'
p2555
S'increases_activity'
p2556
tp2557
(lp2558
s(S'SMAD1'
p2559
S'CYP26A1'
p2560
S'increases'
p2561
tp2562
(lp2563
s(S'PI3K'
p2564
S'FAK'
p2565
S'adds_modification'
p2566
tp2567
(lp2568
S'Our study showed that CHIP induced the degradation of EGFR and inactivated its downstream PI3K/AKT pathway as well as the Src/FAK/paxillin pathways.'
p2569
aS'We will discuss new insights into the mechanisms of ligand activation and the contribution of Erk1/2 MAPK, PI3K/FAK, and Endoglin/Smad1 signaling pathways to the process of fibrosis.'
p2570
aS'Menin inhibits activation of FAK, PI3K and ERK1/2.'
p2571
as(S'NRF1'
p2572
S'MAX'
p2573
S'increases'
p2574
tp2575
(lp2576
s(S'FOXI1'
p2577
S'RUNX2'
p2578
S'increases'
p2579
tp2580
(lp2581
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p2582
S'HRAS MRNA'
p2583
S'increases'
p2584
tp2585
(lp2586
s(S'ETS1'
p2587
S'CBFA2T3'
p2588
S'increases'
p2589
tp2590
(lp2591
s(S'hsa-miR-98-5p'
p2592
S'NRAS'
p2593
S'decreases'
p2594
tp2595
(lp2596
s(S'PHOSPHORYLATED BRF1 (SER92, SER203):MRNA COMPLEX'
p2597
S'YWHAB'
p2598
S'binds'
p2599
tp2600
(lp2601
s(S'LMO2'
p2602
S'CYP26A1'
p2603
S'increases'
p2604
tp2605
(lp2606
s(S'SOS1'
p2607
S'GRB2:PFAK BOUND TO NCAM1:PFYN'
p2608
S'binds'
p2609
tp2610
(lp2611
s(S'GTF3A'
p2612
S'GATA6'
p2613
S'increases'
p2614
tp2615
(lp2616
s(S'ZIC2'
p2617
S'CYP26A1'
p2618
S'increases'
p2619
tp2620
(lp2621
s(S'PAX2'
p2622
S'POU3F2'
p2623
S'increases'
p2624
tp2625
(lp2626
s(S'CEBPD'
p2627
S'FOXO3'
p2628
S'increases'
p2629
tp2630
(lp2631
s(S'NF1'
p2632
S'CYP26A1'
p2633
S'increases'
p2634
tp2635
(lp2636
s(S'BRAF'
p2637
S'MEK2'
p2638
S'adds_modification'
p2639
tp2640
(lp2641
g1389
as(S'TFAP4'
p2642
S'RUNX1'
p2643
S'increases'
p2644
tp2645
(lp2646
s(S'FAK'
p2647
S'SOS'
p2648
S'binds'
p2649
tp2650
(lp2651
s(S'EGR1'
p2652
S'RUNX1'
p2653
S'increases'
p2654
tp2655
(lp2656
s(S'TCF4'
p2657
S'FOXO4'
p2658
S'increases'
p2659
tp2660
(lp2661
s(S'MAZ'
p2662
S'CBFA2T3'
p2663
S'increases'
p2664
tp2665
(lp2666
s(S'MEIS1'
p2667
S'HRAS'
p2668
S'increases'
p2669
tp2670
(lp2671
s(S'RELA'
p2672
S'CYP26A1'
p2673
S'increases'
p2674
tp2675
(lp2676
s(S'hsa-miR-877-3p'
p2677
S'NRAS'
p2678
S'decreases'
p2679
tp2680
(lp2681
s(S'MYC'
p2682
S'LEF1'
p2683
S'increases'
p2684
tp2685
(lp2686
s(S'FOXO4'
p2687
S'RUNX1'
p2688
S'increases'
p2689
tp2690
(lp2691
s(S'LEF1'
p2692
S'RUNX1'
p2693
S'increases'
p2694
tp2695
(lp2696
S'Tissue sections were then blocked with peroxidase blocking agent (DAKO) and then incubated with the HES1, RUNX1 and LEF1 primary antibodies (Cell Signalling).'
p2697
as(S'TFDP2'
p2698
S'GATA1'
p2699
S'increases'
p2700
tp2701
(lp2702
s(S'AHR'
p2703
S'CYP26A1'
p2704
S'increases'
p2705
tp2706
(lp2707
s(S'4-Nitroquinoline-1-oxide'
p2708
S'PTGS2 MRNA'
p2709
S'increases'
p2710
tp2711
(lp2712
s(S'TGIF'
p2713
S'FOXO3'
p2714
S'increases'
p2715
tp2716
(lp2717
s(S'FOXF2'
p2718
S'CEBPA'
p2719
S'increases'
p2720
tp2721
(lp2722
s(S'NFE2L1'
p2723
S'POU2F1'
p2724
S'increases'
p2725
tp2726
(lp2727
s(S'LHX3'
p2728
S'CYP26A1'
p2729
S'increases'
p2730
tp2731
(lp2732
s(S'HMGA1'
p2733
S'MEIS1'
p2734
S'increases'
p2735
tp2736
(lp2737
s(S'POU2F1'
p2738
S'CYP26A1'
p2739
S'increases'
p2740
tp2741
(lp2742
s(S'PRRX2'
p2743
S'HOXA9'
p2744
S'increases'
p2745
tp2746
(lp2747
s(S'ETS2'
p2748
S'CEBPG'
p2749
S'increases'
p2750
tp2751
(lp2752
s(S'hsa-miR-193b-3p'
p2753
S'KRAS'
p2754
S'decreases'
p2755
tp2756
(lp2757
s(S'RREB1'
p2758
S'RUNX1'
p2759
S'increases'
p2760
tp2761
(lp2762
s(S'IL2/IL2R BETA/GAMMA/JAK1/FYN/JAK3'
p2763
S'PI3K'
p2764
S'binds'
p2765
tp2766
(lp2767
s(S'ELK1'
p2768
S'MEIS1'
p2769
S'increases'
p2770
tp2771
(lp2772
s(S'CYP26A1'
p2773
S'HOXA9'
p2774
S'increases'
p2775
tp2776
(lp2777
s(S'SPZ1'
p2778
S'HOXA9'
p2779
S'increases'
p2780
tp2781
(lp2782
s(S'ERK1'
p2783
S'P-S218,222-MEK1'
p2784
S'binds'
p2785
tp2786
(lp2787
s(S'NHLH1'
p2788
S'MYC'
p2789
S'increases'
p2790
tp2791
(lp2792
s(S'Daunorubicin'
p2793
S'NRAS MRNA'
p2794
S'increases'
p2795
tp2796
(lp2797
s(S'HNF1A'
p2798
S'FOXA1'
p2799
S'increases'
p2800
tp2801
(lp2802
s(S'MYC'
p2803
S'ONECUT1'
p2804
S'increases'
p2805
tp2806
(lp2807
s(S'Vanadates'
p2808
S'HRAS PROTEIN'
p2809
S'increases'
p2810
tp2811
(lp2812
s(S'Purine nucleotide'
p2813
S'H+'
p2814
S'translocates'
p2815
tp2816
(lp2817
s(S'NFE2'
p2818
S'BACH1'
p2819
S'increases'
p2820
tp2821
(lp2822
s(S'EGR4'
p2823
S'CYP26A1'
p2824
S'increases'
p2825
tp2826
(lp2827
s(S'NRF1'
p2828
S'ONECUT1'
p2829
S'increases'
p2830
tp2831
(lp2832
s(S'GFI1'
p2833
S'HOXA9'
p2834
S'increases'
p2835
tp2836
(lp2837
s(S'NR1H4'
p2838
S'FOXD3'
p2839
S'increases'
p2840
tp2841
(lp2842
s(S'STAT6'
p2843
S'FOXA1'
p2844
S'increases'
p2845
tp2846
(lp2847
s(S'INSULIN RECEPTOR/INSULI/IRS1/GRB2/SHC'
p2848
S'SOS1'
p2849
S'binds'
p2850
tp2851
(lp2852
s(S'Tetrachlorodibenzodioxin'
p2853
S'KRAS MRNA'
p2854
S'increases'
p2855
tp2856
(lp2857
s(S'TCF3'
p2858
S'MYC'
p2859
S'increases'
p2860
tp2861
(lp2862
s(S'BACH1'
p2863
S'EN1'
p2864
S'increases'
p2865
tp2866
(lp2867
s(S'RFX1'
p2868
S'CYP26A1'
p2869
S'increases'
p2870
tp2871
(lp2872
s(S'ZEB1'
p2873
S'FOXD3'
p2874
S'increases'
p2875
tp2876
(lp2877
s(S'IRF7'
p2878
S'EN1'
p2879
S'increases'
p2880
tp2881
(lp2882
s(S'GAB2/GRB2/SOS1'
p2883
S'IL2/IL2R ALPHA/BETA/GAMMA/JAK1/LCK/JAK3/SHC'
p2884
S'binds'
p2885
tp2886
(lp2887
s(S'GATA3'
p2888
S'FOXA1'
p2889
S'increases'
p2890
tp2891
(lp2892
s(S'TFAP4'
p2893
S'CYP26A1'
p2894
S'increases'
p2895
tp2896
(lp2897
s(S'FOXF2'
p2898
S'MECOM'
p2899
S'increases'
p2900
tp2901
(lp2902
s(S'NF1'
p2903
S'POU2F1'
p2904
S'increases'
p2905
tp2906
(lp2907
s(S'IRF1'
p2908
S'FOXA1'
p2909
S'increases'
p2910
tp2911
(lp2912
s(S'Rho Family GTPase-active'
p2913
S'PIP5K1A'
p2914
S'increases_activity'
p2915
tp2916
(lp2917
s(S'POU6F1'
p2918
S'EN1'
p2919
S'increases'
p2920
tp2921
(lp2922
s(S'TCF4'
p2923
S'LEF1'
p2924
S'increases'
p2925
tp2926
(lp2927
s(S'MAZ'
p2928
S'FOXO3'
p2929
S'increases'
p2930
tp2931
(lp2932
s(S'POU3F2'
p2933
S'MECOM'
p2934
S'increases'
p2935
tp2936
(lp2937
s(S'GTF3A'
p2938
S'CYP26A1'
p2939
S'increases'
p2940
tp2941
(lp2942
s(S'PI-3-4-5-P3'
p2943
S'AKT2'
p2944
S'adds_modification'
p2945
tp2946
(lp2947
s(S'VSX1'
p2948
S'POU2F1'
p2949
S'increases'
p2950
tp2951
(lp2952
s(S'PHOSPHORYLATED TTP:MRNA COMPLEX'
p2953
S'YWHAB'
p2954
S'binds'
p2955
tp2956
(lp2957
s(S'MEIS1'
p2958
S'MYC'
p2959
S'increases'
p2960
tp2961
(lp2962
s(S'Complex (PDGF receptor A/PDGF receptor B)'
p2963
S'RASGAP'
p2964
S'adds_modification'
p2965
tp2966
(lp2967
s(S'RORA'
p2968
S'CYP26A1'
p2969
S'increases'
p2970
tp2971
(lp2972
s(S'ATF4'
p2973
S'CDC5L'
p2974
S'increases'
p2975
tp2976
(lp2977
s(S'SHC/RasGAP'
p2978
S'RAS FAMILY/GTP'
p2979
S'increases_activity'
p2980
tp2981
(lp2982
s(S'NKX2-1'
p2983
S'MYC'
p2984
S'increases'
p2985
tp2986
(lp2987
s(S'NF1'
p2988
S'SRF'
p2989
S'increases'
p2990
tp2991
(lp2992
s(S'STAT4'
p2993
S'NRAS'
p2994
S'increases'
p2995
tp2996
(lp2997
s(S'POU6F1'
p2998
S'MEIS1'
p2999
S'increases'
p3000
tp3001
(lp3002
s(S'P-KIT COMPLEX'
p3003
S'GRB2:SOS1'
p3004
S'binds'
p3005
tp3006
(lp3007
s(S'MYCN'
p3008
S'MAX'
p3009
S'increases'
p3010
tp3011
(lp3012
S'This distance is required for the formation of an anti-parallel tetramer between two MYCN-MAX heterodimers ['
p3013
as(S'STAT5A'
p3014
S'CYP26A1'
p3015
S'increases'
p3016
tp3017
(lp3018
s(S'GATA3'
p3019
S'EN1'
p3020
S'increases'
p3021
tp3022
(lp3023
s(S'E4F1'
p3024
S'FOXD3'
p3025
S'increases'
p3026
tp3027
(lp3028
s(S'MYB'
p3029
S'ONECUT1'
p3030
S'increases'
p3031
tp3032
(lp3033
s(S'Cadmium Chloride'
p3034
S'NRAS PROTEIN'
p3035
S'increases'
p3036
tp3037
(lp3038
s(S'Deoxycholic Acid'
p3039
S'HRAS PROTEIN'
p3040
S'increases_activity'
p3041
tp3042
(lp3043
s(S'HLF'
p3044
S'CYP26A1'
p3045
S'increases'
p3046
tp3047
(lp3048
s(S'GMCSF/GMR ALPHA/CSF2RB/JAK2 (DIMER)'
p3049
S'YWHAZ'
p3050
S'binds'
p3051
tp3052
(lp3053
s(S'HNF1A'
p3054
S'FOXF2'
p3055
S'increases'
p3056
tp3057
(lp3058
s(S'FOXF2'
p3059
S'GATA6'
p3060
S'increases'
p3061
tp3062
(lp3063
s(S'Arsenic'
p3064
S'GSS PROTEIN'
p3065
S'increases'
p3066
tp3067
(lp3068
s(S'COMPLEX (SOS/GRB2)'
p3069
S'FGFR1-4'
p3070
S'binds'
p3071
tp3072
(lp3073
s(S'MYOD1'
p3074
S'NRAS'
p3075
S'increases'
p3076
tp3077
(lp3078
s(S'MECOM'
p3079
S'CYP26A1'
p3080
S'increases'
p3081
tp3082
(lp3083
s(S'PBX1'
p3084
S'CYP26A1'
p3085
S'increases'
p3086
tp3087
(lp3088
s(S'MAZ'
p3089
S'MEIS1'
p3090
S'increases'
p3091
tp3092
(lp3093
s(S'PAX4'
p3094
S'ELK1'
p3095
S'increases'
p3096
tp3097
(lp3098
s(S'ESRRA'
p3099
S'MECOM'
p3100
S'increases'
p3101
tp3102
(lp3103
s(S'CEBPD'
p3104
S'TLX2'
p3105
S'increases'
p3106
tp3107
(lp3108
s(S'CRX'
p3109
S'FOXA1'
p3110
S'increases'
p3111
tp3112
(lp3113
s(S'GABPB1'
p3114
S'NRAS'
p3115
S'increases'
p3116
tp3117
(lp3118
s(S'CRX'
p3119
S'MEIS1'
p3120
S'increases'
p3121
tp3122
(lp3123
s(S'pirinixic acid/PPARA protein'
p3124
S'KRAS MRNA'
p3125
S'increases'
p3126
tp3127
(lp3128
s(S'BACH2'
p3129
S'FOXA1'
p3130
S'increases'
p3131
tp3132
(lp3133
s(S'JUN'
p3134
S'MECOM'
p3135
S'increases'
p3136
tp3137
(lp3138
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p3139
S'KRAS MRNA'
p3140
S'decreases'
p3141
tp3142
(lp3143
s(S'SRY'
p3144
S'FOXO4'
p3145
S'increases'
p3146
tp3147
(lp3148
s(S'PI3K'
p3149
S'AKT1'
p3150
S'adds_modification'
p3151
tp3152
(lp3153
S'AKT1 mutations have been found in around 4% of breast cancers and have also been shown to be tumorigenic through activation of PI3K signaling.'
p3154
aS'(+) Patients positive for alterations in PI3K/AKT1/mTOR pathway.'
p3155
aS'AKT1/3 mutations and mutations in PI3K-AKT positive-regulatory genes (PIK3CA and PIK3CG) and negative-regulatory genes (PIK3R2 and PHLPP1) may up-regulate the PI3K-AKT pathway ['
p3156
aS'Mutations of AKT1, a central kinase in the PI3K pathway, are rare in NSCLC, occurring in ~1.9% of cases, but are more frequent in SQCC (5.5%)['
p3157
aS'The PI3K/AKT1/mTOR signal transduction pathway plays an important role in the response of cells to hypoxia and energy depletion, and these functions are highly relevant for the growth of RCC, which is often characterized by alterations of the von Hippel-Lindau ('
p3158
aS'In fact, the complement anaphylatoxins C3a and C5a have been shown to promote the overexpression of potentially oncogenic proteins such as phosphoniositide-3-kinase (PI3K), AKT1 and mammalian target of rapamycin (mTOR).'
p3159
as(S'GATA3'
p3160
S'CYP26A1'
p3161
S'increases'
p3162
tp3163
(lp3164
s(S'RAS:GTP'
p3165
S'P-EPHBS:EFNBS:RASA1'
p3166
S'binds'
p3167
tp3168
(lp3169
s(S'STAT5A'
p3170
S'MECOM'
p3171
S'increases'
p3172
tp3173
(lp3174
s(S'RAS family/GTP'
p3175
S'RAF1'
p3176
S'increases_activity'
p3177
tp3178
(lp3179
s(S'RHOA/GTP'
p3180
S'PLD1-2'
p3181
S'increases_activity'
p3182
tp3183
(lp3184
s(S'FOXJ2'
p3185
S'CYP26A1'
p3186
S'increases'
p3187
tp3188
(lp3189
s(S'LEF1'
p3190
S'MECOM'
p3191
S'increases'
p3192
tp3193
(lp3194
s(S'GABPB2'
p3195
S'CDC5L'
p3196
S'increases'
p3197
tp3198
(lp3199
s(S'ESRRA'
p3200
S'CYP26A1'
p3201
S'increases'
p3202
tp3203
(lp3204
s(S'PI-3-4-5-P3'
p3205
S'WAVE2/NAP1/SRA1/ABI1/HSPC300'
p3206
S'translocates'
p3207
tp3208
(lp3209
s(S'CUX1'
p3210
S'MECOM'
p3211
S'increases'
p3212
tp3213
(lp3214
s(S'MAX'
p3215
S'CYP26A1'
p3216
S'increases'
p3217
tp3218
(lp3219
s(S'RXRB'
p3220
S'FOXD3'
p3221
S'increases'
p3222
tp3223
(lp3224
s(S'IRF1'
p3225
S'NRAS'
p3226
S'increases'
p3227
tp3228
(lp3229
s(S'MECOM'
p3230
S'MAX'
p3231
S'increases'
p3232
tp3233
(lp3234
s(S'PAX6'
p3235
S'CYP26A1'
p3236
S'increases'
p3237
tp3238
(lp3239
s(S'GRB2/SOS1'
p3240
S'EGFR/EGFR/EGF/EGF/P46 SHC'
p3241
S'binds'
p3242
tp3243
(lp3244
s(S'POU6F1'
p3245
S'POU2F1'
p3246
S'increases'
p3247
tp3248
(lp3249
s(S'RUNX1'
p3250
S'MYOD1'
p3251
S'increases'
p3252
tp3253
(lp3254
s(S'COMPLEX (GRB2/SOS)'
p3255
S'EGFR'
p3256
S'binds'
p3257
tp3258
(lp3259
s(S'MAZ'
p3260
S'MECOM'
p3261
S'increases'
p3262
tp3263
(lp3264
s(S'REPIN1'
p3265
S'EN1'
p3266
S'increases'
p3267
tp3268
(lp3269
s(S'RAS family/GTP'
p3270
S'RAF1'
p3271
S'adds_modification'
p3272
tp3273
(lp3274
s(S'E4F1'
p3275
S'CYP26A1'
p3276
S'increases'
p3277
tp3278
(lp3279
s(S'Rac'
p3280
S'MEKK1-5'
p3281
S'adds_modification'
p3282
tp3283
(lp3284
s(S'HAND1'
p3285
S'CYP26A1'
p3286
S'increases'
p3287
tp3288
(lp3289
s(S'Quercetin'
p3290
S'NRAS PROTEIN'
p3291
S'decreases'
p3292
tp3293
(lp3294
s(S'HRAS:GTP'
p3295
S'CRAF'
p3296
S'binds'
p3297
tp3298
(lp3299
s(S'REPIN1'
p3300
S'FOXA1'
p3301
S'increases'
p3302
tp3303
(lp3304
s(S'hsa-miR-155-5p'
p3305
S'KRAS'
p3306
S'decreases'
p3307
tp3308
(lp3309
s(S'PAX4'
p3310
S'EN1'
p3311
S'increases'
p3312
tp3313
(lp3314
s(S'FOXN1'
p3315
S'JUN'
p3316
S'increases'
p3317
tp3318
(lp3319
s(S'TFCP2'
p3320
S'GATA1'
p3321
S'increases'
p3322
tp3323
(lp3324
s(S'SHC'
p3325
S'GRAP2'
p3326
S'binds'
p3327
tp3328
(lp3329
s(S'CEBPG'
p3330
S'NRAS'
p3331
S'increases'
p3332
tp3333
(lp3334
s(S'FOXN1'
p3335
S'FOXO4'
p3336
S'increases'
p3337
tp3338
(lp3339
s(S'IL2/IL2R ALPHA/BETA/GAMMA/JAK1/LCK/JAK3/IRS1-2'
p3340
S'PI3K'
p3341
S'binds'
p3342
tp3343
(lp3344
s(S'POU1F1'
p3345
S'EN1'
p3346
S'increases'
p3347
tp3348
(lp3349
s(S'FOXJ1'
p3350
S'POU2F1'
p3351
S'increases'
p3352
tp3353
(lp3354
s(S'YY1'
p3355
S'POU2F1'
p3356
S'increases'
p3357
tp3358
(lp3359
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p3360
S'NRAS MRNA'
p3361
S'increases'
p3362
tp3363
(lp3364
s(S'EGF/EGFR'
p3365
S'HRAS/GDP'
p3366
S'increases_activity'
p3367
tp3368
(lp3369
s(S'TFAP4'
p3370
S'GABPB2'
p3371
S'increases'
p3372
tp3373
(lp3374
s(S'TFAP2A'
p3375
S'POU3F2'
p3376
S'increases'
p3377
tp3378
(lp3379
s(S'TCF12'
p3380
S'CBFA2T3'
p3381
S'increases'
p3382
tp3383
(lp3384
s(S'STAT3'
p3385
S'IRF1'
p3386
S'increases'
p3387
tp3388
(lp3389
s(S'MYOD1'
p3390
S'GATA1'
p3391
S'increases'
p3392
tp3393
(lp3394
s(S'REPIN1'
p3395
S'HRAS'
p3396
S'increases'
p3397
tp3398
(lp3399
s(S'PAX4'
p3400
S'MAX'
p3401
S'increases'
p3402
tp3403
(lp3404
s(S'PAX2'
p3405
S'FOXA1'
p3406
S'increases'
p3407
tp3408
(lp3409
s(S'Lipopolysaccharides'
p3410
S'HRAS PROTEIN'
p3411
S'increases_activity'
p3412
tp3413
(lp3414
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p3415
S'KRAS MRNA'
p3416
S'increases'
p3417
tp3418
(lp3419
s(S'REPIN1'
p3420
S'GATA1'
p3421
S'increases'
p3422
tp3423
(lp3424
s(S'Formaldehyde'
p3425
S'HRAS MRNA'
p3426
S'increases'
p3427
tp3428
(lp3429
s(S'ESRRA'
p3430
S'STAT5A'
p3431
S'increases'
p3432
tp3433
(lp3434
s(S'farnesylthiosalicylic acid'
p3435
S'HRAS PROTEIN'
p3436
S'decreases'
p3437
tp3438
(lp3439
s(S'JUN'
p3440
S'RUNX1'
p3441
S'increases'
p3442
tp3443
(lp3444
s(S'FOXD3'
p3445
S'RUNX1'
p3446
S'increases'
p3447
tp3448
(lp3449
s(S'SOX9'
p3450
S'CYP26A1'
p3451
S'increases'
p3452
tp3453
(lp3454
s(S'hexabromocyclododecane'
p3455
S'HRAS MRNA'
p3456
S'increases'
p3457
tp3458
(lp3459
s(S'RUNX2'
p3460
S'KRAS'
p3461
S'increases'
p3462
tp3463
(lp3464
s(S'PGR'
p3465
S'CYP26A1'
p3466
S'increases'
p3467
tp3468
(lp3469
s(S'CYP26A1'
p3470
S'MAZ'
p3471
S'increases'
p3472
tp3473
(lp3474
s(S'RAC1/GTP'
p3475
S'AKT1'
p3476
S'adds_modification'
p3477
tp3478
(lp3479
s(S'FOXO3'
p3480
S'CYP26A1'
p3481
S'increases'
p3482
tp3483
(lp3484
s(S'MAX'
p3485
S'SRF'
p3486
S'increases'
p3487
tp3488
(lp3489
s(S'RUNX2'
p3490
S'NRAS'
p3491
S'increases'
p3492
tp3493
(lp3494
s(S'HSF2'
p3495
S'CYP26A1'
p3496
S'increases'
p3497
tp3498
(lp3499
s(S'IL2/IL2R ALPHA/BETA/GAMMA/JAK1/LCK/JAK3/SHC/GRB2/SOS1/GAB2/SHP2'
p3500
S'PI3K'
p3501
S'binds'
p3502
tp3503
(lp3504
s(S'SPI1'
p3505
S'STAT5A'
p3506
S'increases'
p3507
tp3508
(lp3509
s(S'ZHX2'
p3510
S'MYC'
p3511
S'increases'
p3512
tp3513
(lp3514
s(S'RAF1-BRAF'
p3515
S'MEK1-2'
p3516
S'increases_activity'
p3517
tp3518
(lp3519
s(S'SHC'
p3520
S'GRB2'
p3521
S'binds'
p3522
tp3523
(lp3524
s(S'RB1'
p3525
S'GATA1'
p3526
S'increases'
p3527
tp3528
(lp3529
s(S'TCF3'
p3530
S'FOXJ2'
p3531
S'increases'
p3532
tp3533
(lp3534
s(S'FOXJ2'
p3535
S'NRAS'
p3536
S'increases'
p3537
tp3538
(lp3539
s(S'REPIN1'
p3540
S'LEF1'
p3541
S'increases'
p3542
tp3543
(lp3544
s(S'Aflatoxin B1'
p3545
S'HRAS MRNA'
p3546
S'increases'
p3547
tp3548
(lp3549
s(S'PAX4'
p3550
S'MEIS1'
p3551
S'increases'
p3552
tp3553
(lp3554
s(S'FOXF2'
p3555
S'FOXD3'
p3556
S'increases'
p3557
tp3558
(lp3559
s(S'CBFA2T3'
p3560
S'RUNX1'
p3561
S'increases'
p3562
tp3563
(lp3564
s(S'FOXC1'
p3565
S'HOXA9'
p3566
S'increases'
p3567
tp3568
(lp3569
s(S'DBP'
p3570
S'CYP26A1'
p3571
S'increases'
p3572
tp3573
(lp3574
s(S'TGIF'
p3575
S'EN1'
p3576
S'increases'
p3577
tp3578
(lp3579
s(S'PI-3-4-5-P3'
p3580
S'P62DOK'
p3581
S'adds_modification'
p3582
tp3583
(lp3584
s(S'JUN'
p3585
S'TLX2'
p3586
S'increases'
p3587
tp3588
(lp3589
s(S'Benzo(a)pyrene'
p3590
S'HRAS MRNA'
p3591
S'increases'
p3592
tp3593
(lp3594
s(S'STAT4'
p3595
S'CYP26A1'
p3596
S'increases'
p3597
tp3598
(lp3599
s(S'EGFR/EGFR/EGF/EGF'
p3600
S'SRC'
p3601
S'adds_modification'
p3602
tp3603
(lp3604
s(S'FOXQ1'
p3605
S'FOXD3'
p3606
S'increases'
p3607
tp3608
(lp3609
s(S'FOXJ1'
p3610
S'NRAS'
p3611
S'increases'
p3612
tp3613
(lp3614
s(S'TCF3'
p3615
S'POU2F1'
p3616
S'increases'
p3617
tp3618
(lp3619
s(S'MYB'
p3620
S'CYP26A1'
p3621
S'increases'
p3622
tp3623
(lp3624
s(S'GATA4'
p3625
S'CYP26A1'
p3626
S'increases'
p3627
tp3628
(lp3629
s(S'ELK1'
p3630
S'STAT4'
p3631
S'increases'
p3632
tp3633
(lp3634
s(S'CYP26A1'
p3635
S'LEF1'
p3636
S'increases'
p3637
tp3638
(lp3639
s(S"Guanosine-5'-Diphosphate"
p3640
S'HRAS'
p3641
S'increases_activity'
p3642
tp3643
(lp3644
s(S'ETV4'
p3645
S'CYP26A1'
p3646
S'increases'
p3647
tp3648
(lp3649
s(S'EPHRIN B/EPHB2'
p3650
S'RASGAP'
p3651
S'binds'
p3652
tp3653
(lp3654
s(S'ESR1'
p3655
S'FOXF2'
p3656
S'increases'
p3657
tp3658
(lp3659
s(S'CDC5L'
p3660
S'FOXA1'
p3661
S'increases'
p3662
tp3663
(lp3664
s(S'MAZ'
p3665
S'HOXA9'
p3666
S'increases'
p3667
tp3668
(lp3669
s(S'HIF1A'
p3670
S'MAX'
p3671
S'increases'
p3672
tp3673
(lp3674
s(S'FOXN1'
p3675
S'HOXA9'
p3676
S'increases'
p3677
tp3678
(lp3679
s(S'LEF1'
p3680
S'BACH1'
p3681
S'increases'
p3682
tp3683
(lp3684
s(S'PDX1'
p3685
S'FOXO3'
p3686
S'increases'
p3687
tp3688
(lp3689
s(S'CBFA2T3'
p3690
S'CYP26A1'
p3691
S'increases'
p3692
tp3693
(lp3694
s(S'Rabex5'
p3695
S'HRAS/GTP'
p3696
S'adds_modification'
p3697
tp3698
(lp3699
s(S'CBFA2T3'
p3700
S'RUNX2'
p3701
S'increases'
p3702
tp3703
(lp3704
s(S'PI-3-4-5-P3'
p3705
S'ARAP3'
p3706
S'translocates'
p3707
tp3708
(lp3709
s(S'CART1'
p3710
S'CYP26A1'
p3711
S'increases'
p3712
tp3713
(lp3714
s(S'Arsenic'
p3715
S'NRAS MRNA'
p3716
S'increases'
p3717
tp3718
(lp3719
s(S'NRF1'
p3720
S'CDC5L'
p3721
S'increases'
p3722
tp3723
(lp3724
s(S'Quercetin'
p3725
S'HRAS PROTEIN'
p3726
S'decreases'
p3727
tp3728
(lp3729
s(S"N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE"
p3730
S'HRAS'
p3731
S'increases_activity'
p3732
tp3733
(lp3734
s(S'TFDP1'
p3735
S'FOXD3'
p3736
S'increases'
p3737
tp3738
(lp3739
s(S'AR'
p3740
S'TLX2'
p3741
S'increases'
p3742
tp3743
(lp3744
s(S'hsa-miR-181c-5p'
p3745
S'KRAS'
p3746
S'decreases'
p3747
tp3748
(lp3749
s(S'SMAD3'
p3750
S'CBFA2T3'
p3751
S'increases'
p3752
tp3753
(lp3754
s(S'HOXA9'
p3755
S'NRAS'
p3756
S'increases'
p3757
tp3758
(lp3759
s(S'PITX2'
p3760
S'CYP26A1'
p3761
S'increases'
p3762
tp3763
(lp3764
s(S'ATF3'
p3765
S'CYP26A1'
p3766
S'increases'
p3767
tp3768
(lp3769
s(S'E2F1'
p3770
S'MAZ'
p3771
S'increases'
p3772
tp3773
(lp3774
s(S'Ethyl Methanesulfonate'
p3775
S'HRAS MRNA'
p3776
S'increases'
p3777
tp3778
(lp3779
s(S'LMO2'
p3780
S'FOXA1'
p3781
S'increases'
p3782
tp3783
(lp3784
s(S'FOXC1'
p3785
S'POU2F1'
p3786
S'increases'
p3787
tp3788
(lp3789
s(S'DDIT3'
p3790
S'CYP26A1'
p3791
S'increases'
p3792
tp3793
(lp3794
s(S'PAX8'
p3795
S'CYP26A1'
p3796
S'increases'
p3797
tp3798
(lp3799
s(S'LHX3'
p3800
S'EN1'
p3801
S'increases'
p3802
tp3803
(lp3804
s(S'KAT2B'
p3805
S'CYP26A1'
p3806
S'increases'
p3807
tp3808
(lp3809
s(S'P100'
p3810
S'MYB'
p3811
S'binds'
p3812
tp3813
(lp3814
s(S'SOX9'
p3815
S'FOXA1'
p3816
S'increases'
p3817
tp3818
(lp3819
s(S'HIF1A'
p3820
S'EN1'
p3821
S'increases'
p3822
tp3823
(lp3824
s(S'REPIN1'
p3825
S'RUNX1'
p3826
S'increases'
p3827
tp3828
(lp3829
s(S'MYOD1'
p3830
S'BACH1'
p3831
S'increases'
p3832
tp3833
(lp3834
s(S'EBF2'
p3835
S'REPIN1'
p3836
S'increases'
p3837
tp3838
(lp3839
s(S'bisphenol A'
p3840
S'HRAS MRNA'
p3841
S'increases'
p3842
tp3843
(lp3844
s(S'E2F1'
p3845
S'EN1'
p3846
S'increases'
p3847
tp3848
(lp3849
s(S'MYC/Max/MIZ-1'
p3850
S'GALECTIN-1'
p3851
S'decreases'
p3852
tp3853
(lp3854
s(S'PI-3-4-5-P3'
p3855
S'WAVE2/NAP1/SRA1/ABI1/HSPC300'
p3856
S'adds_modification'
p3857
tp3858
(lp3859
s(S'FOXF2'
p3860
S'FOXO3'
p3861
S'increases'
p3862
tp3863
(lp3864
s(S'REPIN1'
p3865
S'STAT5A'
p3866
S'increases'
p3867
tp3868
(lp3869
s(S'RUNX1'
p3870
S'NRAS'
p3871
S'increases'
p3872
tp3873
(lp3874
s(S'benzo(a)pyrene 7,8-dihydrodiol'
p3875
S'HRAS MRNA'
p3876
S'increases'
p3877
tp3878
(lp3879
s(S'RAC1/GTP'
p3880
S'PAK1 (DIMER)'
p3881
S'adds_modification'
p3882
tp3883
(lp3884
s(S'PAX4'
p3885
S'POU2F1'
p3886
S'increases'
p3887
tp3888
(lp3889
s(S'MYOD1'
p3890
S'CBFA2T3'
p3891
S'increases'
p3892
tp3893
(lp3894
s(S'STAT5A'
p3895
S'RUNX2'
p3896
S'increases'
p3897
tp3898
(lp3899
s(S'EBF2'
p3900
S'FOXJ2'
p3901
S'increases'
p3902
tp3903
(lp3904
s(S'Estradiol'
p3905
S'KRAS MRNA'
p3906
S'increases'
p3907
tp3908
(lp3909
s(S'RXRB'
p3910
S'CYP26A1'
p3911
S'increases'
p3912
tp3913
(lp3914
s(S'bisphenol A'
p3915
S'KRAS MRNA'
p3916
S'decreases'
p3917
tp3918
(lp3919
s(S'COMPLEX (GRB2/SOS)'
p3920
S'FGFR1-4'
p3921
S'binds'
p3922
tp3923
(lp3924
s(S'POU2F1'
p3925
S'RUNX1'
p3926
S'increases'
p3927
tp3928
(lp3929
s(S'TCF3'
p3930
S'TLX2'
p3931
S'increases'
p3932
tp3933
(lp3934
s(S'SPZ1'
p3935
S'POU2F1'
p3936
S'increases'
p3937
tp3938
(lp3939
s(S'TFAP4'
p3940
S'FOXO4'
p3941
S'increases'
p3942
tp3943
(lp3944
s(S'OR5I1'
p3945
S'MECOM'
p3946
S'increases'
p3947
tp3948
(lp3949
s(S'Rho Family GTPase-active'
p3950
S'JNK1'
p3951
S'adds_modification'
p3952
tp3953
(lp3954
s(S'TFDP1'
p3955
S'POU2F1'
p3956
S'increases'
p3957
tp3958
(lp3959
s(S'AHR'
p3960
S'MAX'
p3961
S'increases'
p3962
tp3963
(lp3964
s(S'BACH1'
p3965
S'CYP26A1'
p3966
S'increases'
p3967
tp3968
(lp3969
s(S'ZBTB14'
p3970
S'MAZ'
p3971
S'increases'
p3972
tp3973
(lp3974
s(S'TCF3'
p3975
S'FOXO4'
p3976
S'increases'
p3977
tp3978
(lp3979
s(S'MASTERMIND'
p3980
S'NICS'
p3981
S'binds'
p3982
tp3983
(lp3984
s(S'BPTF'
p3985
S'FOXO4'
p3986
S'increases'
p3987
tp3988
(lp3989
s(S'MYOD1'
p3990
S'RUNX1'
p3991
S'increases'
p3992
tp3993
(lp3994
s(S'JUN'
p3995
S'CYP26A1'
p3996
S'increases'
p3997
tp3998
(lp3999
s(S'BPTF'
p4000
S'CYP26A1'
p4001
S'increases'
p4002
tp4003
(lp4004
s(S'POU3F1'
p4005
S'CYP26A1'
p4006
S'increases'
p4007
tp4008
(lp4009
s(S'NRF1'
p4010
S'CYP26A1'
p4011
S'increases'
p4012
tp4013
(lp4014
s(S'TFAP2C'
p4015
S'POU3F2'
p4016
S'increases'
p4017
tp4018
(lp4019
s(S'NFAT1-C-4-INACTIVE2'
p4020
S'YWHAQ'
p4021
S'binds'
p4022
tp4023
(lp4024
s(S'STAT6'
p4025
S'ONECUT1'
p4026
S'increases'
p4027
tp4028
(lp4029
s(S'RUNX1'
p4030
S'RUNX2'
p4031
S'increases'
p4032
tp4033
(lp4034
g991
ag992
as(S'ZIC3'
p4035
S'MYCN'
p4036
S'increases'
p4037
tp4038
(lp4039
s(S'CYP26A1'
p4040
S'MAX'
p4041
S'increases'
p4042
tp4043
(lp4044
s(S'ETS2'
p4045
S'FOXO4'
p4046
S'increases'
p4047
tp4048
(lp4049
s(S'GATA6'
p4050
S'FOXA1'
p4051
S'increases'
p4052
tp4053
(lp4054
s(S'Doxorubicin'
p4055
S'HRAS MRNA'
p4056
S'increases'
p4057
tp4058
(lp4059
s(S'PPARA'
p4060
S'HOXA9'
p4061
S'increases'
p4062
tp4063
(lp4064
s(S'REPIN1'
p4065
S'GABPB2'
p4066
S'increases'
p4067
tp4068
(lp4069
s(S'FOXN1'
p4070
S'FOXA1'
p4071
S'increases'
p4072
tp4073
(lp4074
s(S'Dronabinol'
p4075
S'KRAS MRNA'
p4076
S'increases'
p4077
tp4078
(lp4079
s(S'FOXO1'
p4080
S'RUNX1'
p4081
S'increases'
p4082
tp4083
(lp4084
s(S'SMAD4'
p4085
S'HOXA9'
p4086
S'increases'
p4087
tp4088
(lp4089
s(S'PAX4'
p4090
S'JUN'
p4091
S'increases'
p4092
tp4093
(lp4094
s(S'Raf-1'
p4095
S'MEK'
p4096
S'adds_modification'
p4097
tp4098
(lp4099
g717
ag766
ag803
ag804
ag822
ag828
as(S'PIM1'
p4100
S'MYC/MAX'
p4101
S'binds'
p4102
tp4103
(lp4104
s(S'YY1'
p4105
S'MECOM'
p4106
S'increases'
p4107
tp4108
(lp4109
s(S'NRF1'
p4110
S'MAZ'
p4111
S'increases'
p4112
tp4113
(lp4114
s(S'GATA1'
p4115
S'MECOM'
p4116
S'increases'
p4117
tp4118
(lp4119
s(S'PDGF/PDGFRA'
p4120
S'SHC/GRB2/SOS1'
p4121
S'increases_activity'
p4122
tp4123
(lp4124
s(S'GRB2/SOS1'
p4125
S'FAK'
p4126
S'binds'
p4127
tp4128
(lp4129
s(S'HNF4A'
p4130
S'HOXA9'
p4131
S'increases'
p4132
tp4133
(lp4134
s(S'FOXA2'
p4135
S'CYP26A1'
p4136
S'increases'
p4137
tp4138
(lp4139
s(S'FOXI1'
p4140
S'CYP26A1'
p4141
S'increases'
p4142
tp4143
(lp4144
s(S'GRB2 BOUND TO TIE2'
p4145
S'SOS1'
p4146
S'binds'
p4147
tp4148
(lp4149
s(S'PHOSPHORYLATED BRF1 (SER54, SER92, SER203):MRNA COMPLEX'
p4150
S'YWHAB'
p4151
S'binds'
p4152
tp4153
(lp4154
s(S'COMPLEX (GRB2/SOS)'
p4155
S'GAB'
p4156
S'binds'
p4157
tp4158
(lp4159
s(S'NFE2'
p4160
S'TLX2'
p4161
S'increases'
p4162
tp4163
(lp4164
s(S'MAX'
p4165
S'FOXF2'
p4166
S'increases'
p4167
tp4168
(lp4169
s(S'GRB2:SOS1'
p4170
S'ACTIVATED FGFR:P-FRS2'
p4171
S'binds'
p4172
tp4173
(lp4174
s(S'FOXO4'
p4175
S'MECOM'
p4176
S'increases'
p4177
tp4178
(lp4179
s(S'TCF3'
p4180
S'LEF1'
p4181
S'increases'
p4182
tp4183
(lp4184
s(S'ZIC1'
p4185
S'LEF1'
p4186
S'increases'
p4187
tp4188
(lp4189
s(S'NFIL3'
p4190
S'CYP26A1'
p4191
S'increases'
p4192
tp4193
(lp4194
s(S'RAF1'
p4195
S'MEK1'
p4196
S'increases_activity'
p4197
tp4198
(lp4199
S"Multipeptide immunoblotting was performed according to the manufacturer's instructions using Kinetworks Phospho-Site Screen 1.3 (Kinexus, Victoria, BC), which tracks the abundance of the following phosphoprotein targets:  Adducin A (S724), Adducin G (S662), CDK1 (Y15), CREB (S133), ERK1 (T202/Y204), ERK2 (T185/Y187), GSK3-alpha (S21, Y279), GSK3-beta (S9, Y216), JUN(S73), JNK/SAPK (T183/Y185), MEK1/2 (S217/S221), MEK3/6 (S189/S207), MSK1 (S376), NR1 (S896), p38-alpha MAP kinase (T180/Y182), S6K p70 (T389), PKB-alpha/AKT (S473/T308), PKC-alpha (S657), PKC-alpha/beta (T638/641), PKC-delta (T507), PKC-epsilon (S729), PKR (T451), RAF1 (S259), RB1 (S780, S807/811), RSK1 (T359/S365), JNK/SAPK (T183/Y185), SMAD1 (S463/465), SRC (Y418/Y529), STAT1 (Y701), STAT3 (S727), and STAT5 (Y694)."
p4200
aS'Proteins that were phosphorylated in HTR-8/SVneo cells but not significantly affected by EGFR activation or blockade, include the following: Adducin a, Adducin g, CDK1, CREB, ERK1, ERK2, GSK3a, GSK3b, JUN, MEK1/2, MEK3/6, MSK1/2, NR1, PKCa, PKCa/b, PKCe, RAF1, SAPK, SRC, and STAT1 ('
p4201
aS'The model depicts PAK1 mechanism of action to activate the RAS-MAPK (Orange) pathway through direct activation of RAF1 and MEK1.'
p4202
as(S'AR'
p4203
S'FOXA1'
p4204
S'increases'
p4205
tp4206
(lp4207
S'FOXA1 is a key component of the AR transcriptional complex yet its role in prostate cancer progression and the relationship between AR and FOXA1 are not completely resolved.'
p4208
aS'We mimicked these conditions by over-expressing FOXA1 in the androgen-responsive LNCaP prostate cancer cell line and observed a significant increase in AR genomic binding at novel regions that possess increased chromatin accessibility.'
p4209
aS'Together these results suggest that in an androgen-depleted state, elevated levels of FOXA1 enhance AR binding at genomic regions not normally occupied by AR, which in turn facilitates prostate cancer cell growth.'
p4210
aS'The forkhead transcription factor FOXA1 is a key member of the AR transcriptional complex, which has been shown to interact directly with AR through the hinge domain ('
p4211
aS'Examination of AR binding events in CRPC cell line models and primary tissues suggests that the unique CRPC AR sites are not reliant upon FOXA1 ('
p4212
aS'In this study, we assessed the downstream effects of elevated FOXA1 levels on AR chromatin binding, gene expression and prostate cancer cell proliferation.'
p4213
aS'We found that in cells expressing higher levels of FOXA1, AR makes novel chromatin associations and is able to drive tumor cell growth even at reduced levels of androgen, suggesting that tumors with higher FOXA1 levels may have a growth advantage following androgen deprivation.'
p4214
aS'In order to infer the mechanism behind the increased AR binding seen after FOXA1 over-expression, we assessed whether there was a global increase in AR protein levels, but we did not detect an appreciable change in AR levels following FOXA1 over-expression ('
p4215
aS'In an effort to identify additional regulatory mechanisms that impinge on the AR-FOXA1 complex, we performed RIME (Rapid IMmunoprecipitation of Endogenous proteins) proteomic analysis ('
p4216
aS'The effect of high levels of FOXA1 on prostate cancer proliferation was assessed in AR+ LNCaP prostate cancer cells and our second AR-driven cancer model, the MDA-MB-453 molecular apocrine breast cancer cell line.'
p4217
aS'Western blot analysis confirmed FOXA1 over-expression in MDA-MB-453 cells with no alteration in AR protein levels ('
p4218
aS'FOXA1 is a well-established member of the AR transcription complex, where it is required to direct AR binding to tissue specific sites by opening up chromatin ('
p4219
aS'In summary, FOXA1 is a key component of the AR transcription factor complex.'
p4220
aS'High levels of FOXA1 result in increased AR binding, a transcription profile akin to CRPC and proliferation in the presence of low levels of androgenic hormones.'
p4221
aS'Pathway analysis of the common AR and FOXA1 partners was performed using GSEA molecular signature database tool version 3.1 ('
p4222
as(S'POU2F1'
p4223
S'POU3F2'
p4224
S'increases'
p4225
tp4226
(lp4227
s(S'PCBP1'
p4228
S'MAZ'
p4229
S'increases'
p4230
tp4231
(lp4232
s(S'LEF1'
p4233
S'HOXA9'
p4234
S'increases'
p4235
tp4236
(lp4237
s(S'NR6A1'
p4238
S'CYP26A1'
p4239
S'increases'
p4240
tp4241
(lp4242
s(S'PI3K'
p4243
S'BTK'
p4244
S'translocates'
p4245
tp4246
(lp4247
s(S'AHR'
p4248
S'RUNX1'
p4249
S'increases'
p4250
tp4251
(lp4252
s(S'NR1H4'
p4253
S'CYP26A1'
p4254
S'increases'
p4255
tp4256
(lp4257
s(S'NR2F2'
p4258
S'CYP26A1'
p4259
S'increases'
p4260
tp4261
(lp4262
s(S'GNB1/GNG2'
p4263
S'PI3K'
p4264
S'binds'
p4265
tp4266
(lp4267
s(S'RHOA/GTP'
p4268
S'PKN2'
p4269
S'increases_activity'
p4270
tp4271
(lp4272
s(S'MAZ'
p4273
S'LEF1'
p4274
S'increases'
p4275
tp4276
(lp4277
s(S'RFX1'
p4278
S'MECOM'
p4279
S'increases'
p4280
tp4281
(lp4282
s(S'RUNX1'
p4283
S'HOXA9'
p4284
S'increases'
p4285
tp4286
(lp4287
s(S'FOXL1'
p4288
S'POU2F1'
p4289
S'increases'
p4290
tp4291
(lp4292
s(S'GRB2:SOS1'
p4293
S'PHOSPHORYLATED ERBB2:EGFR HETERODIMERS'
p4294
S'binds'
p4295
tp4296
(lp4297
s(S'TFAP4'
p4298
S'MYCN'
p4299
S'increases'
p4300
tp4301
(lp4302
s(S'E2F1'
p4303
S'GATA1'
p4304
S'increases'
p4305
tp4306
(lp4307
s(S'PTF1A'
p4308
S'GATA6'
p4309
S'increases'
p4310
tp4311
(lp4312
s(S'REL'
p4313
S'CYP26A1'
p4314
S'increases'
p4315
tp4316
(lp4317
s(S'MTF1'
p4318
S'JUN'
p4319
S'increases'
p4320
tp4321
(lp4322
s(S'ZEB1'
p4323
S'REPIN1'
p4324
S'increases'
p4325
tp4326
(lp4327
s(S'IRF8'
p4328
S'GATA6'
p4329
S'increases'
p4330
tp4331
(lp4332
S'Sequence-specific TFs that may fulfill this role are readily found among transcriptional targets that bind GATA6 in multiple cell lines and show extreme associations in expression space: CEBPG, IRF8, HES1, NR5A2 and CDX2; we propose that these TFs execute many cellular functions downstream of GATA6 ('
p4333
as(S'P-Y349,350-SHC1:PHOSPHORYLATED ERBB2 HETERODIMERS'
p4334
S'GRB2:SOS1'
p4335
S'binds'
p4336
tp4337
(lp4338
s(S'BACH2'
p4339
S'EN1'
p4340
S'increases'
p4341
tp4342
(lp4343
s(S'GFI1'
p4344
S'MEIS1'
p4345
S'increases'
p4346
tp4347
(lp4348
s(S'FOXN1'
p4349
S'LEF1'
p4350
S'increases'
p4351
tp4352
(lp4353
s(S'CYP26A1'
p4354
S'JUN'
p4355
S'increases'
p4356
tp4357
(lp4358
s(S'TCF3'
p4359
S'ONECUT1'
p4360
S'increases'
p4361
tp4362
(lp4363
s(S'FOXF2'
p4364
S'POU2F1'
p4365
S'increases'
p4366
tp4367
(lp4368
s(S'MAZ'
p4369
S'MAX'
p4370
S'increases'
p4371
tp4372
(lp4373
s(S'FOXN1'
p4374
S'CYP26A1'
p4375
S'increases'
p4376
tp4377
(lp4378
s(S'HNF1A'
p4379
S'FOXD3'
p4380
S'increases'
p4381
tp4382
(lp4383
s(S'EGR2'
p4384
S'RUNX1'
p4385
S'increases'
p4386
tp4387
(lp4388
s(S'MYC'
p4389
S'RUNX2'
p4390
S'increases'
p4391
tp4392
(lp4393
s(S'TFAP2A'
p4394
S'IRF1'
p4395
S'increases'
p4396
tp4397
(lp4398
s(S'FOXO4'
p4399
S'YY1'
p4400
S'increases'
p4401
tp4402
(lp4403
s(S'VEGFR2 (dimer)/VEGFA (dimer)'
p4404
S'SRC'
p4405
S'adds_modification'
p4406
tp4407
(lp4408
s(S'resveratrol'
p4409
S'KRAS MRNA'
p4410
S'decreases'
p4411
tp4412
(lp4413
s(S'FOXO4'
p4414
S'CYP26A1'
p4415
S'increases'
p4416
tp4417
(lp4418
s(S'STAT3'
p4419
S'FOXO4'
p4420
S'increases'
p4421
tp4422
(lp4423
s(S'GRB2/SOS1'
p4424
S'FRS2 FAMILY/SHP2'
p4425
S'binds'
p4426
tp4427
(lp4428
s(S'LEF1'
p4429
S'CYP26A1'
p4430
S'increases'
p4431
tp4432
(lp4433
s(S'GTF2A2'
p4434
S'SRF'
p4435
S'increases'
p4436
tp4437
(lp4438
s(S'PPARA'
p4439
S'STAT5A'
p4440
S'increases'
p4441
tp4442
(lp4443
s(S'hsa-miR-143-3p'
p4444
S'KRAS'
p4445
S'decreases'
p4446
tp4447
(lp4448
s(S'GFI1'
p4449
S'CYP26A1'
p4450
S'increases'
p4451
tp4452
(lp4453
s(S'RAC1/GTP'
p4454
S'MKK4-MKK7'
p4455
S'increases_activity'
p4456
tp4457
(lp4458
s(S'REPIN1'
p4459
S'ETS1'
p4460
S'increases'
p4461
tp4462
(lp4463
s(S'ZIC1'
p4464
S'GATA6'
p4465
S'increases'
p4466
tp4467
(lp4468
s(S'INTERLEUKIN RECEPTOR COMPLEXES WITH ACTIVATED SHC1'
p4469
S'GRB2:SOS1'
p4470
S'binds'
p4471
tp4472
(lp4473
s(S'Selenium'
p4474
S'HRAS MRNA'
p4475
S'increases'
p4476
tp4477
(lp4478
s(S'HOXA4'
p4479
S'CYP26A1'
p4480
S'increases'
p4481
tp4482
(lp4483
s(S'NKX2-1'
p4484
S'POU2F1'
p4485
S'increases'
p4486
tp4487
(lp4488
s(S'VSX1'
p4489
S'MAX'
p4490
S'increases'
p4491
tp4492
(lp4493
s(S'FOXD1'
p4494
S'FOXD3'
p4495
S'increases'
p4496
tp4497
(lp4498
s(S'MAX'
p4499
S'NRAS'
p4500
S'increases'
p4501
tp4502
(lp4503
s(S'HOXA9'
p4504
S'TCF3'
p4505
S'increases'
p4506
tp4507
(lp4508
s(S'IRF1'
p4509
S'CYP26A1'
p4510
S'increases'
p4511
tp4512
(lp4513
s(S'HRAS'
p4514
S'RAF1'
p4515
S'adds_modification'
p4516
tp4517
(lp4518
S'Not listed: rare mutations in HRAS, RAF1 and other oncogenes.'
p4519
as(S'CUX1'
p4520
S'HOXA9'
p4521
S'increases'
p4522
tp4523
(lp4524
s(S'ZHX2'
p4525
S'FOXA1'
p4526
S'increases'
p4527
tp4528
(lp4529
s(S'TFDP1'
p4530
S'MYC'
p4531
S'increases'
p4532
tp4533
(lp4534
s(S'RAC1/GTP'
p4535
S'PAK1'
p4536
S'increases_activity'
p4537
tp4538
(lp4539
s(S'AHR'
p4540
S'MAZ'
p4541
S'increases'
p4542
tp4543
(lp4544
s(S'BRAF/14-3-3'
p4545
S'KSR/14-3-3 /MEK1-2'
p4546
S'increases_activity'
p4547
tp4548
(lp4549
s(S'PPARA'
p4550
S'CYP26A1'
p4551
S'increases'
p4552
tp4553
(lp4554
s(S'REPIN1'
p4555
S'SRF'
p4556
S'increases'
p4557
tp4558
(lp4559
s(S'PAX5'
p4560
S'SRF'
p4561
S'increases'
p4562
tp4563
(lp4564
s(S'PAX4'
p4565
S'FOXJ2'
p4566
S'increases'
p4567
tp4568
(lp4569
s(S'REPIN1'
p4570
S'MYCN'
p4571
S'increases'
p4572
tp4573
(lp4574
s(S'RALA/GTP'
p4575
S'SRC'
p4576
S'adds_modification'
p4577
tp4578
(lp4579
s(S'FOXO4'
p4580
S'ETS1'
p4581
S'increases'
p4582
tp4583
(lp4584
s(S'TFDP1'
p4585
S'CDC5L'
p4586
S'increases'
p4587
tp4588
(lp4589
s(S'TFDP1'
p4590
S'CYP26A1'
p4591
S'increases'
p4592
tp4593
(lp4594
s(S'GATA6'
p4595
S'RUNX2'
p4596
S'increases'
p4597
tp4598
(lp4599
s(S'FOXM1'
p4600
S'CYP26A1'
p4601
S'increases'
p4602
tp4603
(lp4604
s(S'sodium arsenite'
p4605
S'HRAS PROTEIN'
p4606
S'increases'
p4607
tp4608
(lp4609
s(S'STAT5A'
p4610
S'RUNX1'
p4611
S'increases'
p4612
tp4613
(lp4614
s(S'CEBPA'
p4615
S'EN1'
p4616
S'increases'
p4617
tp4618
(lp4619
s(S'MSX1'
p4620
S'POU2F1'
p4621
S'increases'
p4622
tp4623
(lp4624
s(S'NHLH1'
p4625
S'CBFA2T3'
p4626
S'increases'
p4627
tp4628
(lp4629
s(S'Parathion'
p4630
S'HRAS PROTEIN'
p4631
S'increases'
p4632
tp4633
(lp4634
s(S'SMAD4'
p4635
S'CYP26A1'
p4636
S'increases'
p4637
tp4638
(lp4639
s(S'E2F1'
p4640
S'MYC'
p4641
S'increases'
p4642
tp4643
(lp4644
S'We also observed that expression of two key factors in G1 progression, cyclin D1 and E2F1, were repressed, mirroring the reduction in MYC expression, by JQ1 treatment.'
p4645
aS'Human E2F1, c-MYC and NFYA/NFDN (dominant negative) were kind gifts from Drs.'
p4646
as(S'CYP26A1'
p4647
S'FOXO3'
p4648
S'increases'
p4649
tp4650
(lp4651
s(S'TCF3'
p4652
S'CBFA2T3'
p4653
S'increases'
p4654
tp4655
(lp4656
s(S'ZHX2'
p4657
S'FOXF2'
p4658
S'increases'
p4659
tp4660
(lp4661
s(S'POU2F1'
p4662
S'MECOM'
p4663
S'increases'
p4664
tp4665
(lp4666
s(S'CYP26A1'
p4667
S'POU2F1'
p4668
S'increases'
p4669
tp4670
(lp4671
s(S'MYOD1'
p4672
S'CYP26A1'
p4673
S'increases'
p4674
tp4675
(lp4676
s(S'RAF'
p4677
S'COMPLEX (RAS/GTP)'
p4678
S'binds'
p4679
tp4680
(lp4681
s(S'RET51/GFRalpha1/GDNF/DOK1'
p4682
S'HRAS/GDP'
p4683
S'increases_activity'
p4684
tp4685
(lp4686
s(S'MAFG'
p4687
S'CYP26A1'
p4688
S'increases'
p4689
tp4690
(lp4691
s(S'CRX'
p4692
S'CYP26A1'
p4693
S'increases'
p4694
tp4695
(lp4696
s(S'hsa-miR-126-3p'
p4697
S'KRAS'
p4698
S'decreases'
p4699
tp4700
(lp4701
s(S'EBF2'
p4702
S'CYP26A1'
p4703
S'increases'
p4704
tp4705
(lp4706
s(S'RUNX1'
p4707
S'CYP26A1'
p4708
S'increases'
p4709
tp4710
(lp4711
s(S'HOXA5'
p4712
S'FOXA1'
p4713
S'increases'
p4714
tp4715
(lp4716
s(S'benzo(a)pyrene-3,6-quinone'
p4717
S'HRAS MRNA'
p4718
S'increases'
p4719
tp4720
(lp4721
s(S'K 7174'
p4722
S'HRAS MRNA'
p4723
S'decreases'
p4724
tp4725
(lp4726
s(S'LEF1'
p4727
S'NRAS'
p4728
S'increases'
p4729
tp4730
(lp4731
s(S'SPI1'
p4732
S'FOXA1'
p4733
S'increases'
p4734
tp4735
(lp4736
s(S'hsa-let-7b-5p'
p4737
S'NRAS'
p4738
S'decreases'
p4739
tp4740
(lp4741
s(S'CEBPA'
p4742
S'JUN'
p4743
S'increases'
p4744
tp4745
(lp4746
s(S'GABPB2'
p4747
S'CYP26A1'
p4748
S'increases'
p4749
tp4750
(lp4751
s(S'PI-3-4-5-P3'
p4752
S'MTOR'
p4753
S'increases_activity'
p4754
tp4755
(lp4756
s(S'GRB2:SOS1'
p4757
S'EGF:P-6Y-EGFR'
p4758
S'binds'
p4759
tp4760
(lp4761
s(S'HNF1A'
p4762
S'CYP26A1'
p4763
S'increases'
p4764
tp4765
(lp4766
s(S'HIF1A'
p4767
S'FOXO4'
p4768
S'increases'
p4769
tp4770
(lp4771
s(S'FOXJ1'
p4772
S'HOXA9'
p4773
S'increases'
p4774
tp4775
(lp4776
s(S'hsa-miR-96-5p'
p4777
S'KRAS'
p4778
S'decreases'
p4779
tp4780
(lp4781
s(S'SRC'
p4782
S'SYNDECAN-2/RASGAP'
p4783
S'binds'
p4784
tp4785
(lp4786
s(S'FOXA1'
p4787
S'MEIS1'
p4788
S'increases'
p4789
tp4790
(lp4791
s(S'LEF1'
p4792
S'MEIS1'
p4793
S'increases'
p4794
tp4795
(lp4796
s(S'PAX3'
p4797
S'CYP26A1'
p4798
S'increases'
p4799
tp4800
(lp4801
s(S'PAX4'
p4802
S'HOXA9'
p4803
S'increases'
p4804
tp4805
(lp4806
s(S'hsa-miR-18a-3p'
p4807
S'KRAS'
p4808
S'decreases'
p4809
tp4810
(lp4811
s(S'FOXF2'
p4812
S'EN1'
p4813
S'increases'
p4814
tp4815
(lp4816
s(S'Pyk2'
p4817
S'SRC FAMILY KINASES'
p4818
S'increases_activity'
p4819
tp4820
(lp4821
s(S'TP53'
p4822
S'HOXA9'
p4823
S'increases'
p4824
tp4825
(lp4826
s(S'Genistein'
p4827
S'KRAS MRNA'
p4828
S'decreases'
p4829
tp4830
(lp4831
s(S'POU1F1'
p4832
S'CYP26A1'
p4833
S'increases'
p4834
tp4835
(lp4836
s(S'manumycin'
p4837
S'KRAS PROTEIN'
p4838
S'decreases_activity'
p4839
tp4840
(lp4841
s(S'Ginkgo biloba extract 761'
p4842
S'GCLC PROTEIN'
p4843
S'increases'
p4844
tp4845
(lp4846
s(S'GATA1'
p4847
S'NRAS'
p4848
S'increases'
p4849
tp4850
(lp4851
s(S'CBFA2T3'
p4852
S'FOXF2'
p4853
S'increases'
p4854
tp4855
(lp4856
s(S'PCBP1'
p4857
S'ELK1'
p4858
S'increases'
p4859
tp4860
(lp4861
s(S'MYC'
p4862
S'FOXF2'
p4863
S'increases'
p4864
tp4865
(lp4866
s(S'hsa-mir-622'
p4867
S'KRAS'
p4868
S'decreases'
p4869
tp4870
(lp4871
s(S'TCF3'
p4872
S'MAZ'
p4873
S'increases'
p4874
tp4875
(lp4876
s(S'STAT2'
p4877
S'MEIS1'
p4878
S'increases'
p4879
tp4880
(lp4881
s(S'CYP26A1'
p4882
S'YY1'
p4883
S'increases'
p4884
tp4885
(lp4886
s(S'CYP26A1'
p4887
S'EN1'
p4888
S'increases'
p4889
tp4890
(lp4891
s(S'GRB2/SOS1'
p4892
S'SHC'
p4893
S'binds'
p4894
tp4895
(lp4896
s(S'BAD'
p4897
S'YWHAZ'
p4898
S'binds'
p4899
tp4900
(lp4901
s(S'SPI1'
p4902
S'MAX'
p4903
S'increases'
p4904
tp4905
(lp4906
s(S'PI-3-4-5-P3'
p4907
S'CENTA1'
p4908
S'translocates'
p4909
tp4910
(lp4911
s(S'XBP1'
p4912
S'CYP26A1'
p4913
S'increases'
p4914
tp4915
(lp4916
s(S'PAX4'
p4917
S'NRAS'
p4918
S'increases'
p4919
tp4920
(lp4921
s(S'PI3K'
p4922
S'EPHRIN A1/EPHA2'
p4923
S'binds'
p4924
tp4925
(lp4926
s(S'POU1F1'
p4927
S'MEIS1'
p4928
S'increases'
p4929
tp4930
(lp4931
s(S'NR3C1'
p4932
S'ETS1'
p4933
S'increases'
p4934
tp4935
(lp4936
s(S'MAZ'
p4937
S'POU3F2'
p4938
S'increases'
p4939
tp4940
(lp4941
s(S'Estradiol'
p4942
S'HRAS MRNA'
p4943
S'increases'
p4944
tp4945
(lp4946
s(S'Aflatoxin B1'
p4947
S'HRAS PROTEIN'
p4948
S'increases'
p4949
tp4950
(lp4951
s(S'ETV7'
p4952
S'STAT4'
p4953
S'increases'
p4954
tp4955
(lp4956
s(S'PBX1'
p4957
S'LEF1'
p4958
S'increases'
p4959
tp4960
(lp4961
s(S'CEBPB'
p4962
S'CYP26A1'
p4963
S'increases'
p4964
tp4965
(lp4966
s(S'MAZ'
p4967
S'JUN'
p4968
S'increases'
p4969
tp4970
(lp4971
s(S'FOXF2'
p4972
S'MYC'
p4973
S'increases'
p4974
tp4975
(lp4976
s(S'FOXJ2'
p4977
S'HOXA9'
p4978
S'increases'
p4979
tp4980
(lp4981
s(S'Capsaicin'
p4982
S'HRAS MRNA'
p4983
S'increases'
p4984
tp4985
(lp4986
s(S'POU3F1'
p4987
S'GATA6'
p4988
S'increases'
p4989
tp4990
(lp4991
s(S'EIF2A'
p4992
S'14-3-3 E'
p4993
S'binds'
p4994
tp4995
(lp4996
s(S'RAS family/GTP'
p4997
S'RAF1-BRAF'
p4998
S'increases_activity'
p4999
tp5000
(lp5001
s(S'GATA6'
p5002
S'GATA1'
p5003
S'increases'
p5004
tp5005
(lp5006
g905
as(S'RASA1'
p5007
S'PHOSPHO PDGF BETA RECEPTOR: PDGF CHAIN B HOMODIMER'
p5008
S'binds'
p5009
tp5010
(lp5011
s(S'CART1'
p5012
S'POU2F1'
p5013
S'increases'
p5014
tp5015
(lp5016
s(S'ZIC3'
p5017
S'POU2F1'
p5018
S'increases'
p5019
tp5020
(lp5021
s(S'TCF4'
p5022
S'FOXA1'
p5023
S'increases'
p5024
tp5025
(lp5026
s(S'PKC theta'
p5027
S'RASGRP1'
p5028
S'adds_modification'
p5029
tp5030
(lp5031
s(S'PTF1A'
p5032
S'STAT5A'
p5033
S'increases'
p5034
tp5035
(lp5036
s(S'SPI1'
p5037
S'FOXO4'
p5038
S'increases'
p5039
tp5040
(lp5041
s(S'HNF1A'
p5042
S'GATA6'
p5043
S'increases'
p5044
tp5045
(lp5046
s(S'FOXJ1'
p5047
S'RUNX1'
p5048
S'increases'
p5049
tp5050
(lp5051
s(S'STAT2'
p5052
S'GATA6'
p5053
S'increases'
p5054
tp5055
(lp5056
s(S'RAS FAMILY/GTP'
p5057
S'PI3K'
p5058
S'binds'
p5059
tp5060
(lp5061
s(S'PAX4'
p5062
S'IRF1'
p5063
S'increases'
p5064
tp5065
(lp5066
s(S'PAX3'
p5067
S'HOXA9'
p5068
S'increases'
p5069
tp5070
(lp5071
s(S'MYB'
p5072
S'MAZ'
p5073
S'increases'
p5074
tp5075
(lp5076
s(S"Guanosine-5'-Triphosphate"
p5077
S'HRAS'
p5078
S'increases_activity'
p5079
tp5080
(lp5081
s(S'alpha9/beta1 Integrin/Tenascin C'
p5082
S'SRC'
p5083
S'adds_modification'
p5084
tp5085
(lp5086
s(S'RAF1'
p5087
S'MEK1'
p5088
S'adds_modification'
p5089
tp5090
(lp5091
g4200
ag4201
ag4202
as(S'JUN'
p5092
S'FOXA1'
p5093
S'increases'
p5094
tp5095
(lp5096
s(S'NFE2L2'
p5097
S'BACH1'
p5098
S'increases'
p5099
tp5100
(lp5101
s(S'CUX1'
p5102
S'FOXD3'
p5103
S'increases'
p5104
tp5105
(lp5106
s(S'JUN'
p5107
S'EN1'
p5108
S'increases'
p5109
tp5110
(lp5111
s(S'ESR1'
p5112
S'CYP26A1'
p5113
S'increases'
p5114
tp5115
(lp5116
s(S'ESRRA'
p5117
S'FOXA1'
p5118
S'increases'
p5119
tp5120
(lp5121
s(S'POU2F1'
p5122
S'MEIS1'
p5123
S'increases'
p5124
tp5125
(lp5126
s(S'TFCP2'
p5127
S'FOXA1'
p5128
S'increases'
p5129
tp5130
(lp5131
s(S'PI-3-4-5-P3'
p5132
S'PDK1'
p5133
S'increases_activity'
p5134
tp5135
(lp5136
s(S'TCF3'
p5137
S'FOXA1'
p5138
S'increases'
p5139
tp5140
(lp5141
s(S'STAT3'
p5142
S'CYP26A1'
p5143
S'increases'
p5144
tp5145
(lp5146
s(S'CYP26A1'
p5147
S'POU3F2'
p5148
S'increases'
p5149
tp5150
(lp5151
s(S'Curcumin'
p5152
S'KRAS MRNA'
p5153
S'decreases'
p5154
tp5155
(lp5156
s(S'STAT1'
p5157
S'CYP26A1'
p5158
S'increases'
p5159
tp5160
(lp5161
s(S'GFI1'
p5162
S'POU2F1'
p5163
S'increases'
p5164
tp5165
(lp5166
s(S'ZIC1'
p5167
S'POU2F1'
p5168
S'increases'
p5169
tp5170
(lp5171
s(S'PI-3-4-5-P3'
p5172
S'AKT3'
p5173
S'adds_modification'
p5174
tp5175
(lp5176
s(S'BACH1'
p5177
S'NRAS'
p5178
S'increases'
p5179
tp5180
(lp5181
s(S'SCF/KIT'
p5182
S'SHC/GRB2/SOS1'
p5183
S'increases_activity'
p5184
tp5185
(lp5186
s(S'CDX2'
p5187
S'CYP26A1'
p5188
S'increases'
p5189
tp5190
(lp5191
s(S'RET51/GFRalpha1/GDNF/DOK/RasGAP/NCK'
p5192
S'HRAS/GDP'
p5193
S'decreases_activity'
p5194
tp5195
(lp5196
s(S'BETAPIX'
p5197
S'RAC1/GTP'
p5198
S'binds'
p5199
tp5200
(lp5201
s(S'RHOA/GTP'
p5202
S'CITRON'
p5203
S'increases_activity'
p5204
tp5205
(lp5206
s(S'P-SHC1:GRB2:SOS'
p5207
S'P-5Y-LAT-2'
p5208
S'binds'
p5209
tp5210
(lp5211
s(S'PAX4'
p5212
S'CYP26A1'
p5213
S'increases'
p5214
tp5215
(lp5216
s(S'TCF3'
p5217
S'KRAS'
p5218
S'increases'
p5219
tp5220
(lp5221
s(S'GRB2:SOS1'
p5222
S'PHOSPHORYLATED ERBB2:ERBB4 HETERODIMERS'
p5223
S'binds'
p5224
tp5225
(lp5226
s(S'CDX2'
p5227
S'MEIS1'
p5228
S'increases'
p5229
tp5230
(lp5231
s(S'SP3'
p5232
S'RUNX1'
p5233
S'increases'
p5234
tp5235
(lp5236
s(S'REST'
p5237
S'CYP26A1'
p5238
S'increases'
p5239
tp5240
(lp5241
s(S'PTF1A'
p5242
S'CYP26A1'
p5243
S'increases'
p5244
tp5245
(lp5246
s(S'PI-3-4-5-P3'
p5247
S'PI3K/GAB1'
p5248
S'translocates'
p5249
tp5250
(lp5251
s(S'LMO2'
p5252
S'FOXO4'
p5253
S'increases'
p5254
tp5255
(lp5256
s(S'STAT4'
p5257
S'ETS1'
p5258
S'increases'
p5259
tp5260
(lp5261
s(S'GTF2A2'
p5262
S'HOXA9'
p5263
S'increases'
p5264
tp5265
(lp5266
s(S'FOXF2'
p5267
S'POU3F2'
p5268
S'increases'
p5269
tp5270
(lp5271
s(S'GATA1'
p5272
S'GABPB2'
p5273
S'increases'
p5274
tp5275
(lp5276
s(S'Polychlorinated Biphenyls'
p5277
S'KRAS MRNA'
p5278
S'decreases'
p5279
tp5280
(lp5281
s(S'GRB2/SOS1'
p5282
S'EGF/EGFR DIMER/SHC'
p5283
S'binds'
p5284
tp5285
(lp5286
s(S'CYP26A1'
p5287
S'FOXF2'
p5288
S'increases'
p5289
tp5290
(lp5291
s(S'EGR1'
p5292
S'CYP26A1'
p5293
S'increases'
p5294
tp5295
(lp5296
s(S'MAX'
p5297
S'FOXO3'
p5298
S'increases'
p5299
tp5300
(lp5301
S'Pre-designed siRNA for mouse FOXO3a (NM_019740) was purchased from Ambion and siRNA was transfected with Lipofectamine RNAiMAX (Invitrogen) according to protocol supplied by the vendor.'
p5302
as(S'T-DHT/AR/PELP1'
p5303
S'SRC'
p5304
S'binds'
p5305
tp5306
(lp5307
s(S'CUX1'
p5308
S'FOXF2'
p5309
S'increases'
p5310
tp5311
(lp5312
s(S'CEBPD'
p5313
S'CYP26A1'
p5314
S'increases'
p5315
tp5316
(lp5317
s(S'CBFA2T3'
p5318
S'NRAS'
p5319
S'increases'
p5320
tp5321
(lp5322
s(S'Cisplatin'
p5323
S'HRAS MRNA'
p5324
S'translocates'
p5325
tp5326
(lp5327
s(S'BAD/BCL-X(L)'
p5328
S'YWHAZ'
p5329
S'binds'
p5330
tp5331
(lp5332
s(S'GATA1'
p5333
S'FOXA1'
p5334
S'increases'
p5335
tp5336
(lp5337
s(S'RREB1'
p5338
S'CYP26A1'
p5339
S'increases'
p5340
tp5341
(lp5342
s(S'STAT4'
p5343
S'RUNX2'
p5344
S'increases'
p5345
tp5346
(lp5347
s(S'FOXD3'
p5348
S'NRAS'
p5349
S'increases'
p5350
tp5351
(lp5352
s(S'NDEL1'
p5353
S'14-3-3 E'
p5354
S'binds'
p5355
tp5356
(lp5357
s(S'CYP26A1'
p5358
S'REPIN1'
p5359
S'increases'
p5360
tp5361
(lp5362
s(S'MAF'
p5363
S'CDC5L'
p5364
S'increases'
p5365
tp5366
(lp5367
s(S'CYP26A1'
p5368
S'ELK1'
p5369
S'increases'
p5370
tp5371
(lp5372
s(S'MYC'
p5373
S'FOXD3'
p5374
S'increases'
p5375
tp5376
(lp5377
s(S'MAX'
p5378
S'FOXD3'
p5379
S'increases'
p5380
tp5381
(lp5382
s(S'POU1F1'
p5383
S'GATA6'
p5384
S'increases'
p5385
tp5386
(lp5387
s(S'POU2F1'
p5388
S'STAT4'
p5389
S'increases'
p5390
tp5391
(lp5392
s(S'GTF3A'
p5393
S'FOXO3'
p5394
S'increases'
p5395
tp5396
(lp5397
s(S'MYB'
p5398
S'FOXF2'
p5399
S'increases'
p5400
tp5401
(lp5402
s(S'ZIC3'
p5403
S'CYP26A1'
p5404
S'increases'
p5405
tp5406
(lp5407
s(S'POU2F1'
p5408
S'EN1'
p5409
S'increases'
p5410
tp5411
(lp5412
s(S'JUN'
p5413
S'STAT1'
p5414
S'increases'
p5415
tp5416
(lp5417
g4200
ag4201
as(S'TEF'
p5418
S'CYP26A1'
p5419
S'increases'
p5420
tp5421
(lp5422
s(S'MAF'
p5423
S'CYP26A1'
p5424
S'increases'
p5425
tp5426
(lp5427
s(S'PAX4'
p5428
S'GATA6'
p5429
S'increases'
p5430
tp5431
(lp5432
s(S'ZIC2'
p5433
S'GATA6'
p5434
S'increases'
p5435
tp5436
(lp5437
s(S'hsa-miR-181d-5p'
p5438
S'HRAS'
p5439
S'decreases'
p5440
tp5441
(lp5442
s(S'BACH2'
p5443
S'CYP26A1'
p5444
S'increases'
p5445
tp5446
(lp5447
s(S'TCF12'
p5448
S'CYP26A1'
p5449
S'increases'
p5450
tp5451
(lp5452
s(S'GATA1'
p5453
S'FOXO4'
p5454
S'increases'
p5455
tp5456
(lp5457
s(S'RFX1'
p5458
S'FOXD3'
p5459
S'increases'
p5460
tp5461
(lp5462
s(S'FOXJ1'
p5463
S'CYP26A1'
p5464
S'increases'
p5465
tp5466
(lp5467
s(S'GTF2A2'
p5468
S'POU2F1'
p5469
S'increases'
p5470
tp5471
(lp5472
s(S'YY1'
p5473
S'SRF'
p5474
S'increases'
p5475
tp5476
(lp5477
s(S'AHR'
p5478
S'REPIN1'
p5479
S'increases'
p5480
tp5481
(lp5482
s(S'MAZ'
p5483
S'CYP26A1'
p5484
S'increases'
p5485
tp5486
(lp5487
s(S'Quercetin'
p5488
S'HRAS MRNA'
p5489
S'increases'
p5490
tp5491
(lp5492
s(S'ELK1'
p5493
S'NRAS'
p5494
S'increases'
p5495
tp5496
(lp5497
s(S'HIF1A'
p5498
S'ONECUT1'
p5499
S'increases'
p5500
tp5501
(lp5502
s(S'FOXF2'
p5503
S'CYP26A1'
p5504
S'increases'
p5505
tp5506
(lp5507
s(S'SOX9'
p5508
S'ETS1'
p5509
S'increases'
p5510
tp5511
(lp5512
s(S'HSF1'
p5513
S'JUN'
p5514
S'increases'
p5515
tp5516
(lp5517
s(S'CEBPA'
p5518
S'CYP26A1'
p5519
S'increases'
p5520
tp5521
(lp5522
s(S'NR1H4'
p5523
S'MEIS1'
p5524
S'increases'
p5525
tp5526
(lp5527
s(S'SMAD1'
p5528
S'GATA1'
p5529
S'increases'
p5530
tp5531
(lp5532
s(S'Quercetin'
p5533
S'HRAS MRNA'
p5534
S'decreases'
p5535
tp5536
(lp5537
s(S'Glycyrrhetinic Acid'
p5538
S'HRAS PROTEIN'
p5539
S'decreases'
p5540
tp5541
(lp5542
s(S'HOXA4'
p5543
S'POU2F1'
p5544
S'increases'
p5545
tp5546
(lp5547
s(S'FOXQ1'
p5548
S'CYP26A1'
p5549
S'increases'
p5550
tp5551
(lp5552
s(S'FOXI1'
p5553
S'CEBPA'
p5554
S'increases'
p5555
tp5556
(lp5557
s(S'GTF3A'
p5558
S'MYCN'
p5559
S'increases'
p5560
tp5561
(lp5562
s(S'LMO2'
p5563
S'IRF1'
p5564
S'increases'
p5565
tp5566
(lp5567
s(S'FOXO1'
p5568
S'CYP26A1'
p5569
S'increases'
p5570
tp5571
(lp5572
s(S'Copper Sulfate'
p5573
S'NRAS MRNA'
p5574
S'increases'
p5575
tp5576
(lp5577
s(S'TFAP2A'
p5578
S'CYP26A1'
p5579
S'increases'
p5580
tp5581
(lp5582
s(S'FOXJ1'
p5583
S'EN1'
p5584
S'increases'
p5585
tp5586
(lp5587
s(S'MEIS1'
p5588
S'RUNX1'
p5589
S'increases'
p5590
tp5591
(lp5592
s(S'MAZ'
p5593
S'FOXA1'
p5594
S'increases'
p5595
tp5596
(lp5597
s(S'ETS1'
p5598
S'FOXO4'
p5599
S'increases'
p5600
tp5601
(lp5602
s(S'ZBTB14'
p5603
S'FOXD3'
p5604
S'increases'
p5605
tp5606
(lp5607
s(S'FOXC1'
p5608
S'LEF1'
p5609
S'increases'
p5610
tp5611
(lp5612
s(S'IRF1'
p5613
S'EN1'
p5614
S'increases'
p5615
tp5616
(lp5617
s(S'NR3C1'
p5618
S'CYP26A1'
p5619
S'increases'
p5620
tp5621
(lp5622
s(S'VSX1'
p5623
S'BACH1'
p5624
S'increases'
p5625
tp5626
(lp5627
s(S'CYP26A1'
p5628
S'ETS1'
p5629
S'increases'
p5630
tp5631
(lp5632
s(S'CEBPA'
p5633
S'MEIS1'
p5634
S'increases'
p5635
tp5636
(lp5637
s(S'ELF1'
p5638
S'FOXO4'
p5639
S'increases'
p5640
tp5641
(lp5642
s(S'RXRA'
p5643
S'CYP26A1'
p5644
S'increases'
p5645
tp5646
(lp5647
s(S'CREB1'
p5648
S'CYP26A1'
p5649
S'increases'
p5650
tp5651
(lp5652
s(S'IRF7'
p5653
S'GATA6'
p5654
S'increases'
p5655
tp5656
(lp5657
s(S'ZEB1'
p5658
S'CYP26A1'
p5659
S'increases'
p5660
tp5661
(lp5662
s(S'AR'
p5663
S'CYP26A1'
p5664
S'increases'
p5665
tp5666
(lp5667
s(S'TFDP2'
p5668
S'MYC'
p5669
S'increases'
p5670
tp5671
(lp5672
s(S'hsa-mir-217'
p5673
S'KRAS'
p5674
S'decreases'
p5675
tp5676
(lp5677
s(S'MEK'
p5678
S'ERK'
p5679
S'adds_modification'
p5680
tp5681
(lp5682
g658
aS'First, sorafenib suppresses the proliferation of tumor cells by inhibiting the RAS/RAF/MEK/ERK signal pathway.'
p5683
aS'More recently, many reports demonstrated that several signaling pathways crosstalk with the canonical Hh pathway, including transforming growth factor, mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinases (ERK), PI3K/Akt, and nuclear factor kappa-light-chain-enhancer of activated B cells pathways.'
p5684
aS'Both EGFR-RAS-MEK-extracellular signal-regulated kinase (ERK) signal transduction and C-MET-PI3K-AKT signal transduction have roles in the prevention of apoptosis, the regulation of cell cycle progression, and cell proliferation.'
p5685
aS'The RAS/RAF/MEK/ERK pathway has been demonstrated to be constitutively activated in a wide variety of tumors including BTC.'
p5686
ag659
ag662
aS'Key mutations that lead to constitutive activation of tumor growth and survival pathways occur in the receptor tyrosine kinase CKIT (CD117), and the RAS/RAF/MEK/ERK and phosphoinositide- 3-OH kinase (PI3K)/Protein Kinase B (AKT)/ phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signal transduction systems ('
p5687
aS'The RAS/RAF/MEK/ERK pathway plays a role in normal organogenesis; however, when aberrantly activated it can lead to malignant cellular proliferation, inhibition of apoptosis, and invasion.'
p5688
ag663
aS'The mitogen-activated protein kinase (MAPK) pathway, consisting of the kinase cascade RAS-RAF-MEK-ERK, is the most commonly activated signaling pathway in melanoma.'
p5689
aS'As this aberrant activity of the MAPK pathway drives tumor cell proliferation and survival, many targeted therapies have been developed to inhibit key proteins in this kinase cascade, such as BRAF, MEK or ERK. '
p5690
aS'The MEKi-induced skin toxicity has been suggested to be mediated by inhibition of ERK activity, which is known to be crucial for the maturation of keratinocytes.'
p5691
aS'It has been postulated that MEKi treatment leads to skin toxicities by inducing downregulation of pERK levels in keratinocytes, whereas the BRAFi-mediated skin toxicity is believed to result from paradoxical upregulation of pERK levels in these cells.'
p5692
aS'The relative quantification of pERK1/2 levels in the skin of treated mice showed that although MEKi-associated skin toxicity was reduced, the decreased pERK1/2 levels upon MEKi treatment were not restored when synchronous BRAFi treatment was used.'
p5693
aS'Thus, whereas reduced levels of pERK1/2 in skin may still contribute to the MEKi-induced skin toxicity, our data indicate that restoring these levels of pERK1/2 to baseline levels is not required to alleviate MEKi-associated skin toxicity.'
p5694
aS'Skin pERK levels do not correlate with reduced MEKi-induced skin toxicity upon synchronous BRAFi.'
p5695
aS'Mechanistic studies revealed that the PI3K/AKT/mTOR and mitogen-activated protein kinase kinase (MEK)/MAPK signaling pathways were activated through elevated expression of phosphorylated (p)-extracellular signal-regulated kinase (ERK), p-AKT, mTOR, p-mTOR, p-P70S6K, and reduced expression of p-P38 and LC3-II (the marker of autophagy) in 231/Gem in comparison to control cells.'
p5696
aS'Antibodies against MEK1/2 (9126, 1:1,000), Phospho-MEK1/2 (2338, 1:1,000), Phospho-ERK1/2 (4376, 1:1,000), AKT (4691, 1:1,000), Phospho-AKT (4060P, 1:1,000), Phospho-P38 (4511, 1:1,000), Phospho-JNK (4668, 1:1,000), E-Cadherin (3195, 1:1,000), Phospho-p53 (9284, 1:1,000), and mTOR Substrates Sampler kit (CST 9862), which includes Phospho-mTOR, mTOR, Phospho-p70s6389 (Thr389), Phospho-P70389 (Thr371), Phospho-4EBP1 (Thr37/46), and anti-rabbit IgG, were purchased from Cell Signaling Technology, Inc., (Danvers, MA, USA).'
p5697
aS'Further mechanistic studies confirmed that PI3K/AKT/mTOR and MEK/MAPK signaling pathways were activated through elevated expression of p-ERK, p-AKT, mTOR, p-mTOR, and p-P70S6K, and reduced expression of p-P38 and LC3-II (the marker of autophagy) in 231/Gem as compared to control cells.'
p5698
aS'Paclitaxel induces activation of the MEK/ERK pathway in human breast cancer'
p5699
aS'Phosphorylation of ERK1/2, downstream molecules of MEK, was effectively inhibited with selumetinib in melanoma, colorectal cancer, pancreatic cancer, non-small-cell lung cancer, and hepatocellular cancer cell lines harboring '
p5700
aS'Because inhibition of ERK phosphorylation has been used as a pharmacodynamic biomarker of MEK inhibitor activity,'
p5701
aS'Activated RAF kinases phosphorylate and activate MEK1/2, which in turn phosphorylate and activate ERK1/2, leading to cellular proliferation, survival, and differentiation, and to an inhibitory feedback toward upstream components of the pathway.'
p5702
aS'The RAS-RAF-MEK-ERK signaling cascade plays a critical role in the transmission of signals to regulate gene expression and cell proliferation ['
p5703
aS'Several studies indicate that melanoma cells are addicted to constitutive activation of the RAS-RAF-MEK-ERK cascade.'
p5704
aS'Mitogen-activated protein kinases (MAPKs) are cytoplasmic Ser/threonine kinases that transduce signals by activating extracellular signal-regulated kinases (ERKs) through the RAS-RAF-MEK-ERK (RAS/MAPK) signal transduction cascade ['
p5705
ag664
aS'To investigate whether inhibiting MEK, an upstream regulator of ERK signaling, affects Hippo pathway activity, we analyzed YAP expression in NSCLC A549 cells treated with the MEK1/2 inhibitor Trametinib (N-(3-(3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6, 8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydropyrido [4,3-d] pyrimidin-1(2H)-yl) phenyl) acetamide, GSK1120212 ['
p5706
aS'Mitogen-activated protein kinase 1 (MEK1) was recently reported to be closely correlated with YAP in human liver cancer cells, but ERK was deemed irrelevant to the Hippo/YAP pathway ['
p5707
ag665
aS'Hh has well documented partially cross-covering intersections with four other growth promoting pathways-1) RAS/RAF/MEK/ERK, 2) PI3K/AKT/mTOR, 3) EGFR ['
p5708
ag666
aS'Western blot analysis of ERK phosphorylation in HCT116, HCT116/vector, and HCT116/RAGE cells (A), in SW620, SW620/vector, and SW620/RAGE cells (C), and in DLD-1, DLD-1/vector, and DLD-1/RAGE cells (C) after incubation for one hour with BSA (lanes 1,2,4), rS100A4 (lanes 3,5,6,7), additional treatment with rsRAGE (lane 6), or treatment with MEK inhibitor U0126 (lane 7).'
p5709
aS'Also, MEK and ERK inhibitors or mutants reduced CTGF-increased cell migration and miR-519d suppression.'
p5710
aS'The MEK/ERK pathway has been reported to regulate MMPs expression and cancer metastasis ['
p5711
aS'(E) MG-63 cells were incubated with rCTGF (50 ng/ml) for indicated time intervals, MEK and ERK phosphorylation examined by western blot.'
p5712
aS'CTGF increases MMP-2/-3 expression and promotes metastasis by down-regulating miR-519d through MEK and ERK pathways; CTGF inhibition presents a new therapeutic target.'
p5713
aS'Fu for providing the MEK1 mutant and Dr. M. Cobb for providing the ERK2 mutant.'
p5714
ag667
ag668
ag670
ag671
ag672
ag673
ag674
ag675
ag676
aS'The broad expression of p-ERK suggests that MEK may be a therapeutic target in AT/RT.'
p5715
aS'They were next analyzed by immunoblotting with antibodies detecting the substrate of MEK, P-ERK, the cyclin A proliferation marker and the mature caspase-2.'
p5716
aS'Analysis of MEK1/2 and ERK1/2 phosphorylation kinetics upon EGF stimulation revealed that PTPRO overexpression dramatically reduced EGF-induced phosphorylation of both ERK1/2 and MEK1/2 (Figure '
p5717
aS'Under hypoxia, activation of ERK signaling is required for lapatinib resistance as treatment with MEK inhibitor trametinib reverses hypoxia-mediated lapatinib resistance.'
p5718
aS'Here, we demonstrate for the first time that hypoxia promotes lapatinib resistance in ERBB2-positive breast cancer cells through activation of the MEK-ERK pathway in a HIF-1-dependent manner via regulation of DUSP2 (Figure '
p5719
aS'BIM is a pro-apoptotic BH3-only domain protein that is regulated both transcriptionally and post-transcriptionally by many signaling pathways including BRAF/MEK/ERK, PI3K/AKT, p38 MAPK and JNK/SAPK ['
p5720
ag678
ag679
ag680
ag681
ag682
ag683
aS'MEK1 phosphorylates extracellular signal regulated kinases 1/2 (ERK1 and 2) at specific T /Y residues ['
p5721
aS'Suppression of MEK and ERK can have profound effects on cell growth, inflammation and aging.'
p5722
ag685
ag686
ag687
ag689
ag690
ag691
ag692
ag693
ag694
ag696
aS'For example when MEK1 is targeted, ERK1,2 is inhibited and the negative feed-back loop on MEK is broken and activated MEK accumulates.'
p5723
ag698
ag699
ag700
ag701
ag702
ag703
ag704
ag705
ag706
ag707
ag708
ag709
ag710
aS'(A) Left panel, MAPK/ERK signaling was highly activated in the Malme-3M cell line according to Western analysis to detect the protein levels of BRAF and phospho-MEK.'
p5724
aS'Furthermore, we also identified STAT3 and MEK/ERK/ BCL2 pathways to be downstream targets of CKS1B activation independent on the complex of SKP2/p27'
p5725
aS'To examine the functional independence of SKP2 and CKS1B, SKP2-shRNA was used to silence SKP2 in KMS28PE, OCI-MY5, and XG-1 cells and protein levels of p-MEK1/2, p-ERK1/2, p-STAT3, and p-BCL2 in these cells were examined.'
p5726
aS'Cell lysates were prepared and subjected to western analysis using antibodies recognizing p-MEK1/2 and p-ERK1/2 proteins.'
p5727
aS'U0126 decreased p-MEK1/2 and p-ERK1/2 in both EV- and CKS1B-transfected myeloma cells (Figure '
p5728
aS'Since inhibitors of MEK/ERK signaling pathway may induce some non-specific effects on myeloma cell growth and survival, we constitutively activated the MEK/ ERK signaling pathway by lentivirus-vector-mediated MEK1-cDNA transfection in CKS1B-silenced KMS28PE, OCI-MY5 and XG1 cells.'
p5729
aS'Western blots showed a larger increase of p-MEK1/2 and p-ERK1/2 levels in MEK1-cDNA and CKS1B-shRNA double-transfected cells compared with SCR- and CKS1B-transfected controls (Figure '
p5730
aS'Our results indicate that BCL2 is a downstream target of the CKS1B and MEK/ERK signaling pathway.'
p5731
aS'Since the STAT3 and MEK/ERK signaling pathways were both involved in CKS1B-induced myeloma cell growth and survival, a combined targeting of these signaling pathways might induce synergistic cytotoxicity in myeloma cells.'
p5732
aS'Targeting STAT3 and MEK/ERK/BCL2 activity by specific inhibitors resulted in significant MM cell death and growth inhibition and their combinations had a synergistic cytotoxic effect on myeloma cells.'
p5733
aS'In this study, we found that CKS1B-knockdown inhibited and CKS1B-overexpression activated STAT3 and MEK/ERK signaling pathways, demonstrating that STAT3 and MEK/ERK signaling pathways are the CKS1B downstream signaling pathways, independent of SKP2/p27'
p5734
aS'We identified STAT3 and MEK/ERK/BCL2 as CKS1B-downstream signaling pathways; and thereby provided targets for the development of new therapeutic approaches for CKS1B over-expressing myeloma and other tumor malignancies.'
p5735
aS'Since CKS1B over-expression and 1q21 gains have been observed in many other malignancies and it is well-documented that JAK/STAT3 and MEK/ERK/BCL2 signaling pathways play a crucial role in tumor cell survival, drug-resistance and cancer progression ['
p5736
aS'Activated ERK levels were higher in SW480-CTHRC1 cells than in SW480-Mock control cells, and the MEK1/2 inhibitor U0126 specifically blocked MMP9 expression at both transcriptional and protein levels.'
p5737
aS'The MEK/ERK pathway controls MMP9 expression in various cells ['
p5738
aS'A lot of studies have indicated that ALK activated various pathways including the JAK/STAT3 pathway, PI3K/AKT pathway, and RAS/RAF/MEK/ERK1/2 pathway, which control cell proliferation and survival ['
p5739
aS'MEK/ERK pathway is involved in tumor cell proliferation and migration, promoting metastatic processes ['
p5740
aS'Accumulated evidences indicate that HCC cell activation by different factors is known to increase MEK/ERK and PI3K/AKT signaling ['
p5741
aS'We then set out to investigate how AKT and ERK1/2 signalling activity, the immediate downstream effectors of PI3K and MEK, alter in H3122 cells treated with TAE684 according to different time schedules.'
p5742
ag711
ag712
ag713
ag715
ag716
aS'PD-184352 (Pfizer) was the first MEK inhibitor to enter clinical trials and it demonstrated inhibition of activated ERK and anti-tumor activity in patients ['
p5743
aS'Human HCC tumors have higher expression and enhanced activity of MEK1/2 and ERK1/2 compared with adjacent non-neoplastic liver ['
p5744
ag719
ag722
ag723
ag724
ag725
aS'The cytotoxic effects of combinations of MEK inhibitors and paclitaxel may be specific for cells of certain origins and may depend on the levels of endogenous activated MEK/ERK present in those cells.'
p5745
aS'In a study with NSCLC cells which constitutively-expressed activated MEK/ERK, no increase in paclitaxel-induced apoptosis was observed when the cells were treated with a MEK inhibitor ['
p5746
ag726
ag727
ag728
ag730
aS'For example when MEK1 is targeted, ERK1,2 is inhibited and the negative feed-back loop on MEK is broken and activated MEK accumulates.'
p5747
ag732
ag734
ag735
ag736
ag737
ag738
ag739
aS'Activated RTKs promote RAS-mediated dimerization of RAF; wild-type RAF, as hetero- or homodimers, phosphorylate and activate MEK1/2, which in turn phosphorylate and activate ERK1/2.'
p5748
aS'Activated RAF kinases phosphorylate and activate MEK1/2, which in turn activate ERK1/2.'
p5749
aS'The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways interact at multiple points, resulting in cross-activation, cross-inhibition, and pathway convergence.'
p5750
aS'COT activates ERK primarily through MEK-dependent mechanisms that do not require RAF signaling.'
p5751
aS'ERKi were more effective than MEKi at overcoming BRAFi resistance conferred by a number of mechanisms (BRAF splice variants, NRAS mutations, MEK mutations, BRAF amplification, RTKs activation) '
p5752
aS'Of 40 treated patients (GC=6; CC=34; median age, 60 years), 8 (20%) had stable disease (SD) &gt; 6 months, 3 (8%) partial response (PR), on protocols with hepatic arterial drug infusion and anti-angiogenic, anti-HER-2/neu or novel MAPK/ERK kinase (MEK) inhibitors.'
p5753
aS'Abbreviations: AC, adenylyl cyclase; BID, BH3-interacting domain death agonist; CD95/Fas (factor-activating Exo S), death receptor; CREB, cAMP-response element binding protein; Csp-1, -3, -6, -8 and -9, caspases-1, -3, -6, -8 and -9; DISC, death-inducing signaling complex; G, a G-protein; JNK, c-Jun-N terminal kinase; LCA, lithocholic acid; MEKK1/2/3, mitogen-activated protein kinase/ERK kinase kinase-1, -2 and -3; MKK4/7, mitogen-activated protein kinase kinase-4 and -7; MOMP, mitochondrial outer membrane permeabilization; PKA, protein kinase A; ROS, reactive oxygen species; TGR5, a member of the G-protein coupled receptor family.'
p5754
ag741
ag743
aS'Previous studies reported that several signaling pathways, including PI3K/AKT, MEK/ERK, and STAT3, are essential for survival and/or resistance to ALK inhibitors in '
p5755
aS'Inhibition of RAF/MEK/ERK signaling is beneficial for many patients with BRAF'
p5756
aS'Dual specific phosphatases (DUSP), SPRY and SPRED family proteins are induced by the RAF/MEK/ERK1/2 pathway ['
p5757
aS'ERK inhibitors have an important advantage of being potentially active in the setting of acquired resistance to inhibitors of BRAF or MEK ['
p5758
aS'Sequencing of seven melanoma cell lines and donor-matched germline cells found MAP2K1 and MAP2K2 (MEK1 and MEK2, respectively) mutations, resulting in constitutive ERK phosphorylation and higher resistance to MEK inhibitors.'
p5759
aS'A recent study demonstrated an essential role for ERK-phosphorylated MEK1 (pT292) in membrane recruitment of PTEN and consequent negative regulation of AKT ['
p5760
aS'In BRAF-mutant melanoma sustained mTORC1 signaling could be driven by alternative mechanisms of ERK activation or concomitant activation of the PI3K-Akt pathway, thus promoting resistance to RAF and MEK inhibitors.'
p5761
aS'ERK activation, independent of classical RAF/MEK/ERK pathways, was shown to occur in resistant lines with mutant BRAF.'
p5762
ag745
ag746
ag747
ag748
ag749
ag750
ag751
ag752
ag753
ag754
aS'Activation of EGFR has been linked to the pro-survival signaling pathways, including Akt, STAT3 and RAF/MEK/ERK mitogen-activated protein kinase (MAPK) ['
p5763
aS'It is known that continued activation of the Philadelphia chromosome causes phosphorylation of downstream proteins such as MEK and ERK, resulting in activation of cell proliferation pathways['
p5764
aS'(D) Expression levels of GATA-1, MEK, p-MEK, ERK and p-ERK were analyzed by western blotting using indicated antibodies.'
p5765
aS'(F) Expression levels of MEK, p-MEK, ERK and p-ERK were analyzed by western blotting using indicated antibodies.'
p5766
aS'Our studies showed that levels of phosphorylated MEK and ERK in primary CML cells were higher than those in K562 cells, and wogonin showed a more inhibitory effect on phosphorylation of MEK and ERK in primary CML cells (Data not shown).'
p5767
aS'Our studies have shown that prolactin produced in breast cancer cells through intracrine activation of PRLR and via at least two signal transduction pathways, JAK2/STAT5 and JAK2/PI3K/MEK/ERK, up-regulates the human prolactin receptor.'
p5768
aS'PI3K/AKT and MEK/ERK signal pathways are the main downstream pathways of EGFR.'
p5769
aS'Additionally, resistance to gefitinib induced by miR-200c down regulation implicated the activation of PI3K/AKT and MEK/ERK pathways.'
p5770
ag757
ag758
ag759
ag760
aS'A profiling of the genetic alterations in human PDAC has shown that simultaneously increased activity of RAS-RAF-MEK-ERK1/2 and PI3K-AKT-mTOR pathways is common ['
p5771
aS'The connection between oncogenic Ras and such downstream effectors as ERKs is believed to be principally mediated by CRAF kinase, which, in turn, supports the activity of ERK activators, MEKs.'
p5772
aS'Consequently, neurofibromin suppresses activation of the downstream effectors of Ras, including PI3K, Akt, mTOR, S6 kinase and RAF, MEK, ERK as well as RAC1 and PAK1.'
p5773
aS'MEK=MAPK-ERK kinase.'
p5774
ag762
aS'Though the absolute majority of melanocytic lesions contain MEK-activating mutations, they exhibit a large degree of heterogeneity with regard to phospho-ERK immunopositivity.'
p5775
aS'An important player in the MEK/ERK/EMT-TF pathway is an AP1 transcription factor family member, FOS-related antigen 1 (FRA1).'
p5776
aS'Overexpression of ESL-1 in prostate cancer cells triggers a signaling kinase cascade, from activation of RAS, MEK, and ERK, consequently inducing the expression transcription factor, and activates a cascade of gene expressions that allows cancer cells to migrate, invade and spread to the secondary organs (Figure '
p5777
aS'(B,D) Quantitation of pMEK1/2, MEK1/2, pERK1/2 and ERK1/2 by Western blotting was as described in the legend to figure '
p5778
ag763
ag764
ag765
aS'Next, we analyzed the phosphoprylation status of ERK and MEK to expect inhibition of downstream signaling by JTP-74057.'
p5779
aS'(A) HT-29 cells (left) and ACHN cells (right) were treated with the indicated concentrations of each compound for 24 h, and the cell lysates were analyzed by western blotting using antibodies specific to phosphorylated and total MEK1/2 and ERK1/2.'
p5780
aS'(B) Time-course analysis of the phosphorylation states of MEK and ERK in HT-29 cells treated with JTP-74057.'
p5781
aS'HT-29 cells were treated with 10 nM JTP-74057 for the indicated times, and the cell lysates were analyzed by western blotting using antibodies specific to MEK or ERK.'
p5782
aS'(C) Prolonged inhibition of ERK phosphorylation via sustained u-MEK status by pulsed JTP-74057, but not PD0325901.'
p5783
aS'The cell lysates were analyzed by western blotting in terms of the phosphorylation state of MEK and ERK.'
p5784
aS'(D) Alteration of the phosphorylation states of MEK and ERK by JTP74057 in various cancer cells.'
p5785
aS'The data showed that ERK phosphorylation was efficiently inhibited in almost all cell lines, except for COLO-320DM, and that the p-MEK levels decreased in HT-29, COLO-205, HCT-116, SW480 and SW620 cells, but did not decrease or decrease to a lesser extent in HCT-15, LS-174T, T84 and LoVo cells.'
p5786
aS'This unique binding to u-MEK could explain why JTP-74057 effectively inhibits ERK phosphorylation and prolongs the unphosphorylation state of MEK.'
p5787
ag766
aS'Antibodies specific to p-MEK1/2 (Ser217/221), p-p44/42MAPK (Thr202/Tyr204), MEK1/2 and ERK1/2 were purchased from Cell Signaling Technology (Beverly, MA).'
p5788
aS'Transfection with HSP90 shRNA resulted in a decrease in EGFR, PI-3K, pAKT, pMEK, pERK and c-Myc expression in both cell lines as compared to SV transfected cells.'
p5789
aS'Treatment with ganetespib downregulated EGFR, PI-3K, pAKT, pMEK, pERK and c-Myc expression in both cell lines that were un-transfected or transfected with SV.'
p5790
aS'Treatment with ganetespib did not affect the expression levels of PI-3K, pAKT, pMEK, pERK, and c-Myc in HSP90 shRNA transfected cells.'
p5791
aS'Decreased protein expression of EGFR, PI-3K, pAKT, pMEK, pERK and c-myc was observed in tumors treated with ganetespib.'
p5792
aS'MAPK kinase (MEK) inhibitor has been shown to suppress growth hormone-induced transcription mediated by STAT5, which can also directly interact with ERK1/2 ['
p5793
ag767
ag768
ag769
ag770
ag771
ag772
ag773
ag774
ag775
ag776
ag777
ag778
ag780
ag781
ag782
ag783
ag784
aS'The cytotoxic effects of combinations of MEK inhibitors and paclitaxel may be specific for cells of certain origins and may depend on the levels of endogenous activated MEK/ERK present in those cells.'
p5794
aS'In a study with NSCLC cells which constitutively-expressed activated MEK/ERK, no increase in paclitaxel-induced apoptosis was observed when the cells were treated with a MEK inhibitor ['
p5795
ag785
ag786
ag787
ag788
ag789
ag790
ag791
ag792
ag793
ag795
aS'For example when MEK1 is targeted, ERK1,2 is inhibited and the negative feed-back loop on MEK is broken and activated MEK accumulates.'
p5796
ag797
ag799
ag800
ag801
ag802
ag1952
aS'IL-7 activates MEK/ERK in T-ALL primary cells, however pharmacological inhibition of MEK/ERK did not have any negative effects on cell cycle progression and survival ['
p5797
aS'For example, crosstalk between the PI3K and MAPK pathways enables mTOR inhibition to enhance ERK phosphorylation and MEK inhibition to activate AKT ['
p5798
aS'Increased ROS can stimulate Ras activity and phosphorylate MEK1/2 and ERK1/2, which are ROS level dependent tumor-associated pathways.'
p5799
ag803
ag804
aS'Among the tested compounds, antagonists of inhibitor of apoptosis proteins (IAP), epidermal growth factor receptor (EGFR), MAPK/ERK kinase-1/2 (MEK1/2) and Src family kinases displayed enhanced efficacy in the context of combined PAK1 knockdown ['
p5800
aS'Using the selective MEK inhibitor PD325901, we demonstrated that blocking this increase in ERK signaling is sufficient to cause synergy in combination with p70S6 kinase inhibition.'
p5801
aS'To better understand the cytoprotective action of ERK in the context of Baf1A-induced cell death, we exposed MDA-MB-231 cells to hypoxia in the presence and absence of Baf1A and quantified c-raf-MEK1/2- ERK1/2 signaling.'
p5802
ag806
aS'We demonstrated that the elevated invasiveness was a result of the activated EGFR-MEK/ERK signaling, which in turn leads to ZEB1 dependent MMP2 induction.'
p5803
aS'These results suggest that the EGFR-MEK/ERK/ZEB1/MMP2 axis is responsible for promoted invasion in EMT-induced NSCLCs.'
p5804
aS'Thereby, these data suggest that the EGFR-MEK/ERK signaling would be a promising molecular target to control aberrant MMP2 expression and consequent invasion in the EMT-induced NSCLCs'
p5805
aS'In this study, we found that the EGFR-MEK/ERK signaling is aberrantly activated by simple depletion of E-cadherin, and is also closely associated to invasion in MMP2 dependent manner.'
p5806
aS'A closer examination revealed that the ZEB1, of which expression is regulated by EGFR-MEK/ERK signaling, is responsible for the invasive property through upregulation of MMP2.'
p5807
aS'Consistently, the positive correlation between loss of E-cadherin and ERK activation was also observed in the disseminating cancer cells of NSCLC patients, demonstrating that the EGFR-MEK/ERK axis would be a promising target for attenuating deviant MMP2 expression and the subsequent invasive trait in EMT-induced NSCLCs.'
p5808
aS'The EGFR-dependent gene expression could primarily be mediated by the MEK/ERK or the PI3K/Akt signaling, or cooperatively by the two pathways.'
p5809
aS'On the basis of MEK/ERK signaling-dependent '
p5810
aS'Our data suggest that EGFR-dependent signaling would be an important therapeutic target for NSCLC treatment, based on the results such as the requirement of MEK/ERK signaling in the invasive properties of EMT-induced A549 cells (Fig. '
p5811
aS'In summary, we show that loss of E-cadherin results in activation of MEK/ERK signaling, showing the positive correlation between loss of E-cadherin and ERK activation.'
p5812
aS'MEK inhibitor, CI-1040, was used to inhibit the mitogen-activated protein kinase kinases (MEK) and the downstream MAPK/ERK activities to decrease phosphorylation of Mcl-1 and hence its stability.'
p5813
ag807
ag808
aS'Inhibition of the BRAF/MEK/ERK signaling cascade may increase TRIM16, as TRIM16 may be a negatively regulated downstream target.'
p5814
aS'In contrast to the reactivation of the MEK and mTOR signaling seen in single drug treatments, when mice were treated with Everolimus and PD-901 in combination, p-AKT, p-4EBP, and p-ERK were all inhibited at early timepoints, and remained low at later time points (Figure '
p5815
aS"(A) Total protein expression (relative units) of p70-S6K, AKT, EGFR, ERK1/2, MTOR, GSK3B, and MEK1/2 in normal and tumor colon tissue at four timepoints of tissue collection: pre, before hepatic pedicle clamping; 10', 10 minutes after resection; 20', 20 minutes after resection; and 45', 45 minutes after resection."
p5816
aS"(B) Percentage of protein phosphorylation of p70-S6K, AKT, EGFR, ERK1/2, MTOR, GSK3B, and MEK1/2 in normal and tumor colon tissue at four timepoints of tissue collection: pre, before hepatic pedicle clamping; 10', 10 minutes after resection; 20', 20 minutes after resection; and 45', 45 minutes after resection."
p5817
aS'This included AKT, MTOR, ERK1/2, and MEK (Figure '
p5818
aS'The following assay kits were used: HIF1alpha singleplex, HSP27/pHSP27(Ser15) duplex, EGFR/pEGFR(Tyr1173) duplex, AKT/pAKT(Ser473) duplex, MTOR/pMTOR(Ser2448) duplex, p70-S6K/pp70-S6K(Thr421, Ser424) duplex, GSK3B/pGSK3B(Ser9) duplex, MEK1/2/pMEK1/2(Ser217/221) duplex and ERK1/2/pERK1/2(Thr202/Tyr204, Thr185/Tyr187) duplex.'
p5819
aS'EGFR dimerization results in autophosphorylation, kinase activation, and subsequent activation of three major signaling pathways,including RAS/RAF/MEK/ERK1/2, PI3K/AKT and STATs pathways.'
p5820
aS'To investigate the mechanisms underlying the melanoma cell resistance to BRAF-I, the expression and activation of the RAF/MEK/ERK and PI3K/AKT pathway components were analyzed in the cell lines both under basal conditions and after treatment with vemurafenib.'
p5821
aS'Therefore both PKC and MEK/ERK pathways are involved in AXL overexpression in TKI-resistant CML cell lines.'
p5822
aS'To validate the microarray data, we performed Western blot and qRT-PCR analyses and focused on a subset of genes that are either down-regulated (ErbB2, AKT, MEK1, ERK1/2, Bcl-2) or up-regulated (p21, Bax).'
p5823
aS'However, we have found that the expression of the other BH3-only protein Noxa is commonly upregulated in melanoma cells, and that this is driven by oncogenic activation of MEK/ERK.'
p5824
aS'A characteristic of human melanoma is constitutive activation of the MEK/ERK signaling pathway ['
p5825
aS'We report here that the increase in Noxa expression is driven by oncogenic activation of MEK/ERK signaling through the transcription factor cAMP responsive element binding protein (CREB), and that Noxa contributes to constitutive activation of autophagy in melanoma cells.'
p5826
aS'To further consolidate that activation of the MEK/ERK pathway upregulates Noxa in melanocytic cells, we infected HEMn-MP human melanocytes with lentiviral constructs expressing BRAF'
p5827
aS'The role of CREB in regulation of Noxa by MEK/ERK signaling was further confirmed by its association with the '
p5828
aS'To test whether constitutive activation of MEK/ERK signaling is essential for the autophagy activity in melanoma cells, we treated IgR3 and Mel-RM cells with U0126 before the addition of bafilomycin A1.'
p5829
aS'Noxa plays a role in induction of autophagy by oncogenic activation of RAS, which is an upstream kinase of RAF/MEK/ERK signaling ['
p5830
aS'In this report, we present evidence that the BH3-only protein Noxa is upregulated by oncogenic activation of MEK/ERK signaling, and that Noxa plays an important role in regulation of autophagy in melanoma cells.'
p5831
aS'While the increase in Noxa expression was associated with melanoma development and progression, inhibition of MEK/ERK signaling downregulated, and activation of the pathway upregulated, the expression of Noxa in melanoma cells.'
p5832
aS'The finding that oncogenic activation of MEK/ERK signaling is responsible for Noxa upregulation in melanoma cells is similarly intriguing, as oncogenic activation of the MEK/ERK pathway is known to be a major driver of the pathogenesis of melanoma that suppresses apoptosis ['
p5833
aS'In summary, we have demonstrated that oncogenic activation of MEK/ERK signaling upregulates the expression of Noxa, which plays an important role in activation of autophagy, in particular, in melanoma cells under nutrient starvation conditions.'
p5834
aS'These results not only reveal an unexpected role of Noxa in protection of melanoma cells from apoptosis through activation of autophagy in a context-dependent manner, but also uncover a novel mechanism by which oncogenic activation of MEK/ERK promotes the pathogenesis of melanoma.'
p5835
aS'MEK1/2 is immediately upstream of extracellular signal-regulated kinase (ERK) 1/2, and has been reported to activate ERK1/2 ['
p5836
aS'Current efforts concentrate on developing inhibitors of RAS and its key downstream effectors, BRAF, MEK, ERK ['
p5837
ag812
aS'First, KRAS can activate also other substrates and not only PI3K/AKT/mTOR pathway, like BRAF/MEK/ERK pathway, Rho and Ral pathways.'
p5838
ag813
aS'KRAS and BRAF mutations lead to the constitutive activation of EGFR signalling through the oncogenic RAS/RAF/MEK/ERK pathway.'
p5839
aS'Mutational status was correlated with growth inhibition and apoptosis induction by the MEK inhibitor CI-1040 that prevented activation of the downstream target, ERK1/2.'
p5840
aS'Recent studies have revealed an additional MEK/ERK pathway that is required for the acquisition of at least one hallmark of senescence: hyper-accumulation of cyclin D1 ['
p5841
aS'Compensatory activation of parallel signaling through the MEK/ERK1/2 pathway in response to PI3K/ Akt inhibition, is an emerging theme in cancer cell signal transduction.'
p5842
aS'Indeed, several recent reports have highlighted the importance of functional cross talks between the MEK/ERK1/2 and PI3K/Akt signaling networks, in response to individual pathway inhibitors ['
p5843
aS'However, MK-2206 increased the phosphorylation levels of ERK 1/2, through a MEK-dependent mechanism, as the hyperphosphorylation was blocked by the MEK inhibitor, AZD6244.'
p5844
aS'Melanomas invariably harbor mutations that constitutively activate the RAF-MEK-ERK pathway, leading to aggressive progression of the disease ['
p5845
aS'Our current data show that MCT-1 is a novel regulator of Shc-Ras-MEK-ERK signaling and MCT-1 is significantly co-activated with Shc gene in human carcinomas.'
p5846
aS'(C) Together with the reduction of Shc proteins, the accumulation of Cyclin D and the phosphorylation of MEK and ERK were all steadily suppressed by depleting MCT-1 in MCF-10A cells.'
p5847
aS'Antibodies (Abs) specific for the cleaved caspase 3 (Asp175), caspase 6, caspase 7, Cyclin D1 (92G2), phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, phospho-MEK1/2 (Ser217/221), MEK1/2, phospho-Rb (Ser780), Rb (4H1) and Shc were purchased from Cell Signaling Technology (Danvers, MA).'
p5848
aS'Depending on the cellular context, PMA can cause either cell cycle progression or cell cycle arrest by inducing both cyclin D1 and p21 via the MEK/ERK pathway ['
p5849
aS'Since PMA activates the MEK/ERK pathway, we investigated whether inhibition of MEK can prevent PMA-induced phosphorylation of S6K and S6.'
p5850
aS'In SKBR3 cells, strong activation of MEK/ERK pathway by PMA causes induction of p21 and cell cycle arrest.'
p5851
aS'The RAF-MEK-ERK pathway regulates many important cellular processes (reviewed in ['
p5852
aS'Consistent with its role as a key regulatory pathway for cell survival and proliferation, RAF-MEK-ERK signaling is frequently dysregulated in cancer.'
p5853
aS'RAF-MEK-ERK signaling can be driven by aberrant activation of growth factor receptor tyrosine kinases (RTKs) or by oncogenic mutations of intracellular components of this pathway.'
p5854
aS'Preclinical data has demonstrated that most BRAF mutant human tumor-derived cell lines are exquisitely sensitive to pharmacologic inhibition of RAF-MEK-ERK signaling.'
p5855
aS'A schematic of the RAF-MEK-ERK signaling pathway is shown with BRAF in red.'
p5856
aS'The vast majority of acquired resistance mechanisms to BRAF or MEK inhibitors that have been identified to date lead to reactivation of ERK signaling despite the presence of inhibitor.'
p5857
aS'Careful evaluation of the dose-response relationship between BRAF inhibitor treatment and phosophorylation of MEK and ERK revealed that, in resistant cells, levels of P-MEK could be reduced by ~50% before any noticeable decrease in P-ERK levels was observed.'
p5858
aS'This was in stark contrast to parental cells, in which a ~50% decrease in P-MEK levels led to a ~50% decrease in P-ERK levels.'
p5859
aS'These findings suggested that the high levels of P-MEK in resistant cells (driven by BRAF amplification) were in excess of levels required for near-maximal ERK phosphorylation.'
p5860
aS'As a result, a much higher concentration of BRAF or MEK inhibitor was required to fully suppress ERK phosphorylation in resistant cells, either by reducing excess P-MEK levels (as in the case of the BRAF inhibitor) or by inhibiting excess MEK activity (as in the case of the MEK inhibitor).'
p5861
aS'However, if resistant cells were treated with a low dose of BRAF inhibitor sufficient to reduce levels of P-MEK to amounts observed under basal conditions in parental cells, the ability of MEK inhibitors to suppress P-ERK was completely restored.'
p5862
aS'As discussed above, the majority of the resistance mechanisms to BRAF and MEK inhibition that have been identified lead to ERK reactivation and retain dependence on ERK signaling.'
p5863
aS'Because RTKs can signal through multiple RAF isoforms by activation of RAS proteins, and since RTKs activate multiple signaling pathways in addition to RAF-MEK-ERK, the authors investigated whether resistant cells showed differences in RTK phosphorylation relative to parental cells.'
p5864
aS'However, pharmacologic inhibition of IGF1R decreased proliferation of resistant cells, and combined inhibition of IGF1R and MEK induced dramatic apoptosis, suggesting that ERK-independent survival signaling was mediated by IGF1R in resistant cells.'
p5865
aS'In addition to activating the RAF-MEK-ERK pathway, IGF1R and other RTKs are known to activate PI3K-AKT signaling, which is known to be an important regulator of cell survival and proliferation ['
p5866
aS'As a result, an alternative approach might be to assess resistant tumor specimens for common indicators of ERK-dependent or ERK-independent resistance, perhaps by assessing biomarkers of RAF-MEK-ERK or PI3K-AKT signaling in a biopsy taken while the patient remains on treatment.'
p5867
aS'B, The protein expression levels of MAP2K1/2, p-MEK1/2, ERK1/2 and p-ERK1/2 were measured by Western blot in Tca-8113 cells transfected with si-IGF-1R and si-Ctrl at 24h.'
p5868
aS'The amount of phosphorylated Akt (Ser-473), ERK1/2 (T201/Y204) and MEK1/2(Ser217/221) were normalized versus that of total Akt, ERK1/2 and MEK1/2.'
p5869
ag815
ag816
ag817
ag818
ag819
ag820
ag821
aS'Bioinformatic analyses of these survival-associated miRs suggested that they might regulate genes involved in ubiquitin proteasome system, TGFb, IGF, PTEN/AKT/mTOR, MAPK, PDGFR/RAF/MEK/ERK, and ErbB/HER pathways.'
p5870
ag822
aS'The MEK5-ERK5 pathway is a mammalian mitogen-activated protein (MAP) kinase cascade that is not well studied compared to other MAP kinase cascades.'
p5871
aS'For the MEK5-ERK5 analysis, the average of all the specified probes, which detect mRNA transcripts of MEK5 and ERK5, were used.'
p5872
aS'Patients were stratified according to the average expression level of MEK5 and ERK5.'
p5873
aS'ALL, acute lymphocytic leukemia; ASCT, autologous stem cell transplantation; CTLA-4, cytotoxic T lymphocyte antigen 4; EGFR, epidermal growth factor receptor; FOLFIRI, 5-fluorouracil, leucovorin, irinotecan; FOLFIRINOX, 5-fluorouracil, leucovorin, irinotecan and oxaliplatin; IGF1R, insulin-like growth factor 1 receptor; GD2, ganglioside GD2; GM-CSF, granulocyte macrophage colony-stimulating factor; HCC, hepatocellular carcinoma; IL, interleukin; mAb, monoclonal antibody; MEK, MAPK/ERK kinase; n.a., not available; NSCLC, non-small cell lung carcinoma; rIL-21, recombinant interleukin-21; PD1, programmed cell death 1; PD-L1, PD1 ligand 1; PS, phosphatidylserine; TBI, total body irradiation; TRAILR2, tumor necrosis factor-related apoptosis-inducing ligand receptor 2; VEGFR2, vascular endothelial growth factor receptor 2.'
p5874
ag823
aS'The most potent activator of MAPK/ERK kinases (MEKs) is the non-receptor kinase '
p5875
aS'Because of its key role in the MEK/ERK signaling pathway, BRAF has been the subject of intense investigation, leading to the approval by regulatory agencies of 2 distinct BRAF inhibitors (BRAFis), vemurafenib and dabrafenib, for use in melanoma patients.'
p5876
aS'One of these strategies involved the concurrent administration of BRAF and MAPK/ERK kinase (MEK) inhibitors, de facto targeting two distinct nodes of the same signaling pathway.'
p5877
aS'One of such strategies relies on the use of mitogen-activate protein kinase (MAPK) inhibitors targeting the BRAF/MEK/ERK pathway, which is constitutively activated in a majority of melanomas.'
p5878
ag824
ag825
ag826
aS'RUNX2-dependent transcription can also be regulated through the MEK/ERK pathway, either via BMP2 and/or PiT-1.'
p5879
aS'Besides induction by BMP2-SMADs, RUNX2-dependent transcription can also be regulated through the MEK/ERK (Extracellular Signal Regulated Kinases) pathway ['
p5880
aS'One example is the autosomal dominantly inherited human developmental syndromes termed the RASopathies caused by (usually) activating mutations of the RAS-RAF-MEK-ERK MAPK pathway ['
p5881
aS'The constitutive hyperactivation of the RAS/RAF/MEK/ERK pathway has been identified in the majority of melanomas as the critical player in the regulation of cell proliferation, invasion and survival ('
p5882
aS'The MEK/ERK and PI3K/AKT pathways are critical for proliferation and survival.'
p5883
aS'As one of the only two upstream molecules in the ERK5 cascade, MEKK2 is crucial in relaying specific cell surface signals to downstream ERK5 following transcription regulation.'
p5884
aS'For instance, GSTM1 functions as a negative regulator of MEKK1, which act as a upstream kinase in MAPK/P38 and JNK/ERK signal pathways ('
p5885
ag828
aS'The BRAF and KRAS molecules share a common RAS/RAF/MEK/ERK signaling pathway, and the ERK kinase is the downstream convergence point of the BRAF and KRAS signaling proteins ('
p5886
aS'Simultaneous activation of the MEK/ERK signaling pathway by CRAF and BRAF occurs individually.'
p5887
aS'BRAF V600E can transphosphorylate and hyperactivate CRAF in the presence of oncogenic KRAS, thus strongly augmenting MEK/ERK signaling activation.'
p5888
aS'In the present study, the MEK inhibitor, which is likely to inactivate ERK, did not affect growth inhibition or cell death in the H'
p5889
ag829
aS'Furthermore, identifying that BANCR induces CRC migration by inducing EMT via an MEK/ERK signalling pathway expands on the current understanding of the molecular mechanisms of BANCR.'
p5890
aS'The first type of tumor develops from hyperplasia, and is characterized by molecular alternations in the RAF/MEK/ERK and PIK3CA signal transduction pathways, while the second, the muscle-invasive tumor type, progresses from a dysplastic urothelium that is characterized by disruptions in the '
p5891
aS'These data indicate that PANC-1 cells may function through the MEK-ERK1/2 pathway of MAPK signaling cascades to regulate proliferation, apoptosis, invasion and migration.'
p5892
aS'The specific signaling cascade involved in this response was explored using a MEK1/2 inhibitor (U0126) specific to the MAPK/ERK pathway.'
p5893
aS'We previously showed that RHL was highly active in targeting the MEK/extracellular signal-regulated kinase (ERK) signal pathway and induced apoptosis and cell cycle arrest in human ovarian cancer cells ('
p5894
aS'However, Taxol in combination with RHL prevented the Taxol-induced ERK activation through the inhibition of MEK phosphorylation ('
p5895
aS'Certain studies have demonstrated that tumor cells are able to produce resistance to Taxol by activating the MEK/ERK signal pathway.'
p5896
aS'The mitogen-activated protein kinase (MAPK) pathway (RAS/MEK/ERK) is a critical growth cascade in oral mucosal melanoma ('
p5897
aS'In the ERK mediated mTORC1 activating pathway, ERK is activated upon Ras induced activation of mitogen activated kinase/ERK kinase (MEK) and then the phosphorylation of TSC2 ensues.'
p5898
aS'The mechanism, in part, involves the MEK/ERK pathway, which in turn is related to protection against oxidative stress.'
p5899
ag830
ag831
ag832
aS'The effect of stress and its relationship with Ras/Rac1/MEK/ERK signaling pathway and epigenetic mechanisms regulation.'
p5900
aS'Ras/Rac1/MEK/ERK signaling pathway seems to be regulated by and regulates superoxide anion production during melan-a anchorage blockade, and its activation could be responsible for the high Dnmt1 protein level and changes in global DNA methylation during the loss of cell adhesion.'
p5901
ag833
aS'ERK1/2 signaling pathway is a distinct Ser-Thr kinase cascade consisting of 3 enzymes: MAPK kinase kinase, MAPK kinase (MAPKK, MEK, MKK), and MAPK ['
p5902
aS'Constitutive active Ras promoted osteoclast survival through activation of the MEK/ERK pathway ('
p5903
aS'Rac and Ras promote osteoclast survival through Akt and MEK/ERK signaling, respectively.'
p5904
ag4200
ag4201
aS'The necessity of PKC and MAP kinase ERK1/2 was demonstrated when the release of S1P was inhibited by using Ro-318220 and BIM (PKC inhibitors), U0126 and PD98059 (MEK inhibitors), as well as SKI-II inhibitor and SphK1-siRNA ['
p5905
ag1391
aS'The activation of ERK was prevented with either MEK inhibitors or anti-HER2 monoclonal antibodies and tyrosine kinase inhibitors.'
p5906
aS'An alternative strategy to block ERK phosphorylation is to use MEK inhibitors, given that MEK is immediately upstream from ERK.'
p5907
aS'The MEK1/2 inhibitor AZD6244 completely abolished the BEZ235-induced phosphorylation of ERK ('
p5908
aS'Anti-HER2 and MEK inhibitors did not only abolish ERK phosphorylation but also increased the anti-proliferative and pro-apoptotic effects of PI3K inhibitors.'
p5909
aS'Our study also highlights the role of the RAS/RAF/MEK/ERK pathway as an escape mechanism to PI3K blockade.'
p5910
aS'The inhibition of the ERK pathway can be achieved by either MEK inhibitors or anti-HER2 agents.'
p5911
aS'BEZ235-induced P-ERK pathway is prevented with agents inhibiting HER2 and MEK1/2 activity.'
p5912
aS'Combined inhibition of PI3K/mTOR and HER2 or PI3K/mTOR and MEK results in greater inhibition of tumor growth and prevents ERK transactivation '
p5913
aS'Collectively, our results indicate that CIB1 is uniquely positioned to regulate PI3K/AKT and MEK/ERK signaling and that simultaneous disruption of these pathways synergistically induces a nuclear GAPDH-dependent cell death.'
p5914
aS'Two frequently mutated and persistently activated oncogenic pathways are PI3K/AKT and Ras/RAF/MEK/ERK ('
p5915
aS'Concurrent activation and crosstalk between the PI3K/AKT and MEK/ERK pathways may contribute to drug resistance by converging on common downstream targets ('
p5916
aS'Tumor cells commonly exhibit hyperactivated PI3K/AKT and Ras/MEK/ERK signaling pathways.'
p5917
aS'Importantly, we confirmed that MPNST cells infected with the NF1-GRD adenovirus have significant reductions in Ras-GTP and downstream phospho-MEK and phospho-ERK protein levels at the 32 hour time point ('
p5918
ag834
ag835
ag836
aS'Recent studies from our laboratory have shown that activation of the RAS, MEK1, and ERK1/2 pathway directs specific cell fate decisions of ovarian granulosa cells in growing and preovulatory follicles as well as in cells that comprise the ovarian surface epithelium ('
p5919
aS'Because the inhibition of PI3K was more effective than inhibition of MEK1/ERK1/2 on cell growth indicates that the PI3K pathway may be a more potent driver of proliferation, perhaps involving the regulatory effects of '
p5920
aS'The MEK1/ERK1/2 and PI3K/AKT pathways drive gene expression and transformation of the mutant OSE cells.'
p5921
aS'Specific miRNAs are expressed in the mutant compared to WT OSE cells and are regulated by inhibitors of MEK1/ERK1/2 and PI3K as shown by real-time RT-PCR.'
p5922
aS'Recent Phase 1 results with PLX4032/RG7204/Vemurafenib, which selectively inhibits B-RAF/MEK/ERK1/2 signaling in mutant B-RAF cells, has given encouragement to this struggling field.'
p5923
aS'MEKK2 regulates ERK5 activation in response to growth factor receptor tyrosine kinases ('
p5924
aS'Because MEKK2 is required for EGF receptor activation of ERK5, we next assessed whether knockdown of ERK5 in MDA-MB-231 cells would show similar tumor growth and metastasis phenotypes as with MEKK2 knockdown.'
p5925
aS'MEKK2 mediates activation of ERK5 by EGFR and Her2 and is required for tumor growth and metastasis.'
p5926
aS'(a) MEKK2 knockdown inhibits ERK5 activation in response to EGF.'
p5927
aS'(c) Lysates from control and MEKK2 shRNA expressing BT474 cells were blotted for ERK5, MEKK2, phospho-ERK1/2, phospho-JNK or tubulin as a loading control.'
p5928
aS'MEKK2 knockdown was accompanied by a marked loss of the super-shifted phospho-ERK5.'
p5929
aS'ERK5 dependent metastasis and MEKK2 dependent release of TF+ microparticles (TF+ MPs).'
p5930
aS'One of 10 mice having ERK5 knockdown cell tumors developed a metastasis (d) Diminished TF from MEKK2 knockdown cells detected by multianalyte profiling of tissue culture supernatants.'
p5931
aS'MAPK activity was reduced through the use of pharmacological inhibitors, including MEK inhibitors (U0126 and PD98059) to block ERK activation and a JNK inhibitor (SP600125) to block JNK activity.'
p5932
aS'Incubation with either MEK inhibitor caused significant reduction in ERK phosphorylation relative to treatment with the negative control (U0124) or DMSO ('
p5933
aS'Growth factor-induced MUC1-C translation was found to be mediated by PI3K->AKT, and not MEK->ERK1/2, signaling.'
p5934
aS'The RAS-RAF-MEK-ERK pathway is deregulated in over 90% of malignant melanomas and targeting MEK as central kinase of this pathway is currently tested in clinical trials.'
p5935
aS'However, dose-limiting side effects are observed, and MEK inhibitors that sufficiently reduce ERK activation in patients show a low clinical response.'
p5936
aS'Moreover, the combination of saracatinib and selumetinib effectively suppressed the growth and invasion of melanoma cells in a 3D environment, suggesting that combined inhibition of MEK and SRC is a promising approach to improve the efficacy of targeting the ERK/MAP kinase pathway in melanoma.'
p5937
aS'The RAS-RAF-MEK-ERK pathway is deregulated in over 90% of malignant melanomas.'
p5938
aS'A potent orally active MEK inhibitor that blocks ERK activation in cells at a concentration of 10-100nM is selumetinib (AZD6244, ARRY-142886) ('
p5939
aS'In melanoma cells expressing the oncogenic mutated BRAF MEK is constitutively active, but treatment with the MEK inhibitor selumetinib suppresses this activity and this can be detected in a loss of phosphorylation of ERK ('
p5940
aS'We demonstrate that knock down of mutant B-RAF or inhibition of MEK/ERK signaling results in an increase in Rac1 activity due to the activation of the Rac1 GEF Tiam1.'
p5941
aS'In melanoma cells expressing BRAFV600E the activity of MEK and ERK is high, leading to low Tiam1 activity followed by low Rac activity.'
p5942
aS'At 32h GRD expression significantly reduces Ras-GTP and downstream P-MEK and P-ERK ('
p5943
ag838
ag839
ag840
ag841
ag842
ag843
ag844
ag845
aS'Once we established this, we wanted to test the role of the PI3K/AKT and the RAS/MEK/ERK pathways in the regulation of FOXO3a cellular localization and activity in HGSOC cells.'
p5944
aS'Overall, our findings suggest a major role for activated PI3K/AKT and RAS/MEK/ERK pathways in nuclear exclusion of FOXO3a and inhibition of its tumor suppressive function in many ovarian cancer cell lines and primary tumors.'
p5945
aS'The MEK/ERK and PI3K/AKT pathways are often concurrently activated by separate genetic alterations in colorectal cancer (CRC), which is associated with CRC progression and poor survival.'
p5946
aS'In CRC cells with coexistent mutational activation of ERK and AKT pathways, inhibition of either MEK or AKT alone showed limited activity in inhibiting cell migration and invasion, but combined inhibition resulted in profound effects.'
p5947
aS'The MAPK intracellular signaling cascade comprises RAS, RAF, MEK and ERK.'
p5948
aS'We and others recently showed that colon tumors with concurrent activation of the MEK/ERK and PI3K/AKT pathways by separate mutations are invariably resistant to inhibition of either pathway alone, but sensitive to combined inhibition of both pathways.'
p5949
aS'Concurrent activation of the RAS/RAF/MEK/ERK and PI3K/AKT pathways occurs in a significant proportion of human CRCs.'
p5950
aS'To test whether the cap-dependent translation apparatus mediates the effects of ERK and AKT activation on CRC motility, the effects of MEK and AKT inhibition, alone or in combination, were determined in HCT116 cells with stable knockdown of 4E-BP1 or expressing control shRNA.'
p5951
aS'We uncover a molecular mechanism that involves the activation of MEK/ERK by mutant p53, leading to Egr-1 transcription.'
p5952
aS'Upon inhibition of MEK by PD98059, dephosphorylation of ERK by specific phosphatases occurs very rapidly (within minutes).'
p5953
aS'Because EGFR stimulates the ERK1/2 pathway, one of the major regulators of Egr-1 expression, the involvement of ERK-1/2 was examined using MEK inhibitor PD98059.'
p5954
aS'Overall, these results suggest that overexpression of Egr-1 results in an increased transcription and secretion of EGFR ligands, therefore initiating a positive feedback loop that leads to autocrine activation of the EGFR and MEK/ERK1/2.'
p5955
aS'Overall our results indicate that the MEK/ERK pathway mediates the activation of Egr-1 transcription by mutant p53.'
p5956
aS'Overexpression of Egr-1 is caused by mutation of p53 and appears to be initiated through activation of the MEK/ERK1/2 signaling cascade by mutant p53.'
p5957
ag846
ag847
ag848
aS'Four to five days after introduction of oncogenic HRAS, there was higher phosphorylated MEK (p-MEK), p-ERK ('
p5958
aS'The higher levels of p-MEK and p-ERK and lower level of p-AKT in wild-type cells ('
p5959
aS'HRAS-induced senescence is promoted by RAF/MEK/ERK pathway and inhibited by the PI3K/AKT pathway.'
p5960
aS'Aberrant activation of the MAP kinase or ERK kinase (MEK) 1/2 and extracellular signal-regulated kinases 1 and 2 (ERK1/2) occurs in many types of human cancers.'
p5961
aS'ERK1/2 phosphorylation can be mediated either by the upstream kinases MEK1/2'
p5962
aS'Papillary thyroid cancer (PTC) is the most common thyroid cancer and is the result of the abnormal activation of the MEK/ERK signaling pathway.'
p5963
aS'In the MAPK cascade, MAPK kinase (MEK) directly phosphorylates ERK1/2 and leads to its activation.'
p5964
aS'To determine whether the proteolytic activity of MMP-9 was dependent on ERK1/2 signaling, the proteolytic activity of PMA-stimulated MEFs was measured after pretreatment with PD 098059, a specific MEK inhibitor that preferentially blocks ERK1/2 phosphorylation ('
p5965
aS'We show that activation of the Hedgehog (HH) pathway, critically involved in the pathogenesis of BCCs, as well as the EGFR/MEK/ERK/c-JUN signaling pathway suppresses miR-203.'
p5966
aS'The oncoprotein c-JUN, part of the AP-1 transcription factor complex, has been shown to synergize with HH/GLI1 in oncogenic transformation via activation of the MEK/ERK/JUN pathway.'
p5967
aS'These results indicate that activation of the EGFR/MEK/ERK/JUN signaling pathway is a possible mechanism underlying reduced miR-203 expression in a subset of BCCs.'
p5968
aS'Indeed, c-JUN has recently been described as a major downstream effector of the HH pathway, whose direct activation by GLI in synergism with the EGFR/MEK/ERK/JUN pathway is essential for oncogenic activity of HH signaling in skin.'
p5969
aS'Activation of the EGFR/MEK/ERK/JUN pathway suppresses miR-203 expression.'
p5970
aS'Activation-state p-p38 (Thr180/Tyr182), p-ERK (Thr202/Tyr204), p-JNK (Thr183/Tyr185), p-MLK3 (Thr277/Ser281) and p-MEK3/MEK6 (Ser189/207) antibodies were from Cell Signaling Technology (Beverly, MA, USA).'
p5971
aS'The ASP, CUR and SFN are reported to modulate ERK-MEK pathway ('
p5972
aS'In order to verify the involvement of ERK1/2 activation in ACS-induced apoptosis, we used MEK1/2 inhibitor, U0126, and analyzed by western blot and cell viability assay.'
p5973
aS'The U0126 blocks MEK1/2 phosphorylation and subsequent activation of ERK1/2.'
p5974
ag849
ag850
ag852
aS'A proportion (~60%) of melanomas harbour mutations in the serine-threonine kinase BRAF, resulting in constitutive activation of the RAS/RAF/MEK/ERK pathway and irregular cell proliferation.'
p5975
ag1962
ag1963
ag853
aS'Our results show that the non-Smad downstream effectors p38MAPK and MEK/ERK regulate actin remodeling and cell motility, but do not contribute to the regulation of the Arp2/3 complex.'
p5976
aS'A gradual decrease in the level of the MEK1/2 phosphorylation was observed in the U0126-treated T47D cells at 1, 3 and 6 h, while it increased after 12 h. The phosphorylation of ERK1/2, on the other hand, was inhibited during the entire observation period and was not affected by activated MEK1/2.'
p5977
as(S'ZBTB18'
p5978
S'ONECUT1'
p5979
S'increases'
p5980
tp5981
(lp5982
s(S'TGIF'
p5983
S'MAX'
p5984
S'increases'
p5985
tp5986
(lp5987
s(S'ETS1'
p5988
S'NRAS'
p5989
S'increases'
p5990
tp5991
(lp5992
s(S'KLF12'
p5993
S'GATA1'
p5994
S'increases'
p5995
tp5996
(lp5997
s(S'HRAS/GTP'
p5998
S'PAK2'
p5999
S'increases_activity'
p6000
tp6001
(lp6002
s(S'CYP26A1'
p6003
S'FOXD3'
p6004
S'increases'
p6005
tp6006
(lp6007
s(S'LMO2'
p6008
S'RUNX1'
p6009
S'increases'
p6010
tp6011
(lp6012
s(S'MLK3'
p6013
S'MKK3/6'
p6014
S'adds_modification'
p6015
tp6016
(lp6017
s(S'TAK'
p6018
S'MKK3/6'
p6019
S'adds_modification'
p6020
tp6021
(lp6022
s(S'GRB2:SOS1'
p6023
S'HB-EGF:P-6Y-EGFR DIMER'
p6024
S'binds'
p6025
tp6026
(lp6027
s(S'FOXO4'
p6028
S'NRAS'
p6029
S'increases'
p6030
tp6031
(lp6032
s(S'MECOM'
p6033
S'NRAS'
p6034
S'increases'
p6035
tp6036
(lp6037
s(S'KLF12'
p6038
S'CYP26A1'
p6039
S'increases'
p6040
tp6041
(lp6042
s(S'RAS family/GTP/PI3K'
p6043
S'TRPV1'
p6044
S'adds_modification'
p6045
tp6046
(lp6047
s(S'hsa-let-7a-5p'
p6048
S'NRAS'
p6049
S'decreases'
p6050
tp6051
(lp6052
s(S'NF1'
p6053
S'HOXA9'
p6054
S'increases'
p6055
tp6056
(lp6057
s(S'REPIN1'
p6058
S'FOXD3'
p6059
S'increases'
p6060
tp6061
(lp6062
s(S'CYP26A1'
p6063
S'FOXJ2'
p6064
S'increases'
p6065
tp6066
(lp6067
s(S'FOXO4'
p6068
S'MEIS1'
p6069
S'increases'
p6070
tp6071
(lp6072
s(S'EBF2'
p6073
S'MECOM'
p6074
S'increases'
p6075
tp6076
(lp6077
s(S'ETS1'
p6078
S'FOXO3'
p6079
S'increases'
p6080
tp6081
(lp6082
s(S'SP3'
p6083
S'CYP26A1'
p6084
S'increases'
p6085
tp6086
(lp6087
s(S'LNXp80'
p6088
S'NUMB'
p6089
S'decreases'
p6090
tp6091
(lp6092
s(S'RUNX2'
p6093
S'CYP26A1'
p6094
S'increases'
p6095
tp6096
(lp6097
s(S'AHR'
p6098
S'FOXO3'
p6099
S'increases'
p6100
tp6101
(lp6102
s(S'VSX1'
p6103
S'FOXF2'
p6104
S'increases'
p6105
tp6106
(lp6107
s(S'BPTF'
p6108
S'RUNX1'
p6109
S'increases'
p6110
tp6111
(lp6112
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p6113
S'HRAS PROTEIN'
p6114
S'increases'
p6115
tp6116
(lp6117
s(S'TCF3'
p6118
S'POU3F2'
p6119
S'increases'
p6120
tp6121
(lp6122
s(S'TCF3'
p6123
S'IRF1'
p6124
S'increases'
p6125
tp6126
(lp6127
s(S'SREBF1'
p6128
S'EN1'
p6129
S'increases'
p6130
tp6131
(lp6132
s(S'FOXO4'
p6133
S'RUNX2'
p6134
S'increases'
p6135
tp6136
(lp6137
s(S'hsa-miR-181a-5p'
p6138
S'HRAS'
p6139
S'decreases'
p6140
tp6141
(lp6142
s(S'Myb'
p6143
S'NRAS'
p6144
S'decreases'
p6145
tp6146
(lp6147
s(S'HSPA8'
p6148
S'ADP'
p6149
S'binds'
p6150
tp6151
(lp6152
s(S'SOCS3'
p6153
S'RASGAP'
p6154
S'binds'
p6155
tp6156
(lp6157
s(S'ONECUT1'
p6158
S'NRAS'
p6159
S'increases'
p6160
tp6161
(lp6162
s(S'PITX2'
p6163
S'EN1'
p6164
S'increases'
p6165
tp6166
(lp6167
s(S'HGF(dimer)/MET(dimer)'
p6168
S'SRC'
p6169
S'adds_modification'
p6170
tp6171
(lp6172
s(S'2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine'
p6173
S'HRAS PROTEIN'
p6174
S'increases'
p6175
tp6176
(lp6177
s(S'GFI1'
p6178
S'POU3F2'
p6179
S'increases'
p6180
tp6181
(lp6182
s(S'FARNESYL DIPHOSPHATE'
p6183
S'KRAS'
p6184
S'increases_activity'
p6185
tp6186
(lp6187
s(S'IL2/IL2R BETA/GAMMA/JAK1/LCK/JAK3'
p6188
S'PI3K'
p6189
S'binds'
p6190
tp6191
(lp6192
s(S'GTF3A'
p6193
S'MECOM'
p6194
S'increases'
p6195
tp6196
(lp6197
s(S'EGR2'
p6198
S'CYP26A1'
p6199
S'increases'
p6200
tp6201
(lp6202
s(S'RUNX1'
p6203
S'FOXF2'
p6204
S'increases'
p6205
tp6206
(lp6207
s(S'IL3/IL3RA/CSF2RB (DODECAMER)'
p6208
S'YWHAZ'
p6209
S'binds'
p6210
tp6211
(lp6212
s(S'RAF1'
p6213
S'BRAF'
p6214
S'binds'
p6215
tp6216
(lp6217
S'Selected cells displayed robust and reproducible enrichment of library-derived cDNAs encoding truncated forms of RAF1 and BRAF proteins, whose silencing reversed the resistant phenotype.'
p6218
aS'To confirm whether RAF1 and BRAF were drivers of resistance to MET inhibition, we transduced full length human RAF1 and BRAF in wild-type GTL-16 cells.'
p6219
aS'RT-PCR and Western Blot analysis confirmed robust expression of both RAF1 and BRAF transcripts and proteins ('
p6220
aS'To evaluate whether resistance to MET inhibition in GTL-16 cells transduced with truncated BRAF or RAF1 was also maintained '
p6221
aS'To investigate whether truncated RAF1 and BRAF could drive resistance to RTK inhibition also in other cell lines and tissues, Hs746T (gastric carcinoma, MET addicted), NCI-H1993 (non-small cell lung cancer, MET addicted), EBC1 (lung squamous cell carcinoma, MET addicted) and NCI-H508 (caecal adenocarcinoma, EGFR addicted), were transduced with truncated RAFs and GFP control vector.'
p6222
aS'However, truncated and fusion RAF1 and BRAF transcripts have been found to occur in several cancer cell lines and tumor samples ['
p6223
aS'Human truncated RAF1 and BRAF cDNAs were custom-synthesized by Geneart and cloned into the pRRLsin-PPThCMV-wpre lentiviral vector ['
p6224
aS'For Western blot the following antibodies were used: polyclonal antibody against human RAF1 (Upstate - Cat.# 07-396), polyclonal antibody against human and murine phosphorilated BRAF (Ser445) (Cell Signaling Technology - Cat.# 2696); monoclonal antibody against murine Raf1 (Santa Cruz Biotechnology - Cat.# sc-7267); and antibody against vinculin (Sigma - Cat.# V9131).'
p6225
aS'PLX4032 and its analogs like PLX4720 have demonstrated selectivity between highly homologous wild-type BRAF and RAF1, and some selectivity for BRAFV600E compared to non-mutated BRAF.'
p6226
aS'Rearrangements of RAF oncogenes (SLC45A-3-BRAF, ESRP1-RAF1) are found in 1-2% of PCa, mostly CRPC ['
p6227
aS'Sorafenib (BAY 43-9006, serine/threonine kinase RAF1, and BRAF inhibitor) and semaxanib (SU5416, vascular endothelial cell growth factor receptor inhibitor) are RTK inhibitors that can block RET signaling and suppress growth of '
p6228
aS'In NS, germline missense mutations in genes such as PTPN11, KRAS, SOS1, RAF1, BRAF, SHOC2, NRAS and CBL ('
p6229
aS'A molecular analysis of PTPN11, KRAS, SOS1, RAF1, BRAF, SHOC2, NRAS and CBL was performed as previously described ('
p6230
as(S'MYC'
p6231
S'CYP26A1'
p6232
S'increases'
p6233
tp6234
(lp6235
s(S'UBP1'
p6236
S'CYP26A1'
p6237
S'increases'
p6238
tp6239
(lp6240
s(S'MTF1'
p6241
S'REPIN1'
p6242
S'increases'
p6243
tp6244
(lp6245
s(S'HNF1A'
p6246
S'RUNX1'
p6247
S'increases'
p6248
tp6249
(lp6250
s(S'NHLH1'
p6251
S'FOXA1'
p6252
S'increases'
p6253
tp6254
(lp6255
s(S'HLF'
p6256
S'FOXA1'
p6257
S'increases'
p6258
tp6259
(lp6260
s(S'MEIS1'
p6261
S'GATA6'
p6262
S'increases'
p6263
tp6264
(lp6265
s(S'PDGF-BB/PDGFRB (DIMER)/SHP2'
p6266
S'GRB2/SOS1'
p6267
S'binds'
p6268
tp6269
(lp6270
s(S'ZBTB14'
p6271
S'EN1'
p6272
S'increases'
p6273
tp6274
(lp6275
s(S'alpha6/beta4 Integrin'
p6276
S'HRAS/GDP'
p6277
S'increases_activity'
p6278
tp6279
(lp6280
s(S'ErbB2'
p6281
S'HRAS/GDP'
p6282
S'increases_activity'
p6283
tp6284
(lp6285
s(S'MEIS1'
p6286
S'FOXO3'
p6287
S'increases'
p6288
tp6289
(lp6290
s(S'RELA'
p6291
S'IRF1'
p6292
S'increases'
p6293
tp6294
(lp6295
s(S'MYCN'
p6296
S'FOXO3'
p6297
S'increases'
p6298
tp6299
(lp6300
s(S'RHOA/GTP'
p6301
S'DIA'
p6302
S'increases_activity'
p6303
tp6304
(lp6305
s(S'Fluorouracil'
p6306
S'KRAS PROTEIN'
p6307
S'decreases'
p6308
tp6309
(lp6310
s(S'ATF2'
p6311
S'CYP26A1'
p6312
S'increases'
p6313
tp6314
(lp6315
s(S'GNAI2/GTP'
p6316
S'SRC FAMILY KINASES'
p6317
S'increases_activity'
p6318
tp6319
(lp6320
s(S'HAND1'
p6321
S'POU2F1'
p6322
S'increases'
p6323
tp6324
(lp6325
s(S'PI5K Type 1 family'
p6326
S'PI-4-P'
p6327
S'translocates'
p6328
tp6329
(lp6330
s(S'HSF1'
p6331
S'CBFA2T3'
p6332
S'increases'
p6333
tp6334
(lp6335
s(S'BACH1'
p6336
S'FOXA1'
p6337
S'increases'
p6338
tp6339
(lp6340
s(S'PI-3-4-5-P3'
p6341
S'SGK1'
p6342
S'adds_modification'
p6343
tp6344
(lp6345
s(S'hsa-miR-20a-5p'
p6346
S'NRAS'
p6347
S'decreases'
p6348
tp6349
(lp6350
s(S'CYP26A1'
p6351
S'MECOM'
p6352
S'increases'
p6353
tp6354
(lp6355
s(S'FOXF2'
p6356
S'RUNX1'
p6357
S'increases'
p6358
tp6359
(lp6360
s(S'EGR2'
p6361
S'SRF'
p6362
S'increases'
p6363
tp6364
(lp6365
s(S'LEF1'
p6366
S'FOXD3'
p6367
S'increases'
p6368
tp6369
(lp6370
s(S'TFAP2C'
p6371
S'MECOM'
p6372
S'increases'
p6373
tp6374
(lp6375
s(S'SHC'
p6376
S'GRB2/SOS1'
p6377
S'binds'
p6378
tp6379
(lp6380
s(S'CA2+'
p6381
S'CAM'
p6382
S'binds'
p6383
tp6384
(lp6385
s(S'MYC'
p6386
S'POU3F2'
p6387
S'increases'
p6388
tp6389
(lp6390
s(S'PAX8'
p6391
S'HOXA9'
p6392
S'increases'
p6393
tp6394
(lp6395
s(S'TFDP2'
p6396
S'CDC5L'
p6397
S'increases'
p6398
tp6399
(lp6400
s(S'RAF1/14-3-3'
p6401
S'KSR/14-3-3 /MEK1-2'
p6402
S'increases_activity'
p6403
tp6404
(lp6405
s(S'DDIT3'
p6406
S'MEIS1'
p6407
S'increases'
p6408
tp6409
(lp6410
s(S'GNB1/GNG2'
p6411
S'HRAS/GDP'
p6412
S'increases_activity'
p6413
tp6414
(lp6415
s(S'ACTIVATED FGFR MUTANTS:P-FRS2ALPHA'
p6416
S'GRB2:SOS1'
p6417
S'binds'
p6418
tp6419
(lp6420
s(S'HIF1A'
p6421
S'CYP26A1'
p6422
S'increases'
p6423
tp6424
(lp6425
s(S'RAF1-BRAF'
p6426
S'ERK1-2'
p6427
S'increases_activity'
p6428
tp6429
(lp6430
s(S'SMAD4'
p6431
S'CBFA2T3'
p6432
S'increases'
p6433
tp6434
(lp6435
s(S'resveratrol'
p6436
S'HRAS PROTEIN'
p6437
S'increases'
p6438
tp6439
(lp6440
s(S'Malathion'
p6441
S'HRAS MRNA'
p6442
S'increases'
p6443
tp6444
(lp6445
s(S'NRF1'
p6446
S'FOXO4'
p6447
S'increases'
p6448
tp6449
(lp6450
s(S'CREB1'
p6451
S'JUN'
p6452
S'increases'
p6453
tp6454
(lp6455
s(S'CDC5L'
p6456
S'HOXA9'
p6457
S'increases'
p6458
tp6459
(lp6460
s(S'CDX2'
p6461
S'HOXA9'
p6462
S'increases'
p6463
tp6464
(lp6465
s(S'HMGA1'
p6466
S'POU2F1'
p6467
S'increases'
p6468
tp6469
(lp6470
s(S'Coumestrol'
p6471
S'KRAS MRNA'
p6472
S'decreases'
p6473
tp6474
(lp6475
s(S'LEF1'
p6476
S'FOXO3'
p6477
S'increases'
p6478
tp6479
(lp6480
s(S'CYP26A1'
p6481
S'MEIS1'
p6482
S'increases'
p6483
tp6484
(lp6485
s(S'GTF2A2'
p6486
S'MEIS1'
p6487
S'increases'
p6488
tp6489
(lp6490
s(S'REPIN1'
p6491
S'CBFA2T3'
p6492
S'increases'
p6493
tp6494
(lp6495
s(S'hsa-miR-143-3p'
p6496
S'HRAS'
p6497
S'decreases'
p6498
tp6499
(lp6500
s(S'[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID'
p6501
S'KRAS'
p6502
S'increases_activity'
p6503
tp6504
(lp6505
s(S'TFDP1'
p6506
S'ONECUT1'
p6507
S'increases'
p6508
tp6509
(lp6510
s(S'YY1'
p6511
S'CYP26A1'
p6512
S'increases'
p6513
tp6514
(lp6515
s(S'PITX2'
p6516
S'RUNX1'
p6517
S'increases'
p6518
tp6519
(lp6520
s(S'STAT5A'
p6521
S'NRAS'
p6522
S'increases'
p6523
tp6524
(lp6525
s(S'Valproic Acid'
p6526
S'HRAS MRNA'
p6527
S'increases'
p6528
tp6529
(lp6530
s(S'Malathion'
p6531
S'HRAS PROTEIN'
p6532
S'increases'
p6533
tp6534
(lp6535
s(S'TFAP4'
p6536
S'CBFA2T3'
p6537
S'increases'
p6538
tp6539
(lp6540
s(S'TFAP4'
p6541
S'EN1'
p6542
S'increases'
p6543
tp6544
(lp6545
s(S'POU3F2'
p6546
S'CYP26A1'
p6547
S'increases'
p6548
tp6549
(lp6550
s(S'PAX3'
p6551
S'FOXD3'
p6552
S'increases'
p6553
tp6554
(lp6555
s(S'FOXA2'
p6556
S'RUNX2'
p6557
S'increases'
p6558
tp6559
(lp6560
s(S'MAX'
p6561
S'BACH1'
p6562
S'increases'
p6563
tp6564
(lp6565
s(S'PDX1'
p6566
S'CYP26A1'
p6567
S'increases'
p6568
tp6569
(lp6570
s(S'EPO/EPOR (dimer)/JAK2'
p6571
S'SHC/GRB2/SOS1'
p6572
S'increases_activity'
p6573
tp6574
(lp6575
s(S'E2F1'
p6576
S'MEIS1'
p6577
S'increases'
p6578
tp6579
(lp6580
s(S'FOXF2'
p6581
S'MEIS1'
p6582
S'increases'
p6583
tp6584
(lp6585
s(S'SPZ1'
p6586
S'FOXJ2'
p6587
S'increases'
p6588
tp6589
(lp6590
s(S'SRY'
p6591
S'NRAS'
p6592
S'increases'
p6593
tp6594
(lp6595
s(S'REPIN1'
p6596
S'CYP26A1'
p6597
S'increases'
p6598
tp6599
(lp6600
s(S'VEGFR3/VEGFC-D'
p6601
S'PKC'
p6602
S'increases_activity'
p6603
tp6604
(lp6605
s(S'MEIS1'
p6606
S'EN1'
p6607
S'increases'
p6608
tp6609
(lp6610
s(S'FOXJ1'
p6611
S'FOXD3'
p6612
S'increases'
p6613
tp6614
(lp6615
s(S'SPZ1'
p6616
S'FOXO4'
p6617
S'increases'
p6618
tp6619
(lp6620
s(S'RHOA/GTP'
p6621
S'ROCK1-ROCK2'
p6622
S'increases_activity'
p6623
tp6624
(lp6625
s(S'HMGA1'
p6626
S'ONECUT1'
p6627
S'increases'
p6628
tp6629
(lp6630
s(S'uPA/uPAR/alphav/beta3 Integrin/Vitronectin'
p6631
S'SRC'
p6632
S'adds_modification'
p6633
tp6634
(lp6635
s(S'ETS1'
p6636
S'CYP26A1'
p6637
S'increases'
p6638
tp6639
(lp6640
s(S'ESRRA'
p6641
S'TLX2'
p6642
S'increases'
p6643
tp6644
(lp6645
s(S'ROCK2'
p6646
S'RHO FAMILY GTPASE-ACTIVE'
p6647
S'binds'
p6648
tp6649
(lp6650
s(S'ATF4'
p6651
S'CYP26A1'
p6652
S'increases'
p6653
tp6654
(lp6655
s(S'OR5I1'
p6656
S'CYP26A1'
p6657
S'increases'
p6658
tp6659
(lp6660
s(S'PITX2'
p6661
S'GATA1'
p6662
S'increases'
p6663
tp6664
(lp6665
s(S'AHR'
p6666
S'ONECUT1'
p6667
S'increases'
p6668
tp6669
(lp6670
s(S'PTF1A'
p6671
S'MECOM'
p6672
S'increases'
p6673
tp6674
(lp6675
s(S'arsenic trioxide'
p6676
S'HRAS MRNA'
p6677
S'increases'
p6678
tp6679
(lp6680
s(S'TCF3'
p6681
S'REPIN1'
p6682
S'increases'
p6683
tp6684
(lp6685
s(S'STAT6'
p6686
S'FOXO3'
p6687
S'increases'
p6688
tp6689
(lp6690
s(S'POU1F1'
p6691
S'POU2F1'
p6692
S'increases'
p6693
tp6694
(lp6695
s(S'RHOA/GTP'
p6696
S'ROCK'
p6697
S'increases_activity'
p6698
tp6699
(lp6700
s(S'PITPNA'
p6701
S'PI-4-5-P2'
p6702
S'translocates'
p6703
tp6704
(lp6705
s(S'MDM-2'
p6706
S'P14/19 ARF'
p6707
S'binds'
p6708
tp6709
(lp6710
s(S'TEAD1'
p6711
S'FOXO3'
p6712
S'increases'
p6713
tp6714
(lp6715
s(S'MYC'
p6716
S'MAX'
p6717
S'increases'
p6718
tp6719
(lp6720
S'Applying a small molecular inhibitor of MYC-MAX heterodimerization ['
p6721
aS'Based on this we went on to study the effects on myeloma cells applying an inhibitor of MYC-MAX heterodimerization; the 10058-F4 compound.'
p6722
aS'Moreover, the 10058-F4 compound represents a new class of protein inhibitors because it does not inhibit enzyme activity but rather the bi-molecular interaction between c-MYC and its partner MAX.'
p6723
aS'SCLC cell line tumors without amplified MYC genes show recurrent inactivation of MAX, a MYC-associated protein.'
p6724
aS'MAX mediates transactivation of pro-differentiation genes by virtue of suppressing activity of MYC, and it suppresses MYC-mediated activation of stemness-related genes ['
p6725
ag3013
as(S'GRB2:SOS1'
p6726
S'EGF:PHOSPHO-EGFR:PHOSPHO-SHC'
p6727
S'binds'
p6728
tp6729
(lp6730
s(S'NF1'
p6731
S'RUNX1'
p6732
S'increases'
p6733
tp6734
(lp6735
s(S'ZEB1'
p6736
S'GATA6'
p6737
S'increases'
p6738
tp6739
(lp6740
s(S'TBP'
p6741
S'EN1'
p6742
S'increases'
p6743
tp6744
(lp6745
s(S'FOXA1'
p6746
S'FOXD3'
p6747
S'increases'
p6748
tp6749
(lp6750
s(S'CART1'
p6751
S'EN1'
p6752
S'increases'
p6753
tp6754
(lp6755
s(S'MAX'
p6756
S'CEBPA'
p6757
S'increases'
p6758
tp6759
(lp6760
s(S'GATA6'
p6761
S'NRAS'
p6762
S'increases'
p6763
tp6764
(lp6765
s(S'PTF1A'
p6766
S'FOXO3'
p6767
S'increases'
p6768
tp6769
(lp6770
s(S'LEF1'
p6771
S'FOXA1'
p6772
S'increases'
p6773
tp6774
(lp6775
s(S'hsa-let-7g-5p'
p6776
S'KRAS'
p6777
S'decreases'
p6778
tp6779
(lp6780
s(S'ZBTB14'
p6781
S'CYP26A1'
p6782
S'increases'
p6783
tp6784
(lp6785
s(S'POU1F1'
p6786
S'FOXO4'
p6787
S'increases'
p6788
tp6789
(lp6790
s(S'PI3K'
p6791
S'PI-4-5-P2'
p6792
S'translocates'
p6793
tp6794
(lp6795
s(S'GABPB2'
p6796
S'NRAS'
p6797
S'increases'
p6798
tp6799
(lp6800
s(S'ELK1'
p6801
S'LEF1'
p6802
S'increases'
p6803
tp6804
(lp6805
s(S'Estrogens'
p6806
S'HRAS MRNA'
p6807
S'increases'
p6808
tp6809
(lp6810
s(S'CYP26A1'
p6811
S'CEBPA'
p6812
S'increases'
p6813
tp6814
(lp6815
s(S'SPI1'
p6816
S'POU2F1'
p6817
S'increases'
p6818
tp6819
(lp6820
s(S'PPARG'
p6821
S'CYP26A1'
p6822
S'increases'
p6823
tp6824
(lp6825
s(S'Asbestos, Serpentine'
p6826
S'HRAS PROTEIN'
p6827
S'increases'
p6828
tp6829
(lp6830
s(S'RET51/GFRALPHA1/GDNF/DOK1'
p6831
S'RASGAP'
p6832
S'binds'
p6833
tp6834
(lp6835
s(S'FOXO1'
p6836
S'GATA6'
p6837
S'increases'
p6838
tp6839
(lp6840
s(S'Cadmium'
p6841
S'KRAS PROTEIN'
p6842
S'increases'
p6843
tp6844
(lp6845
s(S'MAX'
p6846
S'EN1'
p6847
S'increases'
p6848
tp6849
(lp6850
s(S'TLX2'
p6851
S'NRAS'
p6852
S'increases'
p6853
tp6854
(lp6855
s(S'SREBF1'
p6856
S'CYP26A1'
p6857
S'increases'
p6858
tp6859
(lp6860
s(S'SMAD3'
p6861
S'MEIS1'
p6862
S'increases'
p6863
tp6864
(lp6865
s(S'Acetaminophen'
p6866
S'NRAS MRNA'
p6867
S'decreases'
p6868
tp6869
(lp6870
s(S'LEF1'
p6871
S'ETS1'
p6872
S'increases'
p6873
tp6874
(lp6875
s(S'SRF'
p6876
S'MEIS1'
p6877
S'increases'
p6878
tp6879
(lp6880
s(S'BRAF'
p6881
S'MKK3-MKK6'
p6882
S'increases_activity'
p6883
tp6884
(lp6885
s(S'HRAS/GTP'
p6886
S'RAF1'
p6887
S'adds_modification'
p6888
tp6889
(lp6890
s(S'MSX1'
p6891
S'CYP26A1'
p6892
S'increases'
p6893
tp6894
(lp6895
s(S'GATA4'
p6896
S'ETS1'
p6897
S'increases'
p6898
tp6899
(lp6900
s(S'E4F1'
p6901
S'FOXA1'
p6902
S'increases'
p6903
tp6904
(lp6905
s(S'FOXD1'
p6906
S'LEF1'
p6907
S'increases'
p6908
tp6909
(lp6910
s(S'CUX1'
p6911
S'MAX'
p6912
S'increases'
p6913
tp6914
(lp6915
s(S'CYP26A1'
p6916
S'CBFA2T3'
p6917
S'increases'
p6918
tp6919
(lp6920
s(S'CAM/CA2+'
p6921
S'KRAS ISOFORM 4B/GTP'
p6922
S'binds'
p6923
tp6924
(lp6925
s(S'MYOG'
p6926
S'STAT5A'
p6927
S'increases'
p6928
tp6929
(lp6930
s(S'MYOD1'
p6931
S'STAT5A'
p6932
S'increases'
p6933
tp6934
(lp6935
s(S'HNF1A'
p6936
S'POU3F2'
p6937
S'increases'
p6938
tp6939
(lp6940
s(S'EPH'
p6941
S'EPHR'
p6942
S'binds'
p6943
tp6944
(lp6945
s(S'PDGF:PHOSPHO-PDGF RECEPTOR DIMER'
p6946
S'GRB2:SOS1'
p6947
S'binds'
p6948
tp6949
(lp6950
s(S'HRAS/GTP'
p6951
S'PI3K'
p6952
S'increases_activity'
p6953
tp6954
(lp6955
s(S'RUNX1'
p6956
S'TLX2'
p6957
S'increases'
p6958
tp6959
(lp6960
s(S'MYOG'
p6961
S'CYP26A1'
p6962
S'increases'
p6963
tp6964
(lp6965
s(S'PAX2'
p6966
S'EN1'
p6967
S'increases'
p6968
tp6969
(lp6970
s(S'TFCP2'
p6971
S'CYP26A1'
p6972
S'increases'
p6973
tp6974
(lp6975
s(S'hsa-miR-145-5p'
p6976
S'NRAS'
p6977
S'decreases'
p6978
tp6979
(lp6980
s(S'KAT2B'
p6981
S'GATA1'
p6982
S'increases'
p6983
tp6984
(lp6985
s(S'P-EGFR MUTANTS:P-Y349,350-SHC1'
p6986
S'GRB2:SOS1'
p6987
S'binds'
p6988
tp6989
(lp6990
s(S'E2F1'
p6991
S'MECOM'
p6992
S'increases'
p6993
tp6994
(lp6995
s(S'GNB1/GNG2'
p6996
S'SRC'
p6997
S'adds_modification'
p6998
tp6999
(lp7000
s(S'ZBTB14'
p7001
S'MAX'
p7002
S'increases'
p7003
tp7004
(lp7005
s(S'RALGDS'
p7006
S'P21 RAS:GTP'
p7007
S'binds'
p7008
tp7009
(lp7010
s(S'RHOA/GTP'
p7011
S'ROCK2'
p7012
S'increases_activity'
p7013
tp7014
(lp7015
s(S'NR1H3'
p7016
S'FOXD3'
p7017
S'increases'
p7018
tp7019
(lp7020
s(S'TFAP4'
p7021
S'GATA1'
p7022
S'increases'
p7023
tp7024
(lp7025
s(S'FOXA1'
p7026
S'GATA6'
p7027
S'increases'
p7028
tp7029
(lp7030
s(S'GRB2:SOS1'
p7031
S'P-SHC'
p7032
S'binds'
p7033
tp7034
(lp7035
s(S'E2F1'
p7036
S'FOXO3'
p7037
S'increases'
p7038
tp7039
(lp7040
s.